Benign Neoplasm of Vocal Fold - Glottis
Conditions
Keywords
intranasal, dexmedetomidine, early recovery, suspension laryngoscopy
Brief summary
Most patients with preoperative varying degrees of stress, anxiety, which makes the stress response in patients and affect the normal conduct of anesthesia and surgery.The sympathetic system hyperexcitability prone to cause adverse cardiovascular events and affect postoperative recovery. However, phenobarbital, as the traditional premedication, has less sedative, weak anxiolytic and other shortcomings. Midazolam accompanied by inhibition of respiration,excessive sedation, easily induced delirium,prolonged recovery time and so on. Dexmedetomidine is a highly selective α2-adrenergic receptor agonist, it has sedative, anxiolytic, no inhibition of respiration, and also colorless, odorless, non-mucosal stimulation, nasal drip ease of administration, patient acceptance, comfortable. Therefore, dexmedetomidine as premedication has certain advantages. The purpose of this research is to study sedative effect, safety and the impact of anesthesia recovery period of intranasal dexmedetomidine premedication for suspension laryngoscopy.
Detailed description
All patients received intranasal dexmedetomidine (1μg.kg-1) or placebo at approximately 45 min before induction of anesthesia.The study drug was prepared in a 1-ml syringe.An equal volume of dexmedetomidine or placebo was dropped into each nostril by a blinded research assistant in the supine position.Automatic sphygmomanometer measure blood pressure.Oxygen saturation and heart rate were measured by a pulse oximeter. Respiratory rate, sedation score and anxiety levels regularly assessed. Patients with general anesthesia, suspension laryngoscopy surgery and postoperative care, standard monitoring are unified.
Interventions
DRUGDexmedetomidine
intranasal dexmedetomidine 1μg.kg-1，0.9% saline was added to make a final volume of 1 mL.all patients received intranasal medication at approximately 45-60 min before induction of anesthesia.
DRUGplacebo
0.9% saline 1 mL all patients received intranasal medication at approximately 45-60 min before induction of anesthesia.
Sponsors
Guangzhou First People's Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
* Surgery:The laryngoscope vocal polyp excision * Aged 18 to 60 years old * Body mass index (BMI) \< 30 kg/m2 * American society of Anesthesiologist (ASA) I -II
Exclusion criteria
* The investigator refused to participate * Known allergy or hypersensitive reaction to dexmedetomidine or anesthetic * With previous history of heart disease * Pregnant women; no reliable contraceptive measures in postmenopausal women * Preoperative heart rate less than 45bpm; Ⅱ or Ⅲ degree atrioventricular block; ischemic heart disease * Taking antihypertensive drugs such as methyldopa, clonidine and other α2 receptor agonist * Asthma * Sleep apnea syndrome * Liver and kidney dysfunction * Known to suffer from mental illness * Long-term use of sedatives and analgesics in patients
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Extubation Time After Intranasal Dexmedetomidine Premedication | 1 days | The times from stopping anesthetic infusions to adequate ventilation, consciousness and extubation after intranasal dexmedetomidine or placebo administration |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Heart Rate (HR) of Patients Receiving Intranasal Placebo or Dexmedetomidine | 1 day | Heart rate (HR) of patients receiving intranasal placebo or dexmedetomidine. HR was monitored in the study. |
| Number of Participants With Anxiety Score >2 | 1 day | satisfaction using a 3-point satisfaction score (1 = highly satisfactory, 2 = acceptable, and 3 = unacceptable) anxiety levels using a 4-point anxiety score (1 = combative, 2 = anxious, 3 = calm, and 4 = amiable) were collected before intranasal drugs and at pre-induction. Anxiety score \>2 was considered to be better for the patient. |
| Anxiety Score of Patients Receiving Intranasal Placebo or Dexmedetomidine | 1 day | 4-point anxiety score: 1. = combative 2. = anxious 3. = calm 4. = amiable. Anxiety score \>2 was considered to be better for the preoperative patients. |
| Systolic Blood Pressure（SBP）of Patients Receiving Intranasal Placebo or Dexmedetomidine | 1 day | Systolic blood pressure（SBP）of Patients Receiving Intranasal Placebo or Dexmedetomidine. |
| Modified OAA/S Scores of Patients Receiving Intranasal Placebo or Dexmedetomidine | 1 days | Modified Observer's Assessment of Alertness/Sedation scale (OAA/S) scores and 4 point anxiety score of patients receiving intranasal placebo or dexmedetomidine. Modified Observer's Assessment of Alertness/Sedation Scale: 6 Appears alert and awake, responds readily to name spoken in normal tone 5 Appears asleep but responds readily to name spoken in normal tone 4 Lethargic response to name spoken in normal tone 3 Responds only after name is called loudly or repeatedly 2 Responds only after mild prodding or shaking 1 Does not respond to mild prodding or shaking 0 Does not respond to noxious stimulus. |
| Perioperative Bradycardia Episodes | 1 day | Bradycardia was defined as heart rate (HR) \<45 bpm for more than 10 s. |
| Perioperative Tachycardia Episodes | 1 day | Tachycardia was defined as heart rate (HR) \>100 bpm for more than 10 s. |
| Perioperative Hypotension Episodes | 1 day | Hypotension was defined as systolic blood pressure (SBP) decreased more than 30% of the pre-operative value for more than 1 min. |
| Perioperative Hypertonsion Episodes | 1 day | Hypertension was defined as systolic blood pressure (SBP) increased 130% of the pre-operative value for more than 1 min. |
| Number of Participants With Satisfaction Score <2 | 1 day | Patient satisfaction scores using a 3-point satisfaction score (1 = highly satisfactory, 2 = acceptable, and 3 = unacceptable) were collected when patients were discharged from the post-anesthesia care unit (PACU). Satisfaction score \<2 was considered to be better for the patient |
Other
| Measure | Time frame | Description |
|---|---|---|
| Duration of Anesthesia of Patients Receiving Intranasal Dexmedetomidine | 1 day | Duration of anesthesia of patients receiving intranasal dexmedetomidine Duration from anesthesia intubation to anesthesia ending |
| Duration of Surgery of Patients Receiving Intranasal Placebo | 1 day | Duration of surgery of patients receiving intranasal placebo Duration from surgery beginning to anesthesia ending |
| Duration of Surgery of Patients Receiving Intranasal Dexmedetomidine | 1 day | Duration of surgery of patients receiving intranasal dexmedetomidine. Duration from surgery beginning to anesthesia ending |
| Modified OAA/S Score of Patients Receiving Intranasal Placebo Before Intranasal Drugs | 1 day | Modified OAA/S score of patients receiving intranasal placebo Before intranasal drugs Modified Observer's Assessment of Alertness/Sedation Scale (Modified OAA/S score) 6 Appears alert and awake, responds readily to name spoken in normal tone 5 Appears asleep but responds readily to name spoken in normal tone 4 Lethargic response to name spoken in normal tone 3 Responds only after name is called loudly or repeatedly 2 Responds only after mild prodding or shaking 1 Does not respond to mild prodding or shaking 0 Does not respond to noxious stimulus |
| Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine Before Intranasal Drugs | 1 day | Modified OAA/S score of patients receiving intranasal dexmedetomidine Before intranasal drugs Modified Observer's Assessment of Alertness/Sedation Scale (Modified OAA/S score) 6 Appears alert and awake, responds readily to name spoken in normal tone 5 Appears asleep but responds readily to name spoken in normal tone 4 Lethargic response to name spoken in normal tone 3 Responds only after name is called loudly or repeatedly 2 Responds only after mild prodding or shaking 1 Does not respond to mild prodding or shaking 0 Does not respond to noxious stimulus |
| Modified OAA/S Score of Patients Receiving Intranasal Placebo at Pre-induction | 1 day | Modified OAA/S score of patients receiving intranasal placebo at Pre-induction. Modified Observer's Assessment of Alertness/Sedation Scale (Modified OAA/S score): 6 Appears alert and awake, responds readily to name spoken in normal tone 5 Appears asleep but responds readily to name spoken in normal tone 4 Lethargic response to name spoken in normal tone 3 Responds only after name is called loudly or repeatedly 2 Responds only after mild prodding or shaking 1 Does not respond to mild prodding or shaking 0 Does not respond to noxious stimulus |
| Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine at Pre-induction | 1 day | Modified OAA/S score of patients receiving intranasal dexmedetomidine at Pre-induction. Modified Observer's Assessment of Alertness/Sedation Scale (Modified OAA/S score): 6 Appears alert and awake, responds readily to name spoken in normal tone 5 Appears asleep but responds readily to name spoken in normal tone 4 Lethargic response to name spoken in normal tone 3 Responds only after name is called loudly or repeatedly 2 Responds only after mild prodding or shaking 1 Does not respond to mild prodding or shaking 0 Does not respond to noxious stimulus |
| Modified OAA/S Score of Patients Receiving Intranasal Placebo After Extubation | 1 day | Modified OAA/S score of patients receiving intranasal placebo After extubation. Modified Observer's Assessment of Alertness/Sedation Scale (Modified OAA/S score) 6 Appears alert and awake, responds readily to name spoken in normal tone 5 Appears asleep but responds readily to name spoken in normal tone 4 Lethargic response to name spoken in normal tone 3 Responds only after name is called loudly or repeatedly 2 Responds only after mild prodding or shaking 1 Does not respond to mild prodding or shaking 0 Does not respond to noxious stimulus |
| Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine After Extubation | 1 day | Modified OAA/S score of patients receiving intranasal dexmedetomidine after extubation. Modified Observer's Assessment of Alertness/Sedation Scale (Modified OAA/S score): 6 Appears alert and awake, responds readily to name spoken in normal tone 5 Appears asleep but responds readily to name spoken in normal tone 4 Lethargic response to name spoken in normal tone 3 Responds only after name is called loudly or repeatedly 2 Responds only after mild prodding or shaking 1 Does not respond to mild prodding or shaking 0 Does not respond to noxious stimulus |
| Anxiety Score of Patients Receiving Intranasal Placebo Before Intranasal Drugs | 1 day | Anxiety score of Patients Receiving Intranasal Placebo Before Intranasal Drugs. The patients were taught to rate their anxiety levels using a 4-point anxiety score (1 = combative, 2 =anxious, 3 = calm, and 4 = amiable) |
| Anxiety Score of Patients Receiving Intranasal Dexmedetomidine Before Intranasal Drugs | 1 day | Anxiety score of Patients Receiving Intranasal dexmedetomidine Before Intranasal Drugs. The patients were taught to rate their anxiety levels using a 4-point anxiety score (1 = combative, 2 =anxious, 3 = calm, and 4 = amiable) |
| Anxiety Score of Patients Receiving Intranasal Placebo at Pre-induction | 1 day | Anxiety score of Patients Receiving Intranasal Placebo at Pre-induction. The patients were taught to rate their anxiety levels using a 4-point anxiety score (1 = combative, 2 =anxious, 3 = calm, and 4 = amiable) |
| Anxiety Score of Patients Receiving Intranasal Dexmedetomidine at Pre-induction | 1 day | Anxiety score of Patients Receiving Intranasal dexmedetomidine at Pre-induction. The patients were taught to rate their anxiety levels using a 4-point anxiety score (1 = combative, 2 =anxious, 3 = calm, and 4 = amiable) |
| Satisfaction Scores of Patients Receiving Intranasal Placebo | 1 day | Satisfaction scores of patients receiving intranasal placebo. satisfaction was assessed using a 3-point satisfaction score(1 = highly satisfactory, 2 = acceptable, and 3 = unacceptable). |
| Satisfaction Scores of Patients Receiving Intranasal Dexmedetomidine | 1 day | Satisfaction scores of patients receiving intranasal dexmedetomidine. Satisfaction used a 3-point satisfaction score(1 = highly satisfactory, 2 = acceptable, and 3 = unacceptable). |
| Time to Spontaneous Breathing of Patients Receiving Intranasal Placebo | 1 day | Time to spontaneous breathing of patients receiving intranasal placebo. The time elapsed between stopping anesthetic infusions and adequate ventilation |
| Time to Spontaneous Breathing of Patients Receiving Intranasal Dexmedetomidine | 1 day | Time to spontaneous breathing of patients receiving intranasal dexmedetomidine. The time elapsed between stopping anesthetic infusions and adequate ventilation |
| Time to Consciousness of Patients Receiving Intranasal Placebo | 1 day | Time to consciousness of patients receiving intranasal placebo. The time elapsed between stopping anesthetic infusions and consciousness. |
| Time to Consciousness of Patients Receiving Intranasal Dexmedetomidine | 1 day | Time to consciousness of patients receiving intranasal dexmedetomidine. The time elapsed between stopping anesthetic infusions and consciousness. |
| Time to Extubation of Patients Receiving Intranasal Placebo | 1 day | Time to extubation of patients receiving intranasal placebo. The time elapsed between stopping anesthetic infusions and extubation |
| Time to Extubation of Patients Receiving Intranasal Dexmedetomidine | 1 day | Time to extubation of patients receiving intranasal dexmedetomidine. The time elapsed between stopping anesthetic infusions and extubation |
| Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Tracheal Intubation | 1 day | Predicted effect-site concentrations of propofol after intranasal placebo at tracheal intubation. Propofol was infused intraoperatively to a target-controlled infusion (TCI) plasma concentration of 2.5μg∙ml-1 using DiprifusorTM software. The infusion rate was adjusted via plasma concentration increments of 0.5 μg∙ml-1 at 2-min intervals to maintain the Narcotrend index between 'D0' and 'E1' until the end of surgery. |
| Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Tracheal Intubation | 1 day | Predicted effect-site concentrations of propofol after intranasal dexmedetomidine at tracheal intubation. Propofol was infused intraoperatively to a TCI plasma concentration of 2.5μg∙ml-1 using DiprifusorTM software. The infusion rate was adjusted via plasma concentration increments of 0.5 μg∙ml-1 at 2-min intervals to maintain the Narcotrend index between 'D0' and 'E1' until the end of surgery. |
| Predicted Effect-site Concentrations of Propofol After Intranasal Placebo Before Inserting Operative Laryngoscope | 1 day | Predicted effect-site concentrations of propofol after intranasal placebo before inserting operative laryngoscope. Propofol was infused intraoperatively to a TCI plasma concentration of 2.5μg∙ml-1 using DiprifusorTM software. The infusion rate was adjusted via plasma concentration increments of 0.5 μg∙ml-1 at 2-min intervals to maintain the Narcotrend index between 'D0' and 'E1' until the end of surgery. |
| Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine Before Inserting Operative Laryngoscope | 1 day | Predicted effect-site concentrations of propofol after intranasal dexmedetomidine before inserting operative laryngoscope. Propofol was infused intraoperatively to a TCI plasma concentration of 2.5μg∙ml-1 using DiprifusorTM software. The infusion rate was adjusted via plasma concentration increments of 0.5 μg∙ml-1 at 2-min intervals to maintain the Narcotrend index between 'D0' and 'E1' until the end of surgery. |
| Predicted Effect-site Concentrations of Propofol After Intranasal Placebo on Removal of Operative Laryngoscope | 1 day | Predicted effect-site concentrations of propofol after intranasal placebo on removal of operative laryngoscope. Propofol was infused intraoperatively to a TCI plasma concentration of 2.5μg∙ml-1 using DiprifusorTM software. The infusion rate was adjusted via plasma concentration increments of 0.5 μg∙ml-1 at 2-min intervals to maintain the Narcotrend index between 'D0' and 'E1' until the end of surgery. |
| Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine on Removal of Operative Laryngoscope | 1 day | Predicted effect-site concentrations of propofol after intranasal dexmedetomidine on removal of operative laryngoscope. Propofol was infused intraoperatively to a TCI plasma concentration of 2.5μg∙ml-1 using DiprifusorTM software. The infusion rate was adjusted via plasma concentration increments of 0.5 μg∙ml-1 at 2-min intervals to maintain the Narcotrend index between 'D0' and 'E1' until the end of surgery. |
| Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Return of Spontaneous Breathing | 1 day | Predicted effect-site concentrations of propofol after intranasal placebo at return of spontaneous breathing. Propofol was infused intraoperatively to a TCI plasma concentration of 2.5μg∙ml-1 using DiprifusorTM software. The infusion rate was adjusted via plasma concentration increments of 0.5 μg∙ml-1 at 2-min intervals to maintain the Narcotrend index between 'D0' and 'E1' until the end of surgery. |
| Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Return of Spontaneous Breathing | 1 day | Predicted effect-site concentrations of propofol after intranasal dexmedetomidine at return of spontaneous breathing. Propofol was infused intraoperatively to a TCI plasma concentration of 2.5μg∙ml-1 using DiprifusorTM software. The infusion rate was adjusted via plasma concentration increments of 0.5 μg∙ml-1 at 2-min intervals to maintain the Narcotrend index between 'D0' and 'E1' until the end of surgery. |
| Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Emergence | 1 day | Predicted effect-site concentrations of propofol after intranasal placebo at emergence. Propofol was infused intraoperatively to a TCI plasma concentration of 2.5μg∙ml-1 using DiprifusorTM software. The infusion rate was adjusted via plasma concentration increments of 0.5 μg∙ml-1 at 2-min intervals to maintain the Narcotrend index between 'D0' and 'E1' until the end of surgery. |
| Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Emergence | 1 day | Predicted effect-site concentrations of propofol after intranasal dexmedetomidine at emergence. Propofol was infused intraoperatively to a TCI plasma concentration of 2.5μg∙ml-1 using DiprifusorTM software. The infusion rate was adjusted via plasma concentration increments of 0.5 μg∙ml-1 at 2-min intervals to maintain the Narcotrend index between 'D0' and 'E1' until the end of surgery. |
| Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Extubation | 1 day | Predicted effect-site concentrations of propofol after intranasal placebo at extubation. Propofol was infused intraoperatively to a TCI plasma concentration of 2.5μg∙ml-1 using DiprifusorTM software. The infusion rate was adjusted via plasma concentration increments of 0.5 μg∙ml-1 at 2-min intervals to maintain the Narcotrend index between 'D0' and 'E1' until the end of surgery. |
| Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Extubation | 1 day | Predicted effect-site concentrations of propofol after intranasal dexmedetomidine at extubation. Propofol was infused intraoperatively to a TCI plasma concentration of 2.5μg∙ml-1 using DiprifusorTM software. The infusion rate was adjusted via plasma concentration increments of 0.5 μg∙ml-1 at 2-min intervals to maintain the Narcotrend index between 'D0' and 'E1' until the end of surgery. |
| Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Tracheal Intubation | 1 day | Predicted effect-site concentrations of remifentanil after intranasal placebo at tracheal intubation. Remifentanil was infused to achieve a TCI plasma concentration of 3.0 ng∙ml-1 using the Minto pharmacokinetic model 24 and then adjusted to maintain the systolic blood pressure (SBP) at 25% of the pre-operative value and the HR at less than 90 bpm. To maintain a neuromuscular blockade, 0.15 mg∙kg-1 increments of rocuronium were infused upon observation of the first twitch in a train-of-four response with the nerve stimulator |
| Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Tracheal Intubation | 1 day | Predicted effect-site concentrations of remifentanil after intranasal dexmedetomidine at tracheal intubation. Remifentanil was infused to achieve a TCI plasma concentration of 3.0 ng∙ml-1 using the Minto pharmacokinetic model 24 and then adjusted to maintain the systolic blood pressure (SBP) at 25% of the pre-operative value and the HR at less than 90 bpm. To maintain a neuromuscular blockade, 0.15 mg∙kg-1 increments of rocuronium were infused upon observation of the first twitch in a train-of-four response with the nerve stimulator |
| Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo Before Inserting Operative Laryngoscope | 1 day | Predicted effect-site concentrations of remifentanil after intranasal placebo before inserting operative laryngoscope. Remifentanil was infused to achieve a TCI plasma concentration of 3.0 ng∙ml-1 using the Minto pharmacokinetic model 24 and then adjusted to maintain the systolic blood pressure (SBP) at 25% of the pre-operative value and the HR at less than 90 bpm. To maintain a neuromuscular blockade, 0.15 mg∙kg-1 increments of rocuronium were infused upon observation of the first twitch in a train-of-four response with the nerve stimulator |
| Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine Before Inserting Operative Laryngoscope | 1 day | Predicted effect-site concentrations of remifentanil after intranasal dexmedetomidine before inserting operative laryngoscope. Remifentanil was infused to achieve a TCI plasma concentration of 3.0 ng∙ml-1 using the Minto pharmacokinetic model 24 and then adjusted to maintain the systolic blood pressure (SBP) at 25% of the pre-operative value and the HR at less than 90 bpm. To maintain a neuromuscular blockade, 0.15 mg∙kg-1 increments of rocuronium were infused upon observation of the first twitch in a train-of-four response with the nerve stimulator |
| Baseline Characteristic Data (Weight) of Patients Receiving Intranasal Placebo | 1 day | Baseline characteristic data of patients receiving intranasal placebo The weights of 41 adult patients receiving intranasal placebo |
| Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine on Removal of Operative Laryngoscope | 1 day | Predicted effect-site concentrations of remifentanil after intranasal dexmedetomidine on removal of operative laryngoscope. Remifentanil was infused to achieve a TCI plasma concentration of 3.0 ng∙ml-1 using the Minto pharmacokinetic model 24 and then adjusted to maintain the systolic blood pressure (SBP) at 25% of the pre-operative value and the HR at less than 90 bpm. To maintain a neuromuscular blockade, 0.15 mg∙kg-1 increments of rocuronium were infused upon observation of the first twitch in a train-of-four response with the nerve stimulator |
| Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Return of Spontaneous Breathing | 1 day | Predicted effect-site concentrations of remifentanil after intranasal placebo at return of spontaneous breathing. Remifentanil was infused to achieve a TCI plasma concentration of 3.0 ng∙ml-1 using the Minto pharmacokinetic model 24 and then adjusted to maintain the systolic blood pressure (SBP) at 25% of the pre-operative value and the HR at less than 90 bpm. To maintain a neuromuscular blockade, 0.15 mg∙kg-1 increments of rocuronium were infused upon observation of the first twitch in a train-of-four response with the nerve stimulator |
| Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Return of Spontaneous Breathing | 1 day | Predicted effect-site concentrations of remifentanil after intranasal dexmedetomidine at return of spontaneous breathing. Remifentanil was infused to achieve a TCI plasma concentration of 3.0 ng∙ml-1 using the Minto pharmacokinetic model 24 and then adjusted to maintain the systolic blood pressure (SBP) at 25% of the pre-operative value and the HR at less than 90 bpm. To maintain a neuromuscular blockade, 0.15 mg∙kg-1 increments of rocuronium were infused upon observation of the first twitch in a train-of-four response with the nerve stimulator |
| Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Emergence | 1 day | Predicted effect-site concentrations of remifentanil after intranasal placebo at emergence. Remifentanil was infused to achieve a TCI plasma concentration of 3.0 ng∙ml-1 using the Minto pharmacokinetic model 24 and then adjusted to maintain the systolic blood pressure (SBP) at 25% of the pre-operative value and the HR at less than 90 bpm. To maintain a neuromuscular blockade, 0.15 mg∙kg-1 increments of rocuronium were infused upon observation of the first twitch in a train-of-four response with the nerve stimulator |
| Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Emergence | 1 day | Predicted effect-site concentrations of remifentanil after intranasal dexmedetomidine at emergence. Remifentanil was infused to achieve a TCI plasma concentration of 3.0 ng∙ml-1 using the Minto pharmacokinetic model 24 and then adjusted to maintain the systolic blood pressure (SBP) at 25% of the pre-operative value and the HR at less than 90 bpm. To maintain a neuromuscular blockade, 0.15 mg∙kg-1 increments of rocuronium were infused upon observation of the first twitch in a train-of-four response with the nerve stimulator |
| Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Extubation | 1 day | Predicted effect-site concentrations of remifentanil after intranasal placebo at extubation. Remifentanil was infused to achieve a TCI plasma concentration of 3.0 ng∙ml-1 using the Minto pharmacokinetic model 24 and then adjusted to maintain the systolic blood pressure (SBP) at 25% of the pre-operative value and the HR at less than 90 bpm. To maintain a neuromuscular blockade, 0.15 mg∙kg-1 increments of rocuronium were infused upon observation of the first twitch in a train-of-four response with the nerve stimulator |
| Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Extubation | 1 day | Predicted effect-site concentrations of remifentanil after intranasal dexmedetomidine at extubation. Remifentanil was infused to achieve a TCI plasma concentration of 3.0 ng∙ml-1 using the Minto pharmacokinetic model 24 and then adjusted to maintain the systolic blood pressure (SBP) at 25% of the pre-operative value and the HR at less than 90 bpm. To maintain a neuromuscular blockade, 0.15 mg∙kg-1 increments of rocuronium were infused upon observation of the first twitch in a train-of-four response with the nerve stimulator |
| HR in the Placebo Group Before Intranasal Drugs | 1 day | HR in the placebo group Before Intranasal Drugs HR was monitored by fiber-optic pulse oximetry during patient transfer from the ward to the operating room |
| HR in the Dexmedetomidine Group Before Intranasal Drugs | 1 day | HR in the dexmedetomidine group Before Intranasal Drugs . HR was monitored by fiber-optic pulse oximetry during patient transfer from the ward to the operating room |
| HR in the Placebo Group at Pre-induction | 1 day | HR in the placebo group at pre-induction. HR was monitored by fiber-optic pulse oximetry during patient transfer from the ward to the operating room |
| HR in the Dexmedetomidine Group at Pre-induction | 1 day | HR in the dexmedetomidine group at pre-induction. HR was monitored by fiber-optic pulse oximetry during patient transfer from the ward to the operating room |
| Number of Participants With VAS >50 | 1 day | Patients with postoperative analgesia in two groups. analgesic requests within 2 h after extubation were recorded. An investigator who was blinded from the grouping asked the patients to mark their pain level on a 0-100 visual analogue scale (VAS). A VAS higher than 50 was considered a worse outcome and need to be treated with intravenous 40 mg of parecoxib. |
| Patients With Postoperative Nausea in Two Groups | 1 day | Patients With postoperative nausea in Two Groups. Nausea or vomiting was treated with 4 mg of intravenous ondansetron. |
| Patients With Postoperative Vomiting in Two Groups | 1 day | Patients With postoperative vomiting in Two Groups. Nausea or vomiting was treated with 4 mg of intravenous ondansetron. |
| Patients With Postoperative Shivering in Two Groups | 1 day | Patients With postoperative shivering in Two Groups. the occurrence of postoperative shivering |
| Patients With Intra-operative Awareness in Two Groups | 1 day | Patients With intra-operative awareness in Two Groups. patients receiving intranasal placebo or dexmedetomidine |
| Visual Analogue Scale (VAS) in the Placebo Group | 1 day | An investigator who was blinded from the grouping asked the patients to mark their pain level on a 0-100 visual analogue scale (VAS). A VAS higher than 50 was considered a worse outcome and need to be treated with intravenous 40 mg of parecoxib. |
| Visual Analogue Scale (VAS) in the Dexmedetomidine (DEX) Group | 1 day | An investigator who was blinded from the grouping asked the patients to mark their pain level on a 0-100 visual analogue scale (VAS). A VAS higher than 50 was considered a worse outcome and need to be treated with intravenous 40 mg of parecoxib. |
| Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo on Removal of Operative Laryngoscope | 1 day | Predicted effect-site concentrations of remifentanil after intranasal placebo on removal of operative laryngoscope. Remifentanil was infused to achieve a TCI plasma concentration of 3.0 ng∙ml-1 using the Minto pharmacokinetic model 24 and then adjusted to maintain the systolic blood pressure (SBP) at 25% of the pre-operative value and the HR at less than 90 bpm. To maintain a neuromuscular blockade, 0.15 mg∙kg-1 increments of rocuronium were infused upon observation of the first twitch in a train-of-four response with the nerve stimulator |
| Baseline Characteristic Data (Weight) of Patients Receiving Intranasal Dexmedetomidine | 1 day | Baseline characteristic data of patients receiving intranasal dexmedetomidine The weights of 40 adult patients receiving intranasal dexmedetomidine |
| Baseline Characteristic Data (Height) of Patients Receiving Intranasal Placebo | 1 day | Baseline characteristic data of patients receiving intranasal placebo The heights of 41 adult patients receiving intranasal placebo |
| Baseline Characteristic Data (Height) of Patients Receiving Intranasal Dexmedetomidine | 1 day | Baseline characteristic data of patients receiving intranasal dexmedetomidine The heights of 40 adult patients receiving intranasal placebo |
| Baseline Characteristics (Sex)of Patients Receiving Intranasal Placebo or Dexmedetomidine | 1 day | Baseline characteristics (sex)of patients receiving intranasal placebo or dexmedetomidine The sex of 81 adult patients receiving intranasal placebo or dexmedetomidine |
| Baseline Characteristics (ASA Status) of Patients Receiving Intranasal Placebo or Dexmedetomidine | 1 day | American Society of Anesthesiologists (ASA) status of patients receiving intranasal placebo or dexmedetomidine. ASA I: No organic, physiologic, biochemical or psychiatric disturbance ASA II: A patient with mild systemic disease that results in no functional limitation. ASA III: A patient with severe systemic disease that results in functional impairment. ASA IV: Severe systemic disease that is a constant threat to life. ASA V: Moribund condition in a patient who is not expected to survive with or without the operation. ASA VI: Declared brain death patient whose organs are being harvested for transplantation. |
| Duration From Intranasal Drug Administration to Arrival at Operating Room of Patients Receiving Intranasal Placebo | 1 day | Duration from intranasal drug administration to arrival at operating room of patients receiving intranasal placebo surgical data of patients receiving intranasal placebo |
| Duration From Intranasal Drug Administration to Arrival at Operating Room of Patients Receiving Intranasal Dexmedetomidine | 1 day | Duration From Intranasal Drug Administration to Arrival at Operating Room of Patients Receiving Intranasal dexmedetomidine surgical data of patients receiving intranasal dexmedetomidine |
| Duration From Intranasal Drug Administration to Anesthesia Intubation of Patients Receiving Intranasal Placebo | 1 day | Duration from intranasal drug administration to anesthesia intubation of Patients Receiving Intranasal Placebo surgical data of patients receiving intranasal placebo |
| Duration From Intranasal Drug Administration to Anesthesia Intubation of Patients Receiving Intranasal Dexmedetomidine | 1 day | Duration of minutes From Intranasal Drug Administration to Anesthesia Intubation of Patients Receiving Intranasal dexmedetomidine surgical data of Patients Receiving Intranasal dexmedetomidine. |
| Duration of Anesthesia of Patients Receiving Intranasal Placebo | 1 day | Duration of anesthesia of patients receiving intranasal placebo Duration from anesthesia intubation to anesthesia ending |
Countries
China
Participant flow
Recruitment details
Patients of ASA physical status I or II, aged between 18 and 60 yrs, scheduled for elective suspension for remove of benign lesions under general anesthesia between September 2013 and April 2014
Pre-assignment details
40 patients receive intranasal dexmedetomidine (1 µg.kg-1 in 1 ml) and 41 patients receive intranasal saline (1 ml) 45-60 min before anesthetic induction.
Participants by arm
| Arm | Count |
|---|---|
| Dexmedetomidine intranasal dexmedetomidine
Dexmedetomidine: intranasal dexmedetomidine 1μg.kg-1，0.9% saline was added to make a final volume of 1 mL.all patients received intranasal medication at approximately 45-60 min before induction of anesthesia. | 40 |
| Placebo intranasal saline
placebo: 0.9% saline 1 mL all patients received intranasal medication at approximately 45-60 min before induction of anesthesia. | 41 |
| Total | 81 |
Baseline characteristics
| Characteristic | Dexmedetomidine | Placebo | Total |
|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical Between 18 and 65 years | 40 Participants | 41 Participants | 81 Participants |
| Age, Continuous | 45.9 years STANDARD_DEVIATION 10.1 | 43.6 years STANDARD_DEVIATION 9.2 | 44.75 years STANDARD_DEVIATION 9.6 |
| BMI | 22.49 kg per square meter STANDARD_DEVIATION 3.03 | 22.75 kg per square meter STANDARD_DEVIATION 3.07 | 22.62 kg per square meter STANDARD_DEVIATION 3.04 |
| Duration time Duration of surgery | 21.4 min STANDARD_DEVIATION 14.1 | 26.1 min STANDARD_DEVIATION 24.7 | 23.7 min STANDARD_DEVIATION 20.1 |
| Duration time from drug administration to arrival at OR | 42.3 min STANDARD_DEVIATION 20.4 | 39.3 min STANDARD_DEVIATION 18.2 | 40.8 min STANDARD_DEVIATION 19.2 |
| Duration time from drug administration to intubation | 62.1 min STANDARD_DEVIATION 23.4 | 60.8 min STANDARD_DEVIATION 18.9 | 61.5 min STANDARD_DEVIATION 21.2 |
| Height | 162.5 cm STANDARD_DEVIATION 8 | 162.2 cm STANDARD_DEVIATION 6.1 | 162.4 cm STANDARD_DEVIATION 7.1 |
| Sex: Female, Male Female | 24 Participants | 28 Participants | 52 Participants |
| Sex: Female, Male Male | 16 Participants | 13 Participants | 29 Participants |
| Weight | 59.4 kg STANDARD_DEVIATION 9.1 | 60.1 kg STANDARD_DEVIATION 10.4 | 59.76 kg STANDARD_DEVIATION 9.7 |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 20 / 40 | 34 / 41 |
| serious Total, serious adverse events | 0 / 40 | 0 / 41 |
Outcome results
Primary
Extubation Time After Intranasal Dexmedetomidine Premedication
The times from stopping anesthetic infusions to adequate ventilation, consciousness and extubation after intranasal dexmedetomidine or placebo administration
Time frame: 1 days
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Dexmedetomidine | Extubation Time After Intranasal Dexmedetomidine Premedication | Extubation time | 18.58 min | Standard Deviation 7.376 |
| Dexmedetomidine | Extubation Time After Intranasal Dexmedetomidine Premedication | consciousness time | 16.21 min | Standard Deviation 6.278 |
| Dexmedetomidine | Extubation Time After Intranasal Dexmedetomidine Premedication | adequate ventilation time | 8.24 min | Standard Deviation 3.183 |
| Placebo | Extubation Time After Intranasal Dexmedetomidine Premedication | Extubation time | 17.16 min | Standard Deviation 7.142 |
| Placebo | Extubation Time After Intranasal Dexmedetomidine Premedication | consciousness time | 14.74 min | Standard Deviation 6.353 |
| Placebo | Extubation Time After Intranasal Dexmedetomidine Premedication | adequate ventilation time | 7.87 min | Standard Deviation 2.648 |
Secondary
Anxiety Score of Patients Receiving Intranasal Placebo or Dexmedetomidine
4-point anxiety score: 1. = combative 2. = anxious 3. = calm 4. = amiable. Anxiety score \>2 was considered to be better for the preoperative patients.
Time frame: 1 day
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Placebo or Dexmedetomidine | Before intranasal drugs | 3 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Placebo or Dexmedetomidine | Pre-induction | 3 units on a scale |
| Placebo | Anxiety Score of Patients Receiving Intranasal Placebo or Dexmedetomidine | Before intranasal drugs | 3 units on a scale |
| Placebo | Anxiety Score of Patients Receiving Intranasal Placebo or Dexmedetomidine | Pre-induction | 3 units on a scale |
Secondary
Heart Rate (HR) of Patients Receiving Intranasal Placebo or Dexmedetomidine
Heart rate (HR) of patients receiving intranasal placebo or dexmedetomidine. HR was monitored in the study.
Time frame: 1 day
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Dexmedetomidine | Heart Rate (HR) of Patients Receiving Intranasal Placebo or Dexmedetomidine | Before intranasal drops | 71.75 bpm | Standard Deviation 1.493 |
| Dexmedetomidine | Heart Rate (HR) of Patients Receiving Intranasal Placebo or Dexmedetomidine | On arrival at operating room | 66.93 bpm | Standard Deviation 1.732 |
| Dexmedetomidine | Heart Rate (HR) of Patients Receiving Intranasal Placebo or Dexmedetomidine | At pre-induction | 65.63 bpm | Standard Deviation 1.502 |
| Dexmedetomidine | Heart Rate (HR) of Patients Receiving Intranasal Placebo or Dexmedetomidine | After tracheal intubation | 70.62 bpm | Standard Deviation 12.13 |
| Dexmedetomidine | Heart Rate (HR) of Patients Receiving Intranasal Placebo or Dexmedetomidine | After inserting operative laryngoscope | 75.48 bpm | Standard Deviation 16.55 |
| Dexmedetomidine | Heart Rate (HR) of Patients Receiving Intranasal Placebo or Dexmedetomidine | After removal of laryngoscope | 71.76 bpm | Standard Deviation 9.73 |
| Dexmedetomidine | Heart Rate (HR) of Patients Receiving Intranasal Placebo or Dexmedetomidine | On arrival at PACU | 67.14 bpm | Standard Deviation 9.08 |
| Dexmedetomidine | Heart Rate (HR) of Patients Receiving Intranasal Placebo or Dexmedetomidine | At emergency | 67.81 bpm | Standard Deviation 11.85 |
| Dexmedetomidine | Heart Rate (HR) of Patients Receiving Intranasal Placebo or Dexmedetomidine | After tracheal extubation | 64.24 bpm | Standard Deviation 13.19 |
| Dexmedetomidine | Heart Rate (HR) of Patients Receiving Intranasal Placebo or Dexmedetomidine | Before leaving PACU | 65.52 bpm | Standard Deviation 9.21 |
| Placebo | Heart Rate (HR) of Patients Receiving Intranasal Placebo or Dexmedetomidine | At emergency | 72.48 bpm | Standard Deviation 13.45 |
| Placebo | Heart Rate (HR) of Patients Receiving Intranasal Placebo or Dexmedetomidine | Before intranasal drops | 72.2 bpm | Standard Deviation 2.105 |
| Placebo | Heart Rate (HR) of Patients Receiving Intranasal Placebo or Dexmedetomidine | After removal of laryngoscope | 77.06 bpm | Standard Deviation 11.52 |
| Placebo | Heart Rate (HR) of Patients Receiving Intranasal Placebo or Dexmedetomidine | On arrival at operating room | 71.53 bpm | Standard Deviation 1.78 |
| Placebo | Heart Rate (HR) of Patients Receiving Intranasal Placebo or Dexmedetomidine | Before leaving PACU | 69.32 bpm | Standard Deviation 10.04 |
| Placebo | Heart Rate (HR) of Patients Receiving Intranasal Placebo or Dexmedetomidine | At pre-induction | 72 bpm | Standard Deviation 1.721 |
| Placebo | Heart Rate (HR) of Patients Receiving Intranasal Placebo or Dexmedetomidine | On arrival at PACU | 68.9 bpm | Standard Deviation 10.94 |
| Placebo | Heart Rate (HR) of Patients Receiving Intranasal Placebo or Dexmedetomidine | After tracheal intubation | 85.26 bpm | Standard Deviation 16.93 |
| Placebo | Heart Rate (HR) of Patients Receiving Intranasal Placebo or Dexmedetomidine | After tracheal extubation | 73.65 bpm | Standard Deviation 15.5 |
| Placebo | Heart Rate (HR) of Patients Receiving Intranasal Placebo or Dexmedetomidine | After inserting operative laryngoscope | 83.61 bpm | Standard Deviation 18.34 |
Secondary
Modified OAA/S Scores of Patients Receiving Intranasal Placebo or Dexmedetomidine
Modified Observer's Assessment of Alertness/Sedation scale (OAA/S) scores and 4 point anxiety score of patients receiving intranasal placebo or dexmedetomidine. Modified Observer's Assessment of Alertness/Sedation Scale: 6 Appears alert and awake, responds readily to name spoken in normal tone 5 Appears asleep but responds readily to name spoken in normal tone 4 Lethargic response to name spoken in normal tone 3 Responds only after name is called loudly or repeatedly 2 Responds only after mild prodding or shaking 1 Does not respond to mild prodding or shaking 0 Does not respond to noxious stimulus.
Time frame: 1 days
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Dexmedetomidine | Modified OAA/S Scores of Patients Receiving Intranasal Placebo or Dexmedetomidine | Before intranasal drugs | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Scores of Patients Receiving Intranasal Placebo or Dexmedetomidine | Pre-induction | 4 units on a scale |
| Dexmedetomidine | Modified OAA/S Scores of Patients Receiving Intranasal Placebo or Dexmedetomidine | After extubation | 4 units on a scale |
| Placebo | Modified OAA/S Scores of Patients Receiving Intranasal Placebo or Dexmedetomidine | Before intranasal drugs | 6 units on a scale |
| Placebo | Modified OAA/S Scores of Patients Receiving Intranasal Placebo or Dexmedetomidine | Pre-induction | 6 units on a scale |
| Placebo | Modified OAA/S Scores of Patients Receiving Intranasal Placebo or Dexmedetomidine | After extubation | 4 units on a scale |
Secondary
Number of Participants With Anxiety Score >2
satisfaction using a 3-point satisfaction score (1 = highly satisfactory, 2 = acceptable, and 3 = unacceptable) anxiety levels using a 4-point anxiety score (1 = combative, 2 = anxious, 3 = calm, and 4 = amiable) were collected before intranasal drugs and at pre-induction. Anxiety score \>2 was considered to be better for the patient.
Time frame: 1 day
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Dexmedetomidine | Number of Participants With Anxiety Score >2 | Before intranasal drugs | 25 participant |
| Dexmedetomidine | Number of Participants With Anxiety Score >2 | Pre-induction | 39 participant |
| Placebo | Number of Participants With Anxiety Score >2 | Before intranasal drugs | 23 participant |
| Placebo | Number of Participants With Anxiety Score >2 | Pre-induction | 29 participant |
Secondary
Number of Participants With Satisfaction Score <2
Patient satisfaction scores using a 3-point satisfaction score (1 = highly satisfactory, 2 = acceptable, and 3 = unacceptable) were collected when patients were discharged from the post-anesthesia care unit (PACU). Satisfaction score \<2 was considered to be better for the patient
Time frame: 1 day
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Dexmedetomidine | Number of Participants With Satisfaction Score <2 | 34 participant |
| Placebo | Number of Participants With Satisfaction Score <2 | 25 participant |
Secondary
Perioperative Bradycardia Episodes
Bradycardia was defined as heart rate (HR) \<45 bpm for more than 10 s.
Time frame: 1 day
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Dexmedetomidine | Perioperative Bradycardia Episodes | Bradycardiac episode:Pre-induction | 2 participant |
| Dexmedetomidine | Perioperative Bradycardia Episodes | Bradycardiac episode:After intubation | 1 participant |
| Dexmedetomidine | Perioperative Bradycardia Episodes | Bradycardiac episode:Intra-operative | 3 participant |
| Dexmedetomidine | Perioperative Bradycardia Episodes | Bradycardiac episode:After extubation | 7 participant |
| Placebo | Perioperative Bradycardia Episodes | Bradycardiac episode:After extubation | 5 participant |
| Placebo | Perioperative Bradycardia Episodes | Bradycardiac episode:Pre-induction | 0 participant |
| Placebo | Perioperative Bradycardia Episodes | Bradycardiac episode:Intra-operative | 5 participant |
| Placebo | Perioperative Bradycardia Episodes | Bradycardiac episode:After intubation | 1 participant |
Secondary
Perioperative Hypertonsion Episodes
Hypertension was defined as systolic blood pressure (SBP) increased 130% of the pre-operative value for more than 1 min.
Time frame: 1 day
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Dexmedetomidine | Perioperative Hypertonsion Episodes | Hypertensive episode:After intubation | 6 participant |
| Dexmedetomidine | Perioperative Hypertonsion Episodes | Hypertensive episode:Pre-induction | 1 participant |
| Dexmedetomidine | Perioperative Hypertonsion Episodes | Hypertensive episode:Intra-operative | 6 participant |
| Dexmedetomidine | Perioperative Hypertonsion Episodes | Hypertensive episode:After extubation | 14 participant |
| Placebo | Perioperative Hypertonsion Episodes | Hypertensive episode:After extubation | 5 participant |
| Placebo | Perioperative Hypertonsion Episodes | Hypertensive episode:Pre-induction | 0 participant |
| Placebo | Perioperative Hypertonsion Episodes | Hypertensive episode:After intubation | 0 participant |
| Placebo | Perioperative Hypertonsion Episodes | Hypertensive episode:Intra-operative | 5 participant |
Secondary
Perioperative Hypotension Episodes
Hypotension was defined as systolic blood pressure (SBP) decreased more than 30% of the pre-operative value for more than 1 min.
Time frame: 1 day
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Dexmedetomidine | Perioperative Hypotension Episodes | Hypotensive episode:Pre-induction | 0 participant |
| Dexmedetomidine | Perioperative Hypotension Episodes | Hypotensive episode:After intubation | 3 participant |
| Dexmedetomidine | Perioperative Hypotension Episodes | Hypotensive episode:Post-induction | 3 participant |
| Dexmedetomidine | Perioperative Hypotension Episodes | Hypotensive episode:After extubation | 1 participant |
| Placebo | Perioperative Hypotension Episodes | Hypotensive episode:After extubation | 0 participant |
| Placebo | Perioperative Hypotension Episodes | Hypotensive episode:Pre-induction | 2 participant |
| Placebo | Perioperative Hypotension Episodes | Hypotensive episode:Post-induction | 4 participant |
| Placebo | Perioperative Hypotension Episodes | Hypotensive episode:After intubation | 4 participant |
Secondary
Perioperative Tachycardia Episodes
Tachycardia was defined as heart rate (HR) \>100 bpm for more than 10 s.
Time frame: 1 day
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Dexmedetomidine | Perioperative Tachycardia Episodes | Tachycardiac episode:Pre-induction | 0 participant |
| Dexmedetomidine | Perioperative Tachycardia Episodes | Tachycardiac episode:After intubation | 1 participant |
| Dexmedetomidine | Perioperative Tachycardia Episodes | Tachycardiac episode:Intra-operative | 5 participant |
| Dexmedetomidine | Perioperative Tachycardia Episodes | Tachycardiac episode:After extubation | 2 participant |
| Placebo | Perioperative Tachycardia Episodes | Tachycardiac episode:After extubation | 9 participant |
| Placebo | Perioperative Tachycardia Episodes | Tachycardiac episode:Pre-induction | 0 participant |
| Placebo | Perioperative Tachycardia Episodes | Tachycardiac episode:Intra-operative | 11 participant |
| Placebo | Perioperative Tachycardia Episodes | Tachycardiac episode:After intubation | 8 participant |
Secondary
Systolic Blood Pressure（SBP）of Patients Receiving Intranasal Placebo or Dexmedetomidine
Systolic blood pressure（SBP）of Patients Receiving Intranasal Placebo or Dexmedetomidine.
Time frame: 1 day
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Dexmedetomidine | Systolic Blood Pressure（SBP）of Patients Receiving Intranasal Placebo or Dexmedetomidine | After removal of laryngoscope | 126.33 mmHg | Standard Deviation 15.96 |
| Dexmedetomidine | Systolic Blood Pressure（SBP）of Patients Receiving Intranasal Placebo or Dexmedetomidine | At pre-induction | 117.725 mmHg | Standard Deviation 2.73322 |
| Dexmedetomidine | Systolic Blood Pressure（SBP）of Patients Receiving Intranasal Placebo or Dexmedetomidine | On arrival at PACU | 128.52 mmHg | Standard Deviation 17.81 |
| Dexmedetomidine | Systolic Blood Pressure（SBP）of Patients Receiving Intranasal Placebo or Dexmedetomidine | After tracheal intubation | 121.57 mmHg | Standard Deviation 13.97 |
| Dexmedetomidine | Systolic Blood Pressure（SBP）of Patients Receiving Intranasal Placebo or Dexmedetomidine | At emergency | 132.76 mmHg | Standard Deviation 18.2 |
| Dexmedetomidine | Systolic Blood Pressure（SBP）of Patients Receiving Intranasal Placebo or Dexmedetomidine | On arrival at operating room | 120.5641 mmHg | Standard Deviation 2.96079 |
| Dexmedetomidine | Systolic Blood Pressure（SBP）of Patients Receiving Intranasal Placebo or Dexmedetomidine | After tracheal extubation | 136.76 mmHg | Standard Deviation 21.11 |
| Dexmedetomidine | Systolic Blood Pressure（SBP）of Patients Receiving Intranasal Placebo or Dexmedetomidine | After inserting operative laryngoscope | 130.00 mmHg | Standard Deviation 21.24 |
| Dexmedetomidine | Systolic Blood Pressure（SBP）of Patients Receiving Intranasal Placebo or Dexmedetomidine | Before leaving PACU | 130.00 mmHg | Standard Deviation 14.81 |
| Dexmedetomidine | Systolic Blood Pressure（SBP）of Patients Receiving Intranasal Placebo or Dexmedetomidine | Before intranasal drops | 120.8684 mmHg | Standard Deviation 2.07579 |
| Placebo | Systolic Blood Pressure（SBP）of Patients Receiving Intranasal Placebo or Dexmedetomidine | Before leaving PACU | 127.97 mmHg | Standard Deviation 13.41 |
| Placebo | Systolic Blood Pressure（SBP）of Patients Receiving Intranasal Placebo or Dexmedetomidine | Before intranasal drops | 116.8462 mmHg | Standard Deviation 1.71622 |
| Placebo | Systolic Blood Pressure（SBP）of Patients Receiving Intranasal Placebo or Dexmedetomidine | On arrival at operating room | 126.875 mmHg | Standard Deviation 2.6373 |
| Placebo | Systolic Blood Pressure（SBP）of Patients Receiving Intranasal Placebo or Dexmedetomidine | After tracheal intubation | 119.52 mmHg | Standard Deviation 14.94 |
| Placebo | Systolic Blood Pressure（SBP）of Patients Receiving Intranasal Placebo or Dexmedetomidine | After inserting operative laryngoscope | 123.65 mmHg | Standard Deviation 19.6 |
| Placebo | Systolic Blood Pressure（SBP）of Patients Receiving Intranasal Placebo or Dexmedetomidine | After removal of laryngoscope | 123.39 mmHg | Standard Deviation 10.16 |
| Placebo | Systolic Blood Pressure（SBP）of Patients Receiving Intranasal Placebo or Dexmedetomidine | On arrival at PACU | 123.90 mmHg | Standard Deviation 14.61 |
| Placebo | Systolic Blood Pressure（SBP）of Patients Receiving Intranasal Placebo or Dexmedetomidine | At emergency | 130.71 mmHg | Standard Deviation 16.67 |
| Placebo | Systolic Blood Pressure（SBP）of Patients Receiving Intranasal Placebo or Dexmedetomidine | After tracheal extubation | 132.13 mmHg | Standard Deviation 19.14 |
| Placebo | Systolic Blood Pressure（SBP）of Patients Receiving Intranasal Placebo or Dexmedetomidine | At pre-induction | 122.6 mmHg | Standard Deviation 2.5285 |
Other Pre-specified
Anxiety Score of Patients Receiving Intranasal Dexmedetomidine at Pre-induction
Anxiety score of Patients Receiving Intranasal dexmedetomidine at Pre-induction. The patients were taught to rate their anxiety levels using a 4-point anxiety score (1 = combative, 2 =anxious, 3 = calm, and 4 = amiable)
Time frame: 1 day
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Dexmedetomidine at Pre-induction | Patient number2 | 3 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Dexmedetomidine at Pre-induction | Patient number3 | 3 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Dexmedetomidine at Pre-induction | Patient number5 | 2 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Dexmedetomidine at Pre-induction | Patient number6 | 3 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Dexmedetomidine at Pre-induction | Patient number7 | 3 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Dexmedetomidine at Pre-induction | Patient number9 | 3 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Dexmedetomidine at Pre-induction | Patient number10 | 3 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Dexmedetomidine at Pre-induction | Patient number11 | 3 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Dexmedetomidine at Pre-induction | Patient number18 | 3 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Dexmedetomidine at Pre-induction | Patient number24 | 3 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Dexmedetomidine at Pre-induction | Patient number25 | 3 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Dexmedetomidine at Pre-induction | Patient number28 | 3 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Dexmedetomidine at Pre-induction | Patient number29 | 3 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Dexmedetomidine at Pre-induction | Patient number31 | 3 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Dexmedetomidine at Pre-induction | Patient number33 | 3 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Dexmedetomidine at Pre-induction | Patient number36 | 3 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Dexmedetomidine at Pre-induction | Patient number38 | 4 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Dexmedetomidine at Pre-induction | Patient number40 | 4 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Dexmedetomidine at Pre-induction | Patient number44 | 4 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Dexmedetomidine at Pre-induction | Patient number46 | 3 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Dexmedetomidine at Pre-induction | Patient number50 | 4 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Dexmedetomidine at Pre-induction | Patient number52 | 3 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Dexmedetomidine at Pre-induction | Patient number53 | 4 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Dexmedetomidine at Pre-induction | Patient number56 | 4 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Dexmedetomidine at Pre-induction | Patient number57 | 4 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Dexmedetomidine at Pre-induction | Patient number58 | 4 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Dexmedetomidine at Pre-induction | Patient number59 | 3 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Dexmedetomidine at Pre-induction | Patient number61 | 4 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Dexmedetomidine at Pre-induction | Patient number62 | 4 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Dexmedetomidine at Pre-induction | Patient number63 | 3 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Dexmedetomidine at Pre-induction | Patient number65 | 4 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Dexmedetomidine at Pre-induction | Patient number66 | 3 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Dexmedetomidine at Pre-induction | Patient number67 | 3 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Dexmedetomidine at Pre-induction | Patient number71 | 3 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Dexmedetomidine at Pre-induction | Patient number72 | 4 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Dexmedetomidine at Pre-induction | Patient number74 | 4 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Dexmedetomidine at Pre-induction | Patient number75 | 3 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Dexmedetomidine at Pre-induction | Patient number76 | 3 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Dexmedetomidine at Pre-induction | Patient number79 | 3 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Dexmedetomidine at Pre-induction | Patient number80 | 3 units on a scale |
Other Pre-specified
Anxiety Score of Patients Receiving Intranasal Dexmedetomidine Before Intranasal Drugs
Anxiety score of Patients Receiving Intranasal dexmedetomidine Before Intranasal Drugs. The patients were taught to rate their anxiety levels using a 4-point anxiety score (1 = combative, 2 =anxious, 3 = calm, and 4 = amiable)
Time frame: 1 day
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Dexmedetomidine Before Intranasal Drugs | Patient number2 | 3 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Dexmedetomidine Before Intranasal Drugs | Patient number3 | 3 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Dexmedetomidine Before Intranasal Drugs | Patient number5 | 2 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Dexmedetomidine Before Intranasal Drugs | Patient number6 | 2 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Dexmedetomidine Before Intranasal Drugs | Patient number7 | 2 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Dexmedetomidine Before Intranasal Drugs | Patient number9 | 3 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Dexmedetomidine Before Intranasal Drugs | Patient number10 | 3 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Dexmedetomidine Before Intranasal Drugs | Patient number11 | 3 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Dexmedetomidine Before Intranasal Drugs | Patient number18 | 2 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Dexmedetomidine Before Intranasal Drugs | Patient number24 | 2 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Dexmedetomidine Before Intranasal Drugs | Patient number25 | 2 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Dexmedetomidine Before Intranasal Drugs | Patient number28 | 3 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Dexmedetomidine Before Intranasal Drugs | Patient number29 | 2 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Dexmedetomidine Before Intranasal Drugs | Patient number31 | 3 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Dexmedetomidine Before Intranasal Drugs | Patient number33 | 2 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Dexmedetomidine Before Intranasal Drugs | Patient number36 | 3 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Dexmedetomidine Before Intranasal Drugs | Patient number38 | 3 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Dexmedetomidine Before Intranasal Drugs | Patient number40 | 3 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Dexmedetomidine Before Intranasal Drugs | Patient number44 | 3 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Dexmedetomidine Before Intranasal Drugs | Patient number46 | 3 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Dexmedetomidine Before Intranasal Drugs | Patient number50 | 2 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Dexmedetomidine Before Intranasal Drugs | Patient number52 | 3 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Dexmedetomidine Before Intranasal Drugs | Patient number53 | 3 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Dexmedetomidine Before Intranasal Drugs | Patient number56 | 2 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Dexmedetomidine Before Intranasal Drugs | Patient number57 | 3 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Dexmedetomidine Before Intranasal Drugs | Patient number58 | 3 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Dexmedetomidine Before Intranasal Drugs | Patient number59 | 3 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Dexmedetomidine Before Intranasal Drugs | Patient number61 | 3 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Dexmedetomidine Before Intranasal Drugs | Patient number62 | 2 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Dexmedetomidine Before Intranasal Drugs | Patient number63 | 3 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Dexmedetomidine Before Intranasal Drugs | Patient number65 | 3 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Dexmedetomidine Before Intranasal Drugs | Patient number66 | 3 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Dexmedetomidine Before Intranasal Drugs | Patient number67 | 3 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Dexmedetomidine Before Intranasal Drugs | Patient number71 | 2 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Dexmedetomidine Before Intranasal Drugs | Patient number72 | 3 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Dexmedetomidine Before Intranasal Drugs | Patient number74 | 3 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Dexmedetomidine Before Intranasal Drugs | Patient number75 | 3 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Dexmedetomidine Before Intranasal Drugs | Patient number76 | 2 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Dexmedetomidine Before Intranasal Drugs | Patient number79 | 2 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Dexmedetomidine Before Intranasal Drugs | Patient number80 | 2 units on a scale |
Other Pre-specified
Anxiety Score of Patients Receiving Intranasal Placebo at Pre-induction
Anxiety score of Patients Receiving Intranasal Placebo at Pre-induction. The patients were taught to rate their anxiety levels using a 4-point anxiety score (1 = combative, 2 =anxious, 3 = calm, and 4 = amiable)
Time frame: 1 day
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Placebo at Pre-induction | Patient number1 | 3 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Placebo at Pre-induction | Patient number4 | 2 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Placebo at Pre-induction | Patient number8 | 3 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Placebo at Pre-induction | Patient number12 | 3 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Placebo at Pre-induction | Patient number13 | 3 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Placebo at Pre-induction | Patient number14 | 3 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Placebo at Pre-induction | Patient number15 | 2 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Placebo at Pre-induction | Patient number16 | 3 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Placebo at Pre-induction | Patient number17 | 3 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Placebo at Pre-induction | Patient number19 | 3 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Placebo at Pre-induction | Patient number20 | 2 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Placebo at Pre-induction | Patient number21 | 3 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Placebo at Pre-induction | Patient number22 | 3 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Placebo at Pre-induction | Patient number23 | 3 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Placebo at Pre-induction | Patient number26 | 3 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Placebo at Pre-induction | Patient number27 | 3 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Placebo at Pre-induction | Patient number30 | 2 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Placebo at Pre-induction | Patient number32 | 2 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Placebo at Pre-induction | Patient number34 | 4 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Placebo at Pre-induction | Patient number35 | 4 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Placebo at Pre-induction | Patient number37 | 3 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Placebo at Pre-induction | Patient number39 | 3 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Placebo at Pre-induction | Patient number41 | 3 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Placebo at Pre-induction | Patient number42 | 2 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Placebo at Pre-induction | Patient number43 | 3 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Placebo at Pre-induction | Patient number45 | 3 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Placebo at Pre-induction | Patient number47 | 4 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Placebo at Pre-induction | Patient number48 | 4 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Placebo at Pre-induction | Patient number49 | 3 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Placebo at Pre-induction | Patient number51 | 3 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Placebo at Pre-induction | Patient number54 | 4 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Placebo at Pre-induction | Patient number55 | 3 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Placebo at Pre-induction | Patient number60 | 2 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Placebo at Pre-induction | Patient number64 | 2 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Placebo at Pre-induction | Patient number68 | 2 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Placebo at Pre-induction | Patient number69 | 3 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Placebo at Pre-induction | Patient number70 | 3 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Placebo at Pre-induction | Patient number73 | 3 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Placebo at Pre-induction | Patient number77 | 2 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Placebo at Pre-induction | Patient number78 | 2 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Placebo at Pre-induction | Patient number81 | 2 units on a scale |
Other Pre-specified
Anxiety Score of Patients Receiving Intranasal Placebo Before Intranasal Drugs
Anxiety score of Patients Receiving Intranasal Placebo Before Intranasal Drugs. The patients were taught to rate their anxiety levels using a 4-point anxiety score (1 = combative, 2 =anxious, 3 = calm, and 4 = amiable)
Time frame: 1 day
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Placebo Before Intranasal Drugs | Patient number1 | 3 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Placebo Before Intranasal Drugs | Patient number4 | 3 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Placebo Before Intranasal Drugs | Patient number8 | 3 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Placebo Before Intranasal Drugs | Patient number12 | 3 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Placebo Before Intranasal Drugs | Patient number13 | 3 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Placebo Before Intranasal Drugs | Patient number14 | 3 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Placebo Before Intranasal Drugs | Patient number15 | 2 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Placebo Before Intranasal Drugs | Patient number16 | 2 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Placebo Before Intranasal Drugs | Patient number17 | 3 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Placebo Before Intranasal Drugs | Patient number19 | 3 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Placebo Before Intranasal Drugs | Patient number20 | 3 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Placebo Before Intranasal Drugs | Patient number21 | 3 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Placebo Before Intranasal Drugs | Patient number22 | 2 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Placebo Before Intranasal Drugs | Patient number23 | 3 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Placebo Before Intranasal Drugs | Patient number26 | 2 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Placebo Before Intranasal Drugs | Patient number27 | 2 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Placebo Before Intranasal Drugs | Patient number30 | 2 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Placebo Before Intranasal Drugs | Patient number32 | 2 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Placebo Before Intranasal Drugs | Patient number34 | 3 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Placebo Before Intranasal Drugs | Patient number35 | 2 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Placebo Before Intranasal Drugs | Patient number37 | 3 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Placebo Before Intranasal Drugs | Patient number39 | 3 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Placebo Before Intranasal Drugs | Patient number41 | 2 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Placebo Before Intranasal Drugs | Patient number42 | 3 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Placebo Before Intranasal Drugs | Patient number43 | 2 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Placebo Before Intranasal Drugs | Patient number45 | 3 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Placebo Before Intranasal Drugs | Patient number47 | 3 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Placebo Before Intranasal Drugs | Patient number48 | 3 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Placebo Before Intranasal Drugs | Patient number49 | 3 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Placebo Before Intranasal Drugs | Patient number51 | 3 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Placebo Before Intranasal Drugs | Patient number54 | 2 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Placebo Before Intranasal Drugs | Patient number55 | 3 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Placebo Before Intranasal Drugs | Patient number60 | 2 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Placebo Before Intranasal Drugs | Patient number64 | 3 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Placebo Before Intranasal Drugs | Patient number68 | 2 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Placebo Before Intranasal Drugs | Patient number69 | 3 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Placebo Before Intranasal Drugs | Patient number70 | 2 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Placebo Before Intranasal Drugs | Patient number73 | 2 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Placebo Before Intranasal Drugs | Patient number77 | 2 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Placebo Before Intranasal Drugs | Patient number78 | 2 units on a scale |
| Dexmedetomidine | Anxiety Score of Patients Receiving Intranasal Placebo Before Intranasal Drugs | Patient number81 | 2 units on a scale |
Other Pre-specified
Baseline Characteristic Data (Height) of Patients Receiving Intranasal Dexmedetomidine
Baseline characteristic data of patients receiving intranasal dexmedetomidine The heights of 40 adult patients receiving intranasal placebo
Time frame: 1 day
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Dexmedetomidine | Baseline Characteristic Data (Height) of Patients Receiving Intranasal Dexmedetomidine | Patient number2 | 163 cm |
| Dexmedetomidine | Baseline Characteristic Data (Height) of Patients Receiving Intranasal Dexmedetomidine | Patient number3 | 155 cm |
| Dexmedetomidine | Baseline Characteristic Data (Height) of Patients Receiving Intranasal Dexmedetomidine | Patient number5 | 182 cm |
| Dexmedetomidine | Baseline Characteristic Data (Height) of Patients Receiving Intranasal Dexmedetomidine | Patient number6 | 169 cm |
| Dexmedetomidine | Baseline Characteristic Data (Height) of Patients Receiving Intranasal Dexmedetomidine | Patient number7 | 160 cm |
| Dexmedetomidine | Baseline Characteristic Data (Height) of Patients Receiving Intranasal Dexmedetomidine | Patient number9 | 150 cm |
| Dexmedetomidine | Baseline Characteristic Data (Height) of Patients Receiving Intranasal Dexmedetomidine | Patient number10 | 170 cm |
| Dexmedetomidine | Baseline Characteristic Data (Height) of Patients Receiving Intranasal Dexmedetomidine | Patient number11 | 158 cm |
| Dexmedetomidine | Baseline Characteristic Data (Height) of Patients Receiving Intranasal Dexmedetomidine | Patient number18 | 160 cm |
| Dexmedetomidine | Baseline Characteristic Data (Height) of Patients Receiving Intranasal Dexmedetomidine | Patient number24 | 165 cm |
| Dexmedetomidine | Baseline Characteristic Data (Height) of Patients Receiving Intranasal Dexmedetomidine | Patient number25 | 167 cm |
| Dexmedetomidine | Baseline Characteristic Data (Height) of Patients Receiving Intranasal Dexmedetomidine | Patient number28 | 170 cm |
| Dexmedetomidine | Baseline Characteristic Data (Height) of Patients Receiving Intranasal Dexmedetomidine | Patient number29 | 160 cm |
| Dexmedetomidine | Baseline Characteristic Data (Height) of Patients Receiving Intranasal Dexmedetomidine | Patient number31 | 167 cm |
| Dexmedetomidine | Baseline Characteristic Data (Height) of Patients Receiving Intranasal Dexmedetomidine | Patient number33 | 150 cm |
| Dexmedetomidine | Baseline Characteristic Data (Height) of Patients Receiving Intranasal Dexmedetomidine | Patient number36 | 162 cm |
| Dexmedetomidine | Baseline Characteristic Data (Height) of Patients Receiving Intranasal Dexmedetomidine | Patient number38 | 170 cm |
| Dexmedetomidine | Baseline Characteristic Data (Height) of Patients Receiving Intranasal Dexmedetomidine | Patient number40 | 160 cm |
| Dexmedetomidine | Baseline Characteristic Data (Height) of Patients Receiving Intranasal Dexmedetomidine | Patient number44 | 157 cm |
| Dexmedetomidine | Baseline Characteristic Data (Height) of Patients Receiving Intranasal Dexmedetomidine | Patient number46 | 160 cm |
| Dexmedetomidine | Baseline Characteristic Data (Height) of Patients Receiving Intranasal Dexmedetomidine | Patient number50 | 150 cm |
| Dexmedetomidine | Baseline Characteristic Data (Height) of Patients Receiving Intranasal Dexmedetomidine | Patient number52 | 151 cm |
| Dexmedetomidine | Baseline Characteristic Data (Height) of Patients Receiving Intranasal Dexmedetomidine | Patient number53 | 160 cm |
| Dexmedetomidine | Baseline Characteristic Data (Height) of Patients Receiving Intranasal Dexmedetomidine | Patient number56 | 176 cm |
| Dexmedetomidine | Baseline Characteristic Data (Height) of Patients Receiving Intranasal Dexmedetomidine | Patient number57 | 165 cm |
| Dexmedetomidine | Baseline Characteristic Data (Height) of Patients Receiving Intranasal Dexmedetomidine | Patient number58 | 172 cm |
| Dexmedetomidine | Baseline Characteristic Data (Height) of Patients Receiving Intranasal Dexmedetomidine | Patient number59 | 152 cm |
| Dexmedetomidine | Baseline Characteristic Data (Height) of Patients Receiving Intranasal Dexmedetomidine | Patient number61 | 174 cm |
| Dexmedetomidine | Baseline Characteristic Data (Height) of Patients Receiving Intranasal Dexmedetomidine | Patient number62 | 156 cm |
| Dexmedetomidine | Baseline Characteristic Data (Height) of Patients Receiving Intranasal Dexmedetomidine | Patient number63 | 167 cm |
| Dexmedetomidine | Baseline Characteristic Data (Height) of Patients Receiving Intranasal Dexmedetomidine | Patient number65 | 154 cm |
| Dexmedetomidine | Baseline Characteristic Data (Height) of Patients Receiving Intranasal Dexmedetomidine | Patient number66 | 155 cm |
| Dexmedetomidine | Baseline Characteristic Data (Height) of Patients Receiving Intranasal Dexmedetomidine | Patient number67 | 156 cm |
| Dexmedetomidine | Baseline Characteristic Data (Height) of Patients Receiving Intranasal Dexmedetomidine | Patient number71 | 157 cm |
| Dexmedetomidine | Baseline Characteristic Data (Height) of Patients Receiving Intranasal Dexmedetomidine | Patient number72 | 157 cm |
| Dexmedetomidine | Baseline Characteristic Data (Height) of Patients Receiving Intranasal Dexmedetomidine | Patient number74 | 167 cm |
| Dexmedetomidine | Baseline Characteristic Data (Height) of Patients Receiving Intranasal Dexmedetomidine | Patient number75 | 167 cm |
| Dexmedetomidine | Baseline Characteristic Data (Height) of Patients Receiving Intranasal Dexmedetomidine | Patient number76 | 161 cm |
| Dexmedetomidine | Baseline Characteristic Data (Height) of Patients Receiving Intranasal Dexmedetomidine | Patient number79 | 174 cm |
| Dexmedetomidine | Baseline Characteristic Data (Height) of Patients Receiving Intranasal Dexmedetomidine | Patient number80 | 173 cm |
Other Pre-specified
Baseline Characteristic Data (Height) of Patients Receiving Intranasal Placebo
Baseline characteristic data of patients receiving intranasal placebo The heights of 41 adult patients receiving intranasal placebo
Time frame: 1 day
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Dexmedetomidine | Baseline Characteristic Data (Height) of Patients Receiving Intranasal Placebo | Patient number1 | 163 cm |
| Dexmedetomidine | Baseline Characteristic Data (Height) of Patients Receiving Intranasal Placebo | Patient number4 | 171 cm |
| Dexmedetomidine | Baseline Characteristic Data (Height) of Patients Receiving Intranasal Placebo | Patient number8 | 177 cm |
| Dexmedetomidine | Baseline Characteristic Data (Height) of Patients Receiving Intranasal Placebo | Patient number12 | 170 cm |
| Dexmedetomidine | Baseline Characteristic Data (Height) of Patients Receiving Intranasal Placebo | Patient number13 | 168 cm |
| Dexmedetomidine | Baseline Characteristic Data (Height) of Patients Receiving Intranasal Placebo | Patient number14 | 155 cm |
| Dexmedetomidine | Baseline Characteristic Data (Height) of Patients Receiving Intranasal Placebo | Patient number15 | 160 cm |
| Dexmedetomidine | Baseline Characteristic Data (Height) of Patients Receiving Intranasal Placebo | Patient number16 | 165 cm |
| Dexmedetomidine | Baseline Characteristic Data (Height) of Patients Receiving Intranasal Placebo | Patient number17 | 165 cm |
| Dexmedetomidine | Baseline Characteristic Data (Height) of Patients Receiving Intranasal Placebo | Patient number19 | 163 cm |
| Dexmedetomidine | Baseline Characteristic Data (Height) of Patients Receiving Intranasal Placebo | Patient number20 | 162 cm |
| Dexmedetomidine | Baseline Characteristic Data (Height) of Patients Receiving Intranasal Placebo | Patient number21 | 157 cm |
| Dexmedetomidine | Baseline Characteristic Data (Height) of Patients Receiving Intranasal Placebo | Patient number22 | 160 cm |
| Dexmedetomidine | Baseline Characteristic Data (Height) of Patients Receiving Intranasal Placebo | Patient number23 | 159 cm |
| Dexmedetomidine | Baseline Characteristic Data (Height) of Patients Receiving Intranasal Placebo | Patient number26 | 157 cm |
| Dexmedetomidine | Baseline Characteristic Data (Height) of Patients Receiving Intranasal Placebo | Patient number27 | 168 cm |
| Dexmedetomidine | Baseline Characteristic Data (Height) of Patients Receiving Intranasal Placebo | Patient number30 | 168 cm |
| Dexmedetomidine | Baseline Characteristic Data (Height) of Patients Receiving Intranasal Placebo | Patient number32 | 160 cm |
| Dexmedetomidine | Baseline Characteristic Data (Height) of Patients Receiving Intranasal Placebo | Patient number34 | 162 cm |
| Dexmedetomidine | Baseline Characteristic Data (Height) of Patients Receiving Intranasal Placebo | Patient number35 | 165 cm |
| Dexmedetomidine | Baseline Characteristic Data (Height) of Patients Receiving Intranasal Placebo | Patient number37 | 170 cm |
| Dexmedetomidine | Baseline Characteristic Data (Height) of Patients Receiving Intranasal Placebo | Patient number39 | 161 cm |
| Dexmedetomidine | Baseline Characteristic Data (Height) of Patients Receiving Intranasal Placebo | Patient number41 | 160 cm |
| Dexmedetomidine | Baseline Characteristic Data (Height) of Patients Receiving Intranasal Placebo | Patient number42 | 154 cm |
| Dexmedetomidine | Baseline Characteristic Data (Height) of Patients Receiving Intranasal Placebo | Patient number43 | 157 cm |
| Dexmedetomidine | Baseline Characteristic Data (Height) of Patients Receiving Intranasal Placebo | Patient number45 | 150 cm |
| Dexmedetomidine | Baseline Characteristic Data (Height) of Patients Receiving Intranasal Placebo | Patient number47 | 156 cm |
| Dexmedetomidine | Baseline Characteristic Data (Height) of Patients Receiving Intranasal Placebo | Patient number48 | 155 cm |
| Dexmedetomidine | Baseline Characteristic Data (Height) of Patients Receiving Intranasal Placebo | Patient number49 | 160 cm |
| Dexmedetomidine | Baseline Characteristic Data (Height) of Patients Receiving Intranasal Placebo | Patient number51 | 173 cm |
| Dexmedetomidine | Baseline Characteristic Data (Height) of Patients Receiving Intranasal Placebo | Patient number54 | 169 cm |
| Dexmedetomidine | Baseline Characteristic Data (Height) of Patients Receiving Intranasal Placebo | Patient number55 | 165 cm |
| Dexmedetomidine | Baseline Characteristic Data (Height) of Patients Receiving Intranasal Placebo | Patient number60 | 162 cm |
| Dexmedetomidine | Baseline Characteristic Data (Height) of Patients Receiving Intranasal Placebo | Patient number64 | 155 cm |
| Dexmedetomidine | Baseline Characteristic Data (Height) of Patients Receiving Intranasal Placebo | Patient number68 | 155 cm |
| Dexmedetomidine | Baseline Characteristic Data (Height) of Patients Receiving Intranasal Placebo | Patient number69 | 164 cm |
| Dexmedetomidine | Baseline Characteristic Data (Height) of Patients Receiving Intranasal Placebo | Patient number70 | 163 cm |
| Dexmedetomidine | Baseline Characteristic Data (Height) of Patients Receiving Intranasal Placebo | Patient number73 | 162 cm |
| Dexmedetomidine | Baseline Characteristic Data (Height) of Patients Receiving Intranasal Placebo | Patient number77 | 160 cm |
| Dexmedetomidine | Baseline Characteristic Data (Height) of Patients Receiving Intranasal Placebo | Patient number78 | 154 cm |
| Dexmedetomidine | Baseline Characteristic Data (Height) of Patients Receiving Intranasal Placebo | Patient number81 | 172 cm |
Other Pre-specified
Baseline Characteristic Data (Weight) of Patients Receiving Intranasal Dexmedetomidine
Baseline characteristic data of patients receiving intranasal dexmedetomidine The weights of 40 adult patients receiving intranasal dexmedetomidine
Time frame: 1 day
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Dexmedetomidine | Baseline Characteristic Data (Weight) of Patients Receiving Intranasal Dexmedetomidine | Patient number2 | 61 kg |
| Dexmedetomidine | Baseline Characteristic Data (Weight) of Patients Receiving Intranasal Dexmedetomidine | Patient number3 | 50 kg |
| Dexmedetomidine | Baseline Characteristic Data (Weight) of Patients Receiving Intranasal Dexmedetomidine | Patient number5 | 58 kg |
| Dexmedetomidine | Baseline Characteristic Data (Weight) of Patients Receiving Intranasal Dexmedetomidine | Patient number6 | 52 kg |
| Dexmedetomidine | Baseline Characteristic Data (Weight) of Patients Receiving Intranasal Dexmedetomidine | Patient number7 | 64 kg |
| Dexmedetomidine | Baseline Characteristic Data (Weight) of Patients Receiving Intranasal Dexmedetomidine | Patient number9 | 62 kg |
| Dexmedetomidine | Baseline Characteristic Data (Weight) of Patients Receiving Intranasal Dexmedetomidine | Patient number10 | 56 kg |
| Dexmedetomidine | Baseline Characteristic Data (Weight) of Patients Receiving Intranasal Dexmedetomidine | Patient number11 | 53 kg |
| Dexmedetomidine | Baseline Characteristic Data (Weight) of Patients Receiving Intranasal Dexmedetomidine | Patient number18 | 59 kg |
| Dexmedetomidine | Baseline Characteristic Data (Weight) of Patients Receiving Intranasal Dexmedetomidine | Patient number24 | 54 kg |
| Dexmedetomidine | Baseline Characteristic Data (Weight) of Patients Receiving Intranasal Dexmedetomidine | Patient number25 | 65 kg |
| Dexmedetomidine | Baseline Characteristic Data (Weight) of Patients Receiving Intranasal Dexmedetomidine | Patient number28 | 68 kg |
| Dexmedetomidine | Baseline Characteristic Data (Weight) of Patients Receiving Intranasal Dexmedetomidine | Patient number29 | 58 kg |
| Dexmedetomidine | Baseline Characteristic Data (Weight) of Patients Receiving Intranasal Dexmedetomidine | Patient number31 | 78 kg |
| Dexmedetomidine | Baseline Characteristic Data (Weight) of Patients Receiving Intranasal Dexmedetomidine | Patient number33 | 53 kg |
| Dexmedetomidine | Baseline Characteristic Data (Weight) of Patients Receiving Intranasal Dexmedetomidine | Patient number36 | 75 kg |
| Dexmedetomidine | Baseline Characteristic Data (Weight) of Patients Receiving Intranasal Dexmedetomidine | Patient number38 | 75 kg |
| Dexmedetomidine | Baseline Characteristic Data (Weight) of Patients Receiving Intranasal Dexmedetomidine | Patient number40 | 59 kg |
| Dexmedetomidine | Baseline Characteristic Data (Weight) of Patients Receiving Intranasal Dexmedetomidine | Patient number44 | 73 kg |
| Dexmedetomidine | Baseline Characteristic Data (Weight) of Patients Receiving Intranasal Dexmedetomidine | Patient number46 | 56 kg |
| Dexmedetomidine | Baseline Characteristic Data (Weight) of Patients Receiving Intranasal Dexmedetomidine | Patient number50 | 46 kg |
| Dexmedetomidine | Baseline Characteristic Data (Weight) of Patients Receiving Intranasal Dexmedetomidine | Patient number52 | 54 kg |
| Dexmedetomidine | Baseline Characteristic Data (Weight) of Patients Receiving Intranasal Dexmedetomidine | Patient number53 | 47.5 kg |
| Dexmedetomidine | Baseline Characteristic Data (Weight) of Patients Receiving Intranasal Dexmedetomidine | Patient number56 | 75 kg |
| Dexmedetomidine | Baseline Characteristic Data (Weight) of Patients Receiving Intranasal Dexmedetomidine | Patient number57 | 80 kg |
| Dexmedetomidine | Baseline Characteristic Data (Weight) of Patients Receiving Intranasal Dexmedetomidine | Patient number58 | 69 kg |
| Dexmedetomidine | Baseline Characteristic Data (Weight) of Patients Receiving Intranasal Dexmedetomidine | Patient number59 | 57 kg |
| Dexmedetomidine | Baseline Characteristic Data (Weight) of Patients Receiving Intranasal Dexmedetomidine | Patient number61 | 65 kg |
| Dexmedetomidine | Baseline Characteristic Data (Weight) of Patients Receiving Intranasal Dexmedetomidine | Patient number62 | 58 kg |
| Dexmedetomidine | Baseline Characteristic Data (Weight) of Patients Receiving Intranasal Dexmedetomidine | Patient number63 | 60 kg |
| Dexmedetomidine | Baseline Characteristic Data (Weight) of Patients Receiving Intranasal Dexmedetomidine | Patient number65 | 45 kg |
| Dexmedetomidine | Baseline Characteristic Data (Weight) of Patients Receiving Intranasal Dexmedetomidine | Patient number66 | 52 kg |
| Dexmedetomidine | Baseline Characteristic Data (Weight) of Patients Receiving Intranasal Dexmedetomidine | Patient number67 | 45 kg |
| Dexmedetomidine | Baseline Characteristic Data (Weight) of Patients Receiving Intranasal Dexmedetomidine | Patient number71 | 52 kg |
| Dexmedetomidine | Baseline Characteristic Data (Weight) of Patients Receiving Intranasal Dexmedetomidine | Patient number72 | 52 kg |
| Dexmedetomidine | Baseline Characteristic Data (Weight) of Patients Receiving Intranasal Dexmedetomidine | Patient number74 | 58 kg |
| Dexmedetomidine | Baseline Characteristic Data (Weight) of Patients Receiving Intranasal Dexmedetomidine | Patient number75 | 60 kg |
| Dexmedetomidine | Baseline Characteristic Data (Weight) of Patients Receiving Intranasal Dexmedetomidine | Patient number76 | 50 kg |
| Dexmedetomidine | Baseline Characteristic Data (Weight) of Patients Receiving Intranasal Dexmedetomidine | Patient number79 | 60 kg |
| Dexmedetomidine | Baseline Characteristic Data (Weight) of Patients Receiving Intranasal Dexmedetomidine | Patient number80 | 72 kg |
Other Pre-specified
Baseline Characteristic Data (Weight) of Patients Receiving Intranasal Placebo
Baseline characteristic data of patients receiving intranasal placebo The weights of 41 adult patients receiving intranasal placebo
Time frame: 1 day
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Dexmedetomidine | Baseline Characteristic Data (Weight) of Patients Receiving Intranasal Placebo | Patient number1 | 54 kg |
| Dexmedetomidine | Baseline Characteristic Data (Weight) of Patients Receiving Intranasal Placebo | Patient number4 | 67 kg |
| Dexmedetomidine | Baseline Characteristic Data (Weight) of Patients Receiving Intranasal Placebo | Patient number8 | 80 kg |
| Dexmedetomidine | Baseline Characteristic Data (Weight) of Patients Receiving Intranasal Placebo | Patient number12 | 80 kg |
| Dexmedetomidine | Baseline Characteristic Data (Weight) of Patients Receiving Intranasal Placebo | Patient number13 | 65 kg |
| Dexmedetomidine | Baseline Characteristic Data (Weight) of Patients Receiving Intranasal Placebo | Patient number14 | 49 kg |
| Dexmedetomidine | Baseline Characteristic Data (Weight) of Patients Receiving Intranasal Placebo | Patient number15 | 60 kg |
| Dexmedetomidine | Baseline Characteristic Data (Weight) of Patients Receiving Intranasal Placebo | Patient number16 | 55 kg |
| Dexmedetomidine | Baseline Characteristic Data (Weight) of Patients Receiving Intranasal Placebo | Patient number17 | 73 kg |
| Dexmedetomidine | Baseline Characteristic Data (Weight) of Patients Receiving Intranasal Placebo | Patient number19 | 59 kg |
| Dexmedetomidine | Baseline Characteristic Data (Weight) of Patients Receiving Intranasal Placebo | Patient number20 | 71.5 kg |
| Dexmedetomidine | Baseline Characteristic Data (Weight) of Patients Receiving Intranasal Placebo | Patient number21 | 59 kg |
| Dexmedetomidine | Baseline Characteristic Data (Weight) of Patients Receiving Intranasal Placebo | Patient number22 | 57 kg |
| Dexmedetomidine | Baseline Characteristic Data (Weight) of Patients Receiving Intranasal Placebo | Patient number23 | 55 kg |
| Dexmedetomidine | Baseline Characteristic Data (Weight) of Patients Receiving Intranasal Placebo | Patient number26 | 59 kg |
| Dexmedetomidine | Baseline Characteristic Data (Weight) of Patients Receiving Intranasal Placebo | Patient number27 | 53 kg |
| Dexmedetomidine | Baseline Characteristic Data (Weight) of Patients Receiving Intranasal Placebo | Patient number30 | 45 kg |
| Dexmedetomidine | Baseline Characteristic Data (Weight) of Patients Receiving Intranasal Placebo | Patient number32 | 53 kg |
| Dexmedetomidine | Baseline Characteristic Data (Weight) of Patients Receiving Intranasal Placebo | Patient number34 | 58 kg |
| Dexmedetomidine | Baseline Characteristic Data (Weight) of Patients Receiving Intranasal Placebo | Patient number35 | 78 kg |
| Dexmedetomidine | Baseline Characteristic Data (Weight) of Patients Receiving Intranasal Placebo | Patient number37 | 65 kg |
| Dexmedetomidine | Baseline Characteristic Data (Weight) of Patients Receiving Intranasal Placebo | Patient number39 | 69 kg |
| Dexmedetomidine | Baseline Characteristic Data (Weight) of Patients Receiving Intranasal Placebo | Patient number41 | 47 kg |
| Dexmedetomidine | Baseline Characteristic Data (Weight) of Patients Receiving Intranasal Placebo | Patient number42 | 61 kg |
| Dexmedetomidine | Baseline Characteristic Data (Weight) of Patients Receiving Intranasal Placebo | Patient number43 | 50 kg |
| Dexmedetomidine | Baseline Characteristic Data (Weight) of Patients Receiving Intranasal Placebo | Patient number45 | 40 kg |
| Dexmedetomidine | Baseline Characteristic Data (Weight) of Patients Receiving Intranasal Placebo | Patient number47 | 55 kg |
| Dexmedetomidine | Baseline Characteristic Data (Weight) of Patients Receiving Intranasal Placebo | Patient number48 | 51 kg |
| Dexmedetomidine | Baseline Characteristic Data (Weight) of Patients Receiving Intranasal Placebo | Patient number49 | 50 kg |
| Dexmedetomidine | Baseline Characteristic Data (Weight) of Patients Receiving Intranasal Placebo | Patient number51 | 71 kg |
| Dexmedetomidine | Baseline Characteristic Data (Weight) of Patients Receiving Intranasal Placebo | Patient number54 | 69 kg |
| Dexmedetomidine | Baseline Characteristic Data (Weight) of Patients Receiving Intranasal Placebo | Patient number55 | 79 kg |
| Dexmedetomidine | Baseline Characteristic Data (Weight) of Patients Receiving Intranasal Placebo | Patient number60 | 60 kg |
| Dexmedetomidine | Baseline Characteristic Data (Weight) of Patients Receiving Intranasal Placebo | Patient number64 | 54 kg |
| Dexmedetomidine | Baseline Characteristic Data (Weight) of Patients Receiving Intranasal Placebo | Patient number68 | 47 kg |
| Dexmedetomidine | Baseline Characteristic Data (Weight) of Patients Receiving Intranasal Placebo | Patient number69 | 51 kg |
| Dexmedetomidine | Baseline Characteristic Data (Weight) of Patients Receiving Intranasal Placebo | Patient number70 | 60 kg |
| Dexmedetomidine | Baseline Characteristic Data (Weight) of Patients Receiving Intranasal Placebo | Patient number73 | 60 kg |
| Dexmedetomidine | Baseline Characteristic Data (Weight) of Patients Receiving Intranasal Placebo | Patient number77 | 57 kg |
| Dexmedetomidine | Baseline Characteristic Data (Weight) of Patients Receiving Intranasal Placebo | Patient number78 | 61 kg |
| Dexmedetomidine | Baseline Characteristic Data (Weight) of Patients Receiving Intranasal Placebo | Patient number81 | 78 kg |
Other Pre-specified
Baseline Characteristics (ASA Status) of Patients Receiving Intranasal Placebo or Dexmedetomidine
American Society of Anesthesiologists (ASA) status of patients receiving intranasal placebo or dexmedetomidine. ASA I: No organic, physiologic, biochemical or psychiatric disturbance ASA II: A patient with mild systemic disease that results in no functional limitation. ASA III: A patient with severe systemic disease that results in functional impairment. ASA IV: Severe systemic disease that is a constant threat to life. ASA V: Moribund condition in a patient who is not expected to survive with or without the operation. ASA VI: Declared brain death patient whose organs are being harvested for transplantation.
Time frame: 1 day
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Dexmedetomidine | Baseline Characteristics (ASA Status) of Patients Receiving Intranasal Placebo or Dexmedetomidine | ASA I | 36 participant |
| Dexmedetomidine | Baseline Characteristics (ASA Status) of Patients Receiving Intranasal Placebo or Dexmedetomidine | ASA II | 4 participant |
| Dexmedetomidine | Baseline Characteristics (ASA Status) of Patients Receiving Intranasal Placebo or Dexmedetomidine | ASA III | 0 participant |
| Dexmedetomidine | Baseline Characteristics (ASA Status) of Patients Receiving Intranasal Placebo or Dexmedetomidine | ASA IV | 0 participant |
| Dexmedetomidine | Baseline Characteristics (ASA Status) of Patients Receiving Intranasal Placebo or Dexmedetomidine | ASA V | 0 participant |
| Dexmedetomidine | Baseline Characteristics (ASA Status) of Patients Receiving Intranasal Placebo or Dexmedetomidine | ASA VI | 0 participant |
| Placebo | Baseline Characteristics (ASA Status) of Patients Receiving Intranasal Placebo or Dexmedetomidine | ASA V | 0 participant |
| Placebo | Baseline Characteristics (ASA Status) of Patients Receiving Intranasal Placebo or Dexmedetomidine | ASA I | 38 participant |
| Placebo | Baseline Characteristics (ASA Status) of Patients Receiving Intranasal Placebo or Dexmedetomidine | ASA IV | 0 participant |
| Placebo | Baseline Characteristics (ASA Status) of Patients Receiving Intranasal Placebo or Dexmedetomidine | ASA II | 3 participant |
| Placebo | Baseline Characteristics (ASA Status) of Patients Receiving Intranasal Placebo or Dexmedetomidine | ASA VI | 0 participant |
| Placebo | Baseline Characteristics (ASA Status) of Patients Receiving Intranasal Placebo or Dexmedetomidine | ASA III | 0 participant |
Other Pre-specified
Baseline Characteristics (Sex)of Patients Receiving Intranasal Placebo or Dexmedetomidine
Baseline characteristics (sex)of patients receiving intranasal placebo or dexmedetomidine The sex of 81 adult patients receiving intranasal placebo or dexmedetomidine
Time frame: 1 day
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Dexmedetomidine | Baseline Characteristics (Sex)of Patients Receiving Intranasal Placebo or Dexmedetomidine | Female | 24 participants |
| Dexmedetomidine | Baseline Characteristics (Sex)of Patients Receiving Intranasal Placebo or Dexmedetomidine | Male | 16 participants |
| Placebo | Baseline Characteristics (Sex)of Patients Receiving Intranasal Placebo or Dexmedetomidine | Male | 13 participants |
| Placebo | Baseline Characteristics (Sex)of Patients Receiving Intranasal Placebo or Dexmedetomidine | Female | 28 participants |
Other Pre-specified
Duration From Intranasal Drug Administration to Anesthesia Intubation of Patients Receiving Intranasal Dexmedetomidine
Duration of minutes From Intranasal Drug Administration to Anesthesia Intubation of Patients Receiving Intranasal dexmedetomidine surgical data of Patients Receiving Intranasal dexmedetomidine.
Time frame: 1 day
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Dexmedetomidine | Duration From Intranasal Drug Administration to Anesthesia Intubation of Patients Receiving Intranasal Dexmedetomidine | Patient number2 | 112 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Anesthesia Intubation of Patients Receiving Intranasal Dexmedetomidine | Patient number3 | 40 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Anesthesia Intubation of Patients Receiving Intranasal Dexmedetomidine | Patient number5 | 52 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Anesthesia Intubation of Patients Receiving Intranasal Dexmedetomidine | Patient number6 | 56 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Anesthesia Intubation of Patients Receiving Intranasal Dexmedetomidine | Patient number7 | 50 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Anesthesia Intubation of Patients Receiving Intranasal Dexmedetomidine | Patient number9 | 49 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Anesthesia Intubation of Patients Receiving Intranasal Dexmedetomidine | Patient number10 | 45 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Anesthesia Intubation of Patients Receiving Intranasal Dexmedetomidine | Patient number11 | 45 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Anesthesia Intubation of Patients Receiving Intranasal Dexmedetomidine | Patient number18 | 105 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Anesthesia Intubation of Patients Receiving Intranasal Dexmedetomidine | Patient number24 | 53 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Anesthesia Intubation of Patients Receiving Intranasal Dexmedetomidine | Patient number25 | 47 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Anesthesia Intubation of Patients Receiving Intranasal Dexmedetomidine | Patient number28 | 105 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Anesthesia Intubation of Patients Receiving Intranasal Dexmedetomidine | Patient number29 | 45 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Anesthesia Intubation of Patients Receiving Intranasal Dexmedetomidine | Patient number31 | 32 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Anesthesia Intubation of Patients Receiving Intranasal Dexmedetomidine | Patient number33 | 55 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Anesthesia Intubation of Patients Receiving Intranasal Dexmedetomidine | Patient number36 | 52 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Anesthesia Intubation of Patients Receiving Intranasal Dexmedetomidine | Patient number38 | 46 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Anesthesia Intubation of Patients Receiving Intranasal Dexmedetomidine | Patient number40 | 81 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Anesthesia Intubation of Patients Receiving Intranasal Dexmedetomidine | Patient number44 | 46 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Anesthesia Intubation of Patients Receiving Intranasal Dexmedetomidine | Patient number46 | 41 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Anesthesia Intubation of Patients Receiving Intranasal Dexmedetomidine | Patient number50 | 52 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Anesthesia Intubation of Patients Receiving Intranasal Dexmedetomidine | Patient number52 | 55 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Anesthesia Intubation of Patients Receiving Intranasal Dexmedetomidine | Patient number53 | 101 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Anesthesia Intubation of Patients Receiving Intranasal Dexmedetomidine | Patient number56 | 54 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Anesthesia Intubation of Patients Receiving Intranasal Dexmedetomidine | Patient number57 | 45 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Anesthesia Intubation of Patients Receiving Intranasal Dexmedetomidine | Patient number58 | 43 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Anesthesia Intubation of Patients Receiving Intranasal Dexmedetomidine | Patient number59 | 33 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Anesthesia Intubation of Patients Receiving Intranasal Dexmedetomidine | Patient number61 | 78 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Anesthesia Intubation of Patients Receiving Intranasal Dexmedetomidine | Patient number62 | 60 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Anesthesia Intubation of Patients Receiving Intranasal Dexmedetomidine | Patient number63 | 88 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Anesthesia Intubation of Patients Receiving Intranasal Dexmedetomidine | Patient number65 | 63 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Anesthesia Intubation of Patients Receiving Intranasal Dexmedetomidine | Patient number66 | 62 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Anesthesia Intubation of Patients Receiving Intranasal Dexmedetomidine | Patient number67 | 69 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Anesthesia Intubation of Patients Receiving Intranasal Dexmedetomidine | Patient number71 | 141 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Anesthesia Intubation of Patients Receiving Intranasal Dexmedetomidine | Patient number72 | 74 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Anesthesia Intubation of Patients Receiving Intranasal Dexmedetomidine | Patient number74 | 73 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Anesthesia Intubation of Patients Receiving Intranasal Dexmedetomidine | Patient number75 | 61 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Anesthesia Intubation of Patients Receiving Intranasal Dexmedetomidine | Patient number76 | 62 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Anesthesia Intubation of Patients Receiving Intranasal Dexmedetomidine | Patient number79 | 55 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Anesthesia Intubation of Patients Receiving Intranasal Dexmedetomidine | Patient number80 | 58 minutes |
Other Pre-specified
Duration From Intranasal Drug Administration to Anesthesia Intubation of Patients Receiving Intranasal Placebo
Duration from intranasal drug administration to anesthesia intubation of Patients Receiving Intranasal Placebo surgical data of patients receiving intranasal placebo
Time frame: 1 day
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Dexmedetomidine | Duration From Intranasal Drug Administration to Anesthesia Intubation of Patients Receiving Intranasal Placebo | Patient number1 | 60 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Anesthesia Intubation of Patients Receiving Intranasal Placebo | Patient number4 | 77 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Anesthesia Intubation of Patients Receiving Intranasal Placebo | Patient number8 | 96 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Anesthesia Intubation of Patients Receiving Intranasal Placebo | Patient number12 | 48 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Anesthesia Intubation of Patients Receiving Intranasal Placebo | Patient number13 | 54 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Anesthesia Intubation of Patients Receiving Intranasal Placebo | Patient number14 | 55 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Anesthesia Intubation of Patients Receiving Intranasal Placebo | Patient number15 | 77 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Anesthesia Intubation of Patients Receiving Intranasal Placebo | Patient number16 | 83 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Anesthesia Intubation of Patients Receiving Intranasal Placebo | Patient number17 | 84 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Anesthesia Intubation of Patients Receiving Intranasal Placebo | Patient number19 | 54 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Anesthesia Intubation of Patients Receiving Intranasal Placebo | Patient number20 | 70 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Anesthesia Intubation of Patients Receiving Intranasal Placebo | Patient number21 | 73 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Anesthesia Intubation of Patients Receiving Intranasal Placebo | Patient number22 | 45 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Anesthesia Intubation of Patients Receiving Intranasal Placebo | Patient number23 | 48 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Anesthesia Intubation of Patients Receiving Intranasal Placebo | Patient number26 | 45 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Anesthesia Intubation of Patients Receiving Intranasal Placebo | Patient number27 | 45 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Anesthesia Intubation of Patients Receiving Intranasal Placebo | Patient number30 | 50 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Anesthesia Intubation of Patients Receiving Intranasal Placebo | Patient number32 | 48 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Anesthesia Intubation of Patients Receiving Intranasal Placebo | Patient number34 | 51 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Anesthesia Intubation of Patients Receiving Intranasal Placebo | Patient number35 | 47 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Anesthesia Intubation of Patients Receiving Intranasal Placebo | Patient number37 | 47 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Anesthesia Intubation of Patients Receiving Intranasal Placebo | Patient number39 | 69 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Anesthesia Intubation of Patients Receiving Intranasal Placebo | Patient number41 | 54 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Anesthesia Intubation of Patients Receiving Intranasal Placebo | Patient number42 | 49 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Anesthesia Intubation of Patients Receiving Intranasal Placebo | Patient number43 | 46 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Anesthesia Intubation of Patients Receiving Intranasal Placebo | Patient number45 | 23 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Anesthesia Intubation of Patients Receiving Intranasal Placebo | Patient number47 | 40 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Anesthesia Intubation of Patients Receiving Intranasal Placebo | Patient number48 | 79 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Anesthesia Intubation of Patients Receiving Intranasal Placebo | Patient number49 | 57 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Anesthesia Intubation of Patients Receiving Intranasal Placebo | Patient number51 | 49 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Anesthesia Intubation of Patients Receiving Intranasal Placebo | Patient number54 | 53 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Anesthesia Intubation of Patients Receiving Intranasal Placebo | Patient number55 | 54 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Anesthesia Intubation of Patients Receiving Intranasal Placebo | Patient number60 | 69 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Anesthesia Intubation of Patients Receiving Intranasal Placebo | Patient number64 | 115 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Anesthesia Intubation of Patients Receiving Intranasal Placebo | Patient number68 | 62 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Anesthesia Intubation of Patients Receiving Intranasal Placebo | Patient number69 | 113 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Anesthesia Intubation of Patients Receiving Intranasal Placebo | Patient number70 | 68 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Anesthesia Intubation of Patients Receiving Intranasal Placebo | Patient number73 | 71 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Anesthesia Intubation of Patients Receiving Intranasal Placebo | Patient number77 | 54 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Anesthesia Intubation of Patients Receiving Intranasal Placebo | Patient number78 | 51 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Anesthesia Intubation of Patients Receiving Intranasal Placebo | Patient number81 | 54 minutes |
Other Pre-specified
Duration From Intranasal Drug Administration to Arrival at Operating Room of Patients Receiving Intranasal Dexmedetomidine
Duration From Intranasal Drug Administration to Arrival at Operating Room of Patients Receiving Intranasal dexmedetomidine surgical data of patients receiving intranasal dexmedetomidine
Time frame: 1 day
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Dexmedetomidine | Duration From Intranasal Drug Administration to Arrival at Operating Room of Patients Receiving Intranasal Dexmedetomidine | Patient number2 | 100 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Arrival at Operating Room of Patients Receiving Intranasal Dexmedetomidine | Patient number3 | 35 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Arrival at Operating Room of Patients Receiving Intranasal Dexmedetomidine | Patient number5 | 40 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Arrival at Operating Room of Patients Receiving Intranasal Dexmedetomidine | Patient number6 | 45 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Arrival at Operating Room of Patients Receiving Intranasal Dexmedetomidine | Patient number7 | 40 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Arrival at Operating Room of Patients Receiving Intranasal Dexmedetomidine | Patient number9 | 41 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Arrival at Operating Room of Patients Receiving Intranasal Dexmedetomidine | Patient number10 | 35 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Arrival at Operating Room of Patients Receiving Intranasal Dexmedetomidine | Patient number11 | 35 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Arrival at Operating Room of Patients Receiving Intranasal Dexmedetomidine | Patient number18 | 95 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Arrival at Operating Room of Patients Receiving Intranasal Dexmedetomidine | Patient number24 | 40 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Arrival at Operating Room of Patients Receiving Intranasal Dexmedetomidine | Patient number25 | 40 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Arrival at Operating Room of Patients Receiving Intranasal Dexmedetomidine | Patient number28 | 30 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Arrival at Operating Room of Patients Receiving Intranasal Dexmedetomidine | Patient number29 | 40 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Arrival at Operating Room of Patients Receiving Intranasal Dexmedetomidine | Patient number31 | 30 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Arrival at Operating Room of Patients Receiving Intranasal Dexmedetomidine | Patient number33 | 5 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Arrival at Operating Room of Patients Receiving Intranasal Dexmedetomidine | Patient number36 | 5 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Arrival at Operating Room of Patients Receiving Intranasal Dexmedetomidine | Patient number38 | 6 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Arrival at Operating Room of Patients Receiving Intranasal Dexmedetomidine | Patient number40 | 75 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Arrival at Operating Room of Patients Receiving Intranasal Dexmedetomidine | Patient number44 | 40 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Arrival at Operating Room of Patients Receiving Intranasal Dexmedetomidine | Patient number46 | 32 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Arrival at Operating Room of Patients Receiving Intranasal Dexmedetomidine | Patient number50 | 5 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Arrival at Operating Room of Patients Receiving Intranasal Dexmedetomidine | Patient number52 | 45 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Arrival at Operating Room of Patients Receiving Intranasal Dexmedetomidine | Patient number53 | 65 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Arrival at Operating Room of Patients Receiving Intranasal Dexmedetomidine | Patient number56 | 38 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Arrival at Operating Room of Patients Receiving Intranasal Dexmedetomidine | Patient number57 | 38 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Arrival at Operating Room of Patients Receiving Intranasal Dexmedetomidine | Patient number58 | 30 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Arrival at Operating Room of Patients Receiving Intranasal Dexmedetomidine | Patient number59 | 25 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Arrival at Operating Room of Patients Receiving Intranasal Dexmedetomidine | Patient number61 | 60 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Arrival at Operating Room of Patients Receiving Intranasal Dexmedetomidine | Patient number62 | 50 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Arrival at Operating Room of Patients Receiving Intranasal Dexmedetomidine | Patient number63 | 62 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Arrival at Operating Room of Patients Receiving Intranasal Dexmedetomidine | Patient number65 | 44 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Arrival at Operating Room of Patients Receiving Intranasal Dexmedetomidine | Patient number66 | 47 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Arrival at Operating Room of Patients Receiving Intranasal Dexmedetomidine | Patient number67 | 55 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Arrival at Operating Room of Patients Receiving Intranasal Dexmedetomidine | Patient number71 | 60 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Arrival at Operating Room of Patients Receiving Intranasal Dexmedetomidine | Patient number72 | 50 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Arrival at Operating Room of Patients Receiving Intranasal Dexmedetomidine | Patient number74 | 60 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Arrival at Operating Room of Patients Receiving Intranasal Dexmedetomidine | Patient number75 | 45 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Arrival at Operating Room of Patients Receiving Intranasal Dexmedetomidine | Patient number76 | 43 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Arrival at Operating Room of Patients Receiving Intranasal Dexmedetomidine | Patient number79 | 32 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Arrival at Operating Room of Patients Receiving Intranasal Dexmedetomidine | Patient number80 | 30 minutes |
Other Pre-specified
Duration From Intranasal Drug Administration to Arrival at Operating Room of Patients Receiving Intranasal Placebo
Duration from intranasal drug administration to arrival at operating room of patients receiving intranasal placebo surgical data of patients receiving intranasal placebo
Time frame: 1 day
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Dexmedetomidine | Duration From Intranasal Drug Administration to Arrival at Operating Room of Patients Receiving Intranasal Placebo | Patient number1 | 50 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Arrival at Operating Room of Patients Receiving Intranasal Placebo | Patient number4 | 45 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Arrival at Operating Room of Patients Receiving Intranasal Placebo | Patient number8 | 60 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Arrival at Operating Room of Patients Receiving Intranasal Placebo | Patient number12 | 30 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Arrival at Operating Room of Patients Receiving Intranasal Placebo | Patient number13 | 45 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Arrival at Operating Room of Patients Receiving Intranasal Placebo | Patient number14 | 45 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Arrival at Operating Room of Patients Receiving Intranasal Placebo | Patient number15 | 65 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Arrival at Operating Room of Patients Receiving Intranasal Placebo | Patient number16 | 75 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Arrival at Operating Room of Patients Receiving Intranasal Placebo | Patient number17 | 78 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Arrival at Operating Room of Patients Receiving Intranasal Placebo | Patient number19 | 35 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Arrival at Operating Room of Patients Receiving Intranasal Placebo | Patient number20 | 60 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Arrival at Operating Room of Patients Receiving Intranasal Placebo | Patient number21 | 60 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Arrival at Operating Room of Patients Receiving Intranasal Placebo | Patient number22 | 40 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Arrival at Operating Room of Patients Receiving Intranasal Placebo | Patient number23 | 0 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Arrival at Operating Room of Patients Receiving Intranasal Placebo | Patient number26 | 33 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Arrival at Operating Room of Patients Receiving Intranasal Placebo | Patient number27 | 35 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Arrival at Operating Room of Patients Receiving Intranasal Placebo | Patient number30 | 0 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Arrival at Operating Room of Patients Receiving Intranasal Placebo | Patient number32 | 40 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Arrival at Operating Room of Patients Receiving Intranasal Placebo | Patient number34 | 35 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Arrival at Operating Room of Patients Receiving Intranasal Placebo | Patient number35 | 45 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Arrival at Operating Room of Patients Receiving Intranasal Placebo | Patient number37 | 40 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Arrival at Operating Room of Patients Receiving Intranasal Placebo | Patient number39 | 55 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Arrival at Operating Room of Patients Receiving Intranasal Placebo | Patient number41 | 40 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Arrival at Operating Room of Patients Receiving Intranasal Placebo | Patient number42 | 40 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Arrival at Operating Room of Patients Receiving Intranasal Placebo | Patient number43 | 18 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Arrival at Operating Room of Patients Receiving Intranasal Placebo | Patient number45 | 15 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Arrival at Operating Room of Patients Receiving Intranasal Placebo | Patient number47 | 30 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Arrival at Operating Room of Patients Receiving Intranasal Placebo | Patient number48 | 35 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Arrival at Operating Room of Patients Receiving Intranasal Placebo | Patient number49 | 0 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Arrival at Operating Room of Patients Receiving Intranasal Placebo | Patient number51 | 40 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Arrival at Operating Room of Patients Receiving Intranasal Placebo | Patient number54 | 5 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Arrival at Operating Room of Patients Receiving Intranasal Placebo | Patient number55 | 40 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Arrival at Operating Room of Patients Receiving Intranasal Placebo | Patient number60 | 45 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Arrival at Operating Room of Patients Receiving Intranasal Placebo | Patient number64 | 27 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Arrival at Operating Room of Patients Receiving Intranasal Placebo | Patient number68 | 50 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Arrival at Operating Room of Patients Receiving Intranasal Placebo | Patient number69 | 40 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Arrival at Operating Room of Patients Receiving Intranasal Placebo | Patient number70 | 52 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Arrival at Operating Room of Patients Receiving Intranasal Placebo | Patient number73 | 45 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Arrival at Operating Room of Patients Receiving Intranasal Placebo | Patient number77 | 40 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Arrival at Operating Room of Patients Receiving Intranasal Placebo | Patient number78 | 40 minutes |
| Dexmedetomidine | Duration From Intranasal Drug Administration to Arrival at Operating Room of Patients Receiving Intranasal Placebo | Patient number81 | 40 minutes |
Other Pre-specified
Duration of Anesthesia of Patients Receiving Intranasal Dexmedetomidine
Duration of anesthesia of patients receiving intranasal dexmedetomidine Duration from anesthesia intubation to anesthesia ending
Time frame: 1 day
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Dexmedetomidine | Duration of Anesthesia of Patients Receiving Intranasal Dexmedetomidine | Patient number2 | 42 minutes |
| Dexmedetomidine | Duration of Anesthesia of Patients Receiving Intranasal Dexmedetomidine | Patient number3 | 28 minutes |
| Dexmedetomidine | Duration of Anesthesia of Patients Receiving Intranasal Dexmedetomidine | Patient number5 | 87 minutes |
| Dexmedetomidine | Duration of Anesthesia of Patients Receiving Intranasal Dexmedetomidine | Patient number6 | 53 minutes |
| Dexmedetomidine | Duration of Anesthesia of Patients Receiving Intranasal Dexmedetomidine | Patient number7 | 16 minutes |
| Dexmedetomidine | Duration of Anesthesia of Patients Receiving Intranasal Dexmedetomidine | Patient number9 | 73 minutes |
| Dexmedetomidine | Duration of Anesthesia of Patients Receiving Intranasal Dexmedetomidine | Patient number10 | 36 minutes |
| Dexmedetomidine | Duration of Anesthesia of Patients Receiving Intranasal Dexmedetomidine | Patient number11 | 30 minutes |
| Dexmedetomidine | Duration of Anesthesia of Patients Receiving Intranasal Dexmedetomidine | Patient number18 | 27 minutes |
| Dexmedetomidine | Duration of Anesthesia of Patients Receiving Intranasal Dexmedetomidine | Patient number24 | 24 minutes |
| Dexmedetomidine | Duration of Anesthesia of Patients Receiving Intranasal Dexmedetomidine | Patient number25 | 49 minutes |
| Dexmedetomidine | Duration of Anesthesia of Patients Receiving Intranasal Dexmedetomidine | Patient number28 | 35 minutes |
| Dexmedetomidine | Duration of Anesthesia of Patients Receiving Intranasal Dexmedetomidine | Patient number29 | 29 minutes |
| Dexmedetomidine | Duration of Anesthesia of Patients Receiving Intranasal Dexmedetomidine | Patient number31 | 37 minutes |
| Dexmedetomidine | Duration of Anesthesia of Patients Receiving Intranasal Dexmedetomidine | Patient number33 | 27 minutes |
| Dexmedetomidine | Duration of Anesthesia of Patients Receiving Intranasal Dexmedetomidine | Patient number36 | 31 minutes |
| Dexmedetomidine | Duration of Anesthesia of Patients Receiving Intranasal Dexmedetomidine | Patient number38 | 34 minutes |
| Dexmedetomidine | Duration of Anesthesia of Patients Receiving Intranasal Dexmedetomidine | Patient number40 | 36 minutes |
| Dexmedetomidine | Duration of Anesthesia of Patients Receiving Intranasal Dexmedetomidine | Patient number44 | 48 minutes |
| Dexmedetomidine | Duration of Anesthesia of Patients Receiving Intranasal Dexmedetomidine | Patient number46 | 31 minutes |
| Dexmedetomidine | Duration of Anesthesia of Patients Receiving Intranasal Dexmedetomidine | Patient number50 | 53 minutes |
| Dexmedetomidine | Duration of Anesthesia of Patients Receiving Intranasal Dexmedetomidine | Patient number52 | 37 minutes |
| Dexmedetomidine | Duration of Anesthesia of Patients Receiving Intranasal Dexmedetomidine | Patient number53 | 29 minutes |
| Dexmedetomidine | Duration of Anesthesia of Patients Receiving Intranasal Dexmedetomidine | Patient number56 | 31 minutes |
| Dexmedetomidine | Duration of Anesthesia of Patients Receiving Intranasal Dexmedetomidine | Patient number57 | 35 minutes |
| Dexmedetomidine | Duration of Anesthesia of Patients Receiving Intranasal Dexmedetomidine | Patient number58 | 80 minutes |
| Dexmedetomidine | Duration of Anesthesia of Patients Receiving Intranasal Dexmedetomidine | Patient number59 | 49 minutes |
| Dexmedetomidine | Duration of Anesthesia of Patients Receiving Intranasal Dexmedetomidine | Patient number61 | 52 minutes |
| Dexmedetomidine | Duration of Anesthesia of Patients Receiving Intranasal Dexmedetomidine | Patient number62 | 45 minutes |
| Dexmedetomidine | Duration of Anesthesia of Patients Receiving Intranasal Dexmedetomidine | Patient number63 | 30 minutes |
| Dexmedetomidine | Duration of Anesthesia of Patients Receiving Intranasal Dexmedetomidine | Patient number65 | 28 minutes |
| Dexmedetomidine | Duration of Anesthesia of Patients Receiving Intranasal Dexmedetomidine | Patient number66 | 17 minutes |
| Dexmedetomidine | Duration of Anesthesia of Patients Receiving Intranasal Dexmedetomidine | Patient number67 | 36 minutes |
| Dexmedetomidine | Duration of Anesthesia of Patients Receiving Intranasal Dexmedetomidine | Patient number71 | 50 minutes |
| Dexmedetomidine | Duration of Anesthesia of Patients Receiving Intranasal Dexmedetomidine | Patient number72 | 24 minutes |
| Dexmedetomidine | Duration of Anesthesia of Patients Receiving Intranasal Dexmedetomidine | Patient number74 | 31 minutes |
| Dexmedetomidine | Duration of Anesthesia of Patients Receiving Intranasal Dexmedetomidine | Patient number75 | 26 minutes |
| Dexmedetomidine | Duration of Anesthesia of Patients Receiving Intranasal Dexmedetomidine | Patient number76 | 25 minutes |
| Dexmedetomidine | Duration of Anesthesia of Patients Receiving Intranasal Dexmedetomidine | Patient number79 | 44 minutes |
| Dexmedetomidine | Duration of Anesthesia of Patients Receiving Intranasal Dexmedetomidine | Patient number80 | 72 minutes |
Other Pre-specified
Duration of Anesthesia of Patients Receiving Intranasal Placebo
Duration of anesthesia of patients receiving intranasal placebo Duration from anesthesia intubation to anesthesia ending
Time frame: 1 day
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Dexmedetomidine | Duration of Anesthesia of Patients Receiving Intranasal Placebo | Patient number47 | 40 minutes |
| Dexmedetomidine | Duration of Anesthesia of Patients Receiving Intranasal Placebo | Patient number48 | 56 minutes |
| Dexmedetomidine | Duration of Anesthesia of Patients Receiving Intranasal Placebo | Patient number49 | 43 minutes |
| Dexmedetomidine | Duration of Anesthesia of Patients Receiving Intranasal Placebo | Patient number32 | 30 minutes |
| Dexmedetomidine | Duration of Anesthesia of Patients Receiving Intranasal Placebo | Patient number34 | 28 minutes |
| Dexmedetomidine | Duration of Anesthesia of Patients Receiving Intranasal Placebo | Patient number35 | 28 minutes |
| Dexmedetomidine | Duration of Anesthesia of Patients Receiving Intranasal Placebo | Patient number37 | 43 minutes |
| Dexmedetomidine | Duration of Anesthesia of Patients Receiving Intranasal Placebo | Patient number39 | 35 minutes |
| Dexmedetomidine | Duration of Anesthesia of Patients Receiving Intranasal Placebo | Patient number41 | 40 minutes |
| Dexmedetomidine | Duration of Anesthesia of Patients Receiving Intranasal Placebo | Patient number42 | 28 minutes |
| Dexmedetomidine | Duration of Anesthesia of Patients Receiving Intranasal Placebo | Patient number43 | 34 minutes |
| Dexmedetomidine | Duration of Anesthesia of Patients Receiving Intranasal Placebo | Patient number45 | 69 minutes |
| Dexmedetomidine | Duration of Anesthesia of Patients Receiving Intranasal Placebo | Patient number51 | 78 minutes |
| Dexmedetomidine | Duration of Anesthesia of Patients Receiving Intranasal Placebo | Patient number54 | 54 minutes |
| Dexmedetomidine | Duration of Anesthesia of Patients Receiving Intranasal Placebo | Patient number55 | 38 minutes |
| Dexmedetomidine | Duration of Anesthesia of Patients Receiving Intranasal Placebo | Patient number60 | 88 minutes |
| Dexmedetomidine | Duration of Anesthesia of Patients Receiving Intranasal Placebo | Patient number64 | 38 minutes |
| Dexmedetomidine | Duration of Anesthesia of Patients Receiving Intranasal Placebo | Patient number68 | 31 minutes |
| Dexmedetomidine | Duration of Anesthesia of Patients Receiving Intranasal Placebo | Patient number69 | 106 minutes |
| Dexmedetomidine | Duration of Anesthesia of Patients Receiving Intranasal Placebo | Patient number70 | 29 minutes |
| Dexmedetomidine | Duration of Anesthesia of Patients Receiving Intranasal Placebo | Patient number73 | 31 minutes |
| Dexmedetomidine | Duration of Anesthesia of Patients Receiving Intranasal Placebo | Patient number77 | 21 minutes |
| Dexmedetomidine | Duration of Anesthesia of Patients Receiving Intranasal Placebo | Patient number78 | 49 minutes |
| Dexmedetomidine | Duration of Anesthesia of Patients Receiving Intranasal Placebo | Patient number81 | 60 minutes |
| Dexmedetomidine | Duration of Anesthesia of Patients Receiving Intranasal Placebo | Patient number1 | 45 minutes |
| Dexmedetomidine | Duration of Anesthesia of Patients Receiving Intranasal Placebo | Patient number4 | 33 minutes |
| Dexmedetomidine | Duration of Anesthesia of Patients Receiving Intranasal Placebo | Patient number8 | 26 minutes |
| Dexmedetomidine | Duration of Anesthesia of Patients Receiving Intranasal Placebo | Patient number12 | 37 minutes |
| Dexmedetomidine | Duration of Anesthesia of Patients Receiving Intranasal Placebo | Patient number13 | 45 minutes |
| Dexmedetomidine | Duration of Anesthesia of Patients Receiving Intranasal Placebo | Patient number14 | 34 minutes |
| Dexmedetomidine | Duration of Anesthesia of Patients Receiving Intranasal Placebo | Patient number15 | 18 minutes |
| Dexmedetomidine | Duration of Anesthesia of Patients Receiving Intranasal Placebo | Patient number16 | 37 minutes |
| Dexmedetomidine | Duration of Anesthesia of Patients Receiving Intranasal Placebo | Patient number17 | 54 minutes |
| Dexmedetomidine | Duration of Anesthesia of Patients Receiving Intranasal Placebo | Patient number19 | 48 minutes |
| Dexmedetomidine | Duration of Anesthesia of Patients Receiving Intranasal Placebo | Patient number20 | 40 minutes |
| Dexmedetomidine | Duration of Anesthesia of Patients Receiving Intranasal Placebo | Patient number21 | 29 minutes |
| Dexmedetomidine | Duration of Anesthesia of Patients Receiving Intranasal Placebo | Patient number22 | 31 minutes |
| Dexmedetomidine | Duration of Anesthesia of Patients Receiving Intranasal Placebo | Patient number23 | 32 minutes |
| Dexmedetomidine | Duration of Anesthesia of Patients Receiving Intranasal Placebo | Patient number26 | 158 minutes |
| Dexmedetomidine | Duration of Anesthesia of Patients Receiving Intranasal Placebo | Patient number27 | 38 minutes |
| Dexmedetomidine | Duration of Anesthesia of Patients Receiving Intranasal Placebo | Patient number30 | 41 minutes |
Other Pre-specified
Duration of Surgery of Patients Receiving Intranasal Dexmedetomidine
Duration of surgery of patients receiving intranasal dexmedetomidine. Duration from surgery beginning to anesthesia ending
Time frame: 1 day
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Dexmedetomidine | Duration of Surgery of Patients Receiving Intranasal Dexmedetomidine | Patient number2 | 19 minutes |
| Dexmedetomidine | Duration of Surgery of Patients Receiving Intranasal Dexmedetomidine | Patient number3 | 14 minutes |
| Dexmedetomidine | Duration of Surgery of Patients Receiving Intranasal Dexmedetomidine | Patient number5 | 61 minutes |
| Dexmedetomidine | Duration of Surgery of Patients Receiving Intranasal Dexmedetomidine | Patient number6 | 34 minutes |
| Dexmedetomidine | Duration of Surgery of Patients Receiving Intranasal Dexmedetomidine | Patient number7 | 4 minutes |
| Dexmedetomidine | Duration of Surgery of Patients Receiving Intranasal Dexmedetomidine | Patient number9 | 50 minutes |
| Dexmedetomidine | Duration of Surgery of Patients Receiving Intranasal Dexmedetomidine | Patient number10 | 22 minutes |
| Dexmedetomidine | Duration of Surgery of Patients Receiving Intranasal Dexmedetomidine | Patient number11 | 15 minutes |
| Dexmedetomidine | Duration of Surgery of Patients Receiving Intranasal Dexmedetomidine | Patient number18 | 13 minutes |
| Dexmedetomidine | Duration of Surgery of Patients Receiving Intranasal Dexmedetomidine | Patient number24 | 10 minutes |
| Dexmedetomidine | Duration of Surgery of Patients Receiving Intranasal Dexmedetomidine | Patient number25 | 27 minutes |
| Dexmedetomidine | Duration of Surgery of Patients Receiving Intranasal Dexmedetomidine | Patient number28 | 13 minutes |
| Dexmedetomidine | Duration of Surgery of Patients Receiving Intranasal Dexmedetomidine | Patient number29 | 9 minutes |
| Dexmedetomidine | Duration of Surgery of Patients Receiving Intranasal Dexmedetomidine | Patient number31 | 19 minutes |
| Dexmedetomidine | Duration of Surgery of Patients Receiving Intranasal Dexmedetomidine | Patient number33 | 9 minutes |
| Dexmedetomidine | Duration of Surgery of Patients Receiving Intranasal Dexmedetomidine | Patient number36 | 7 minutes |
| Dexmedetomidine | Duration of Surgery of Patients Receiving Intranasal Dexmedetomidine | Patient number38 | 18 minutes |
| Dexmedetomidine | Duration of Surgery of Patients Receiving Intranasal Dexmedetomidine | Patient number40 | 20 minutes |
| Dexmedetomidine | Duration of Surgery of Patients Receiving Intranasal Dexmedetomidine | Patient number44 | 34 minutes |
| Dexmedetomidine | Duration of Surgery of Patients Receiving Intranasal Dexmedetomidine | Patient number46 | 10 minutes |
| Dexmedetomidine | Duration of Surgery of Patients Receiving Intranasal Dexmedetomidine | Patient number50 | 30 minutes |
| Dexmedetomidine | Duration of Surgery of Patients Receiving Intranasal Dexmedetomidine | Patient number52 | 24 minutes |
| Dexmedetomidine | Duration of Surgery of Patients Receiving Intranasal Dexmedetomidine | Patient number53 | 16 minutes |
| Dexmedetomidine | Duration of Surgery of Patients Receiving Intranasal Dexmedetomidine | Patient number56 | 16 minutes |
| Dexmedetomidine | Duration of Surgery of Patients Receiving Intranasal Dexmedetomidine | Patient number58 | 61 minutes |
| Dexmedetomidine | Duration of Surgery of Patients Receiving Intranasal Dexmedetomidine | Patient number57 | 18 minutes |
| Dexmedetomidine | Duration of Surgery of Patients Receiving Intranasal Dexmedetomidine | Patient number59 | 29 minutes |
| Dexmedetomidine | Duration of Surgery of Patients Receiving Intranasal Dexmedetomidine | Patient number61 | 27 minutes |
| Dexmedetomidine | Duration of Surgery of Patients Receiving Intranasal Dexmedetomidine | Patient number62 | 25 minutes |
| Dexmedetomidine | Duration of Surgery of Patients Receiving Intranasal Dexmedetomidine | Patient number63 | 11 minutes |
| Dexmedetomidine | Duration of Surgery of Patients Receiving Intranasal Dexmedetomidine | Patient number65 | 12 minutes |
| Dexmedetomidine | Duration of Surgery of Patients Receiving Intranasal Dexmedetomidine | Patient number66 | 7 minutes |
| Dexmedetomidine | Duration of Surgery of Patients Receiving Intranasal Dexmedetomidine | Patient number67 | 21 minutes |
| Dexmedetomidine | Duration of Surgery of Patients Receiving Intranasal Dexmedetomidine | Patient number71 | 33 minutes |
| Dexmedetomidine | Duration of Surgery of Patients Receiving Intranasal Dexmedetomidine | Patient number72 | 9 minutes |
| Dexmedetomidine | Duration of Surgery of Patients Receiving Intranasal Dexmedetomidine | Patient number74 | 15 minutes |
| Dexmedetomidine | Duration of Surgery of Patients Receiving Intranasal Dexmedetomidine | Patient number75 | 9 minutes |
| Dexmedetomidine | Duration of Surgery of Patients Receiving Intranasal Dexmedetomidine | Patient number76 | 7 minutes |
| Dexmedetomidine | Duration of Surgery of Patients Receiving Intranasal Dexmedetomidine | Patient number79 | 29 minutes |
| Dexmedetomidine | Duration of Surgery of Patients Receiving Intranasal Dexmedetomidine | Patient number80 | 45 minutes |
Other Pre-specified
Duration of Surgery of Patients Receiving Intranasal Placebo
Duration of surgery of patients receiving intranasal placebo Duration from surgery beginning to anesthesia ending
Time frame: 1 day
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Dexmedetomidine | Duration of Surgery of Patients Receiving Intranasal Placebo | Patient number1 | 30 minutes |
| Dexmedetomidine | Duration of Surgery of Patients Receiving Intranasal Placebo | Patient number4 | 19 minutes |
| Dexmedetomidine | Duration of Surgery of Patients Receiving Intranasal Placebo | Patient number8 | 10 minutes |
| Dexmedetomidine | Duration of Surgery of Patients Receiving Intranasal Placebo | Patient number12 | 13 minutes |
| Dexmedetomidine | Duration of Surgery of Patients Receiving Intranasal Placebo | Patient number13 | 29 minutes |
| Dexmedetomidine | Duration of Surgery of Patients Receiving Intranasal Placebo | Patient number14 | 14 minutes |
| Dexmedetomidine | Duration of Surgery of Patients Receiving Intranasal Placebo | Patient number15 | 5 minutes |
| Dexmedetomidine | Duration of Surgery of Patients Receiving Intranasal Placebo | Patient number16 | 18 minutes |
| Dexmedetomidine | Duration of Surgery of Patients Receiving Intranasal Placebo | Patient number17 | 20 minutes |
| Dexmedetomidine | Duration of Surgery of Patients Receiving Intranasal Placebo | Patient number19 | 56 minutes |
| Dexmedetomidine | Duration of Surgery of Patients Receiving Intranasal Placebo | Patient number20 | 19 minutes |
| Dexmedetomidine | Duration of Surgery of Patients Receiving Intranasal Placebo | Patient number21 | 12 minutes |
| Dexmedetomidine | Duration of Surgery of Patients Receiving Intranasal Placebo | Patient number22 | 11 minutes |
| Dexmedetomidine | Duration of Surgery of Patients Receiving Intranasal Placebo | Patient number23 | 10 minutes |
| Dexmedetomidine | Duration of Surgery of Patients Receiving Intranasal Placebo | Patient number26 | 132 minutes |
| Dexmedetomidine | Duration of Surgery of Patients Receiving Intranasal Placebo | Patient number27 | 18 minutes |
| Dexmedetomidine | Duration of Surgery of Patients Receiving Intranasal Placebo | Patient number30 | 16 minutes |
| Dexmedetomidine | Duration of Surgery of Patients Receiving Intranasal Placebo | Patient number32 | 11 minutes |
| Dexmedetomidine | Duration of Surgery of Patients Receiving Intranasal Placebo | Patient number34 | 9 minutes |
| Dexmedetomidine | Duration of Surgery of Patients Receiving Intranasal Placebo | Patient number35 | 16 minutes |
| Dexmedetomidine | Duration of Surgery of Patients Receiving Intranasal Placebo | Patient number37 | 25 minutes |
| Dexmedetomidine | Duration of Surgery of Patients Receiving Intranasal Placebo | Patient number39 | 12 minutes |
| Dexmedetomidine | Duration of Surgery of Patients Receiving Intranasal Placebo | Patient number41 | 18 minutes |
| Dexmedetomidine | Duration of Surgery of Patients Receiving Intranasal Placebo | Patient number42 | 9 minutes |
| Dexmedetomidine | Duration of Surgery of Patients Receiving Intranasal Placebo | Patient number43 | 13 minutes |
| Dexmedetomidine | Duration of Surgery of Patients Receiving Intranasal Placebo | Patient number45 | 48 minutes |
| Dexmedetomidine | Duration of Surgery of Patients Receiving Intranasal Placebo | Patient number47 | 21 minutes |
| Dexmedetomidine | Duration of Surgery of Patients Receiving Intranasal Placebo | Patient number48 | 30 minutes |
| Dexmedetomidine | Duration of Surgery of Patients Receiving Intranasal Placebo | Patient number49 | 25 minutes |
| Dexmedetomidine | Duration of Surgery of Patients Receiving Intranasal Placebo | Patient number51 | 60 minutes |
| Dexmedetomidine | Duration of Surgery of Patients Receiving Intranasal Placebo | Patient number54 | 29 minutes |
| Dexmedetomidine | Duration of Surgery of Patients Receiving Intranasal Placebo | Patient number55 | 18 minutes |
| Dexmedetomidine | Duration of Surgery of Patients Receiving Intranasal Placebo | Patient number60 | 58 minutes |
| Dexmedetomidine | Duration of Surgery of Patients Receiving Intranasal Placebo | Patient number64 | 19 minutes |
| Dexmedetomidine | Duration of Surgery of Patients Receiving Intranasal Placebo | Patient number68 | 17 minutes |
| Dexmedetomidine | Duration of Surgery of Patients Receiving Intranasal Placebo | Patient number69 | 90 minutes |
| Dexmedetomidine | Duration of Surgery of Patients Receiving Intranasal Placebo | Patient number70 | 10 minutes |
| Dexmedetomidine | Duration of Surgery of Patients Receiving Intranasal Placebo | Patient number73 | 16 minutes |
| Dexmedetomidine | Duration of Surgery of Patients Receiving Intranasal Placebo | Patient number77 | 8 minutes |
| Dexmedetomidine | Duration of Surgery of Patients Receiving Intranasal Placebo | Patient number78 | 31 minutes |
| Dexmedetomidine | Duration of Surgery of Patients Receiving Intranasal Placebo | Patient number81 | 28 minutes |
Other Pre-specified
HR in the Dexmedetomidine Group at Pre-induction
HR in the dexmedetomidine group at pre-induction. HR was monitored by fiber-optic pulse oximetry during patient transfer from the ward to the operating room
Time frame: 1 day
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Dexmedetomidine | HR in the Dexmedetomidine Group at Pre-induction | Patient number61 | 63 bpm |
| Dexmedetomidine | HR in the Dexmedetomidine Group at Pre-induction | Patient number58 | 54 bpm |
| Dexmedetomidine | HR in the Dexmedetomidine Group at Pre-induction | Patient number2 | 62 bpm |
| Dexmedetomidine | HR in the Dexmedetomidine Group at Pre-induction | Patient number3 | 62 bpm |
| Dexmedetomidine | HR in the Dexmedetomidine Group at Pre-induction | Patient number5 | 93 bpm |
| Dexmedetomidine | HR in the Dexmedetomidine Group at Pre-induction | Patient number6 | 70 bpm |
| Dexmedetomidine | HR in the Dexmedetomidine Group at Pre-induction | Patient number59 | 54 bpm |
| Dexmedetomidine | HR in the Dexmedetomidine Group at Pre-induction | Patient number7 | 53 bpm |
| Dexmedetomidine | HR in the Dexmedetomidine Group at Pre-induction | Patient number9 | 75 bpm |
| Dexmedetomidine | HR in the Dexmedetomidine Group at Pre-induction | Patient number10 | 62 bpm |
| Dexmedetomidine | HR in the Dexmedetomidine Group at Pre-induction | Patient number11 | 55 bpm |
| Dexmedetomidine | HR in the Dexmedetomidine Group at Pre-induction | Patient number18 | 59 bpm |
| Dexmedetomidine | HR in the Dexmedetomidine Group at Pre-induction | Patient number24 | 68 bpm |
| Dexmedetomidine | HR in the Dexmedetomidine Group at Pre-induction | Patient number25 | 60 bpm |
| Dexmedetomidine | HR in the Dexmedetomidine Group at Pre-induction | Patient number28 | 88 bpm |
| Dexmedetomidine | HR in the Dexmedetomidine Group at Pre-induction | Patient number29 | 66 bpm |
| Dexmedetomidine | HR in the Dexmedetomidine Group at Pre-induction | Patient number31 | 64 bpm |
| Dexmedetomidine | HR in the Dexmedetomidine Group at Pre-induction | Patient number33 | 69 bpm |
| Dexmedetomidine | HR in the Dexmedetomidine Group at Pre-induction | Patient number36 | 61 bpm |
| Dexmedetomidine | HR in the Dexmedetomidine Group at Pre-induction | Patient number38 | 48 bpm |
| Dexmedetomidine | HR in the Dexmedetomidine Group at Pre-induction | Patient number40 | 55 bpm |
| Dexmedetomidine | HR in the Dexmedetomidine Group at Pre-induction | Patient number44 | 76 bpm |
| Dexmedetomidine | HR in the Dexmedetomidine Group at Pre-induction | Patient number46 | 80 bpm |
| Dexmedetomidine | HR in the Dexmedetomidine Group at Pre-induction | Patient number50 | 70 bpm |
| Dexmedetomidine | HR in the Dexmedetomidine Group at Pre-induction | Patient number52 | 72 bpm |
| Dexmedetomidine | HR in the Dexmedetomidine Group at Pre-induction | Patient number53 | 64 bpm |
| Dexmedetomidine | HR in the Dexmedetomidine Group at Pre-induction | Patient number56 | 68 bpm |
| Dexmedetomidine | HR in the Dexmedetomidine Group at Pre-induction | Patient number57 | 63 bpm |
| Dexmedetomidine | HR in the Dexmedetomidine Group at Pre-induction | Patient number62 | 83 bpm |
| Dexmedetomidine | HR in the Dexmedetomidine Group at Pre-induction | Patient number63 | 73 bpm |
| Dexmedetomidine | HR in the Dexmedetomidine Group at Pre-induction | Patient number65 | 68 bpm |
| Dexmedetomidine | HR in the Dexmedetomidine Group at Pre-induction | Patient number66 | 66 bpm |
| Dexmedetomidine | HR in the Dexmedetomidine Group at Pre-induction | Patient number67 | 61 bpm |
| Dexmedetomidine | HR in the Dexmedetomidine Group at Pre-induction | Patient number71 | 53 bpm |
| Dexmedetomidine | HR in the Dexmedetomidine Group at Pre-induction | Patient number72 | 64 bpm |
| Dexmedetomidine | HR in the Dexmedetomidine Group at Pre-induction | Patient number74 | 55 bpm |
| Dexmedetomidine | HR in the Dexmedetomidine Group at Pre-induction | Patient number75 | 67 bpm |
| Dexmedetomidine | HR in the Dexmedetomidine Group at Pre-induction | Patient number76 | 71 bpm |
| Dexmedetomidine | HR in the Dexmedetomidine Group at Pre-induction | Patient number79 | 62 bpm |
| Dexmedetomidine | HR in the Dexmedetomidine Group at Pre-induction | Patient number80 | 65 bpm |
Other Pre-specified
HR in the Dexmedetomidine Group Before Intranasal Drugs
HR in the dexmedetomidine group Before Intranasal Drugs . HR was monitored by fiber-optic pulse oximetry during patient transfer from the ward to the operating room
Time frame: 1 day
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Dexmedetomidine | HR in the Dexmedetomidine Group Before Intranasal Drugs | Patient number56 | 75 bpm |
| Dexmedetomidine | HR in the Dexmedetomidine Group Before Intranasal Drugs | Patient number2 | 73 bpm |
| Dexmedetomidine | HR in the Dexmedetomidine Group Before Intranasal Drugs | Patient number3 | 68 bpm |
| Dexmedetomidine | HR in the Dexmedetomidine Group Before Intranasal Drugs | Patient number5 | 80 bpm |
| Dexmedetomidine | HR in the Dexmedetomidine Group Before Intranasal Drugs | Patient number6 | 80 bpm |
| Dexmedetomidine | HR in the Dexmedetomidine Group Before Intranasal Drugs | Patient number7 | 67 bpm |
| Dexmedetomidine | HR in the Dexmedetomidine Group Before Intranasal Drugs | Patient number9 | 70 bpm |
| Dexmedetomidine | HR in the Dexmedetomidine Group Before Intranasal Drugs | Patient number10 | 69 bpm |
| Dexmedetomidine | HR in the Dexmedetomidine Group Before Intranasal Drugs | Patient number11 | 70 bpm |
| Dexmedetomidine | HR in the Dexmedetomidine Group Before Intranasal Drugs | Patient number18 | 75 bpm |
| Dexmedetomidine | HR in the Dexmedetomidine Group Before Intranasal Drugs | Patient number24 | 80 bpm |
| Dexmedetomidine | HR in the Dexmedetomidine Group Before Intranasal Drugs | Patient number25 | 75 bpm |
| Dexmedetomidine | HR in the Dexmedetomidine Group Before Intranasal Drugs | Patient number28 | 87 bpm |
| Dexmedetomidine | HR in the Dexmedetomidine Group Before Intranasal Drugs | Patient number29 | 73 bpm |
| Dexmedetomidine | HR in the Dexmedetomidine Group Before Intranasal Drugs | Patient number33 | 60 bpm |
| Dexmedetomidine | HR in the Dexmedetomidine Group Before Intranasal Drugs | Patient number33 | 90 bpm |
| Dexmedetomidine | HR in the Dexmedetomidine Group Before Intranasal Drugs | Patient number36 | 73 bpm |
| Dexmedetomidine | HR in the Dexmedetomidine Group Before Intranasal Drugs | Patient number38 | 58 bpm |
| Dexmedetomidine | HR in the Dexmedetomidine Group Before Intranasal Drugs | Patient number40 | 66 bpm |
| Dexmedetomidine | HR in the Dexmedetomidine Group Before Intranasal Drugs | Patient number44 | 80 bpm |
| Dexmedetomidine | HR in the Dexmedetomidine Group Before Intranasal Drugs | Patient number46 | 85 bpm |
| Dexmedetomidine | HR in the Dexmedetomidine Group Before Intranasal Drugs | Patient number50 | 71 bpm |
| Dexmedetomidine | HR in the Dexmedetomidine Group Before Intranasal Drugs | Patient number52 | 79 bpm |
| Dexmedetomidine | HR in the Dexmedetomidine Group Before Intranasal Drugs | Patient number53 | 69 bpm |
| Dexmedetomidine | HR in the Dexmedetomidine Group Before Intranasal Drugs | Patient number57 | 76 bpm |
| Dexmedetomidine | HR in the Dexmedetomidine Group Before Intranasal Drugs | Patient number58 | 61 bpm |
| Dexmedetomidine | HR in the Dexmedetomidine Group Before Intranasal Drugs | Patient number59 | 70 bpm |
| Dexmedetomidine | HR in the Dexmedetomidine Group Before Intranasal Drugs | Patient number61 | 55 bpm |
| Dexmedetomidine | HR in the Dexmedetomidine Group Before Intranasal Drugs | Patient number62 | 97 bpm |
| Dexmedetomidine | HR in the Dexmedetomidine Group Before Intranasal Drugs | Patient number63 | 68 bpm |
| Dexmedetomidine | HR in the Dexmedetomidine Group Before Intranasal Drugs | Patient number65 | 65 bpm |
| Dexmedetomidine | HR in the Dexmedetomidine Group Before Intranasal Drugs | Patient number66 | 65 bpm |
| Dexmedetomidine | HR in the Dexmedetomidine Group Before Intranasal Drugs | Patient number67 | 67 bpm |
| Dexmedetomidine | HR in the Dexmedetomidine Group Before Intranasal Drugs | Patient number71 | 80 bpm |
| Dexmedetomidine | HR in the Dexmedetomidine Group Before Intranasal Drugs | Patient number72 | 55 bpm |
| Dexmedetomidine | HR in the Dexmedetomidine Group Before Intranasal Drugs | Patient number74 | 62 bpm |
| Dexmedetomidine | HR in the Dexmedetomidine Group Before Intranasal Drugs | Patient number75 | 69 bpm |
| Dexmedetomidine | HR in the Dexmedetomidine Group Before Intranasal Drugs | Patient number76 | 80 bpm |
| Dexmedetomidine | HR in the Dexmedetomidine Group Before Intranasal Drugs | Patient number79 | 55 bpm |
| Dexmedetomidine | HR in the Dexmedetomidine Group Before Intranasal Drugs | Patient number80 | 69 bpm |
Other Pre-specified
HR in the Placebo Group at Pre-induction
HR in the placebo group at pre-induction. HR was monitored by fiber-optic pulse oximetry during patient transfer from the ward to the operating room
Time frame: 1 day
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Dexmedetomidine | HR in the Placebo Group at Pre-induction | Patient number48 | 61 bpm |
| Dexmedetomidine | HR in the Placebo Group at Pre-induction | Patient number1 | 76 bpm |
| Dexmedetomidine | HR in the Placebo Group at Pre-induction | Patient number4 | 85 bpm |
| Dexmedetomidine | HR in the Placebo Group at Pre-induction | Patient number8 | 63 bpm |
| Dexmedetomidine | HR in the Placebo Group at Pre-induction | Patient number12 | 80 bpm |
| Dexmedetomidine | HR in the Placebo Group at Pre-induction | Patient number13 | 53 bpm |
| Dexmedetomidine | HR in the Placebo Group at Pre-induction | Patient number14 | 79 bpm |
| Dexmedetomidine | HR in the Placebo Group at Pre-induction | Patient number15 | 62 bpm |
| Dexmedetomidine | HR in the Placebo Group at Pre-induction | Patient number16 | 72 bpm |
| Dexmedetomidine | HR in the Placebo Group at Pre-induction | Patient number17 | 70 bpm |
| Dexmedetomidine | HR in the Placebo Group at Pre-induction | Patient number19 | 59 bpm |
| Dexmedetomidine | HR in the Placebo Group at Pre-induction | Patient number20 | 74 bpm |
| Dexmedetomidine | HR in the Placebo Group at Pre-induction | Patient number21 | 73 bpm |
| Dexmedetomidine | HR in the Placebo Group at Pre-induction | Patient number22 | 90 bpm |
| Dexmedetomidine | HR in the Placebo Group at Pre-induction | Patient number23 | 82 bpm |
| Dexmedetomidine | HR in the Placebo Group at Pre-induction | Patient number26 | 78 bpm |
| Dexmedetomidine | HR in the Placebo Group at Pre-induction | Patient number27 | 61 bpm |
| Dexmedetomidine | HR in the Placebo Group at Pre-induction | Patient number30 | 92 bpm |
| Dexmedetomidine | HR in the Placebo Group at Pre-induction | Patient number32 | 85 bpm |
| Dexmedetomidine | HR in the Placebo Group at Pre-induction | Patient number34 | 54 bpm |
| Dexmedetomidine | HR in the Placebo Group at Pre-induction | Patient number35 | 66 bpm |
| Dexmedetomidine | HR in the Placebo Group at Pre-induction | Patient number37 | 75 bpm |
| Dexmedetomidine | HR in the Placebo Group at Pre-induction | Patient number39 | 60 bpm |
| Dexmedetomidine | HR in the Placebo Group at Pre-induction | Patient number41 | 94 bpm |
| Dexmedetomidine | HR in the Placebo Group at Pre-induction | Patient number42 | 72 bpm |
| Dexmedetomidine | HR in the Placebo Group at Pre-induction | Patient number43 | 85 bpm |
| Dexmedetomidine | HR in the Placebo Group at Pre-induction | Patient number45 | 87 bpm |
| Dexmedetomidine | HR in the Placebo Group at Pre-induction | Patient number47 | 81 bpm |
| Dexmedetomidine | HR in the Placebo Group at Pre-induction | Patient number49 | 72 bpm |
| Dexmedetomidine | HR in the Placebo Group at Pre-induction | Patient number51 | 53 bpm |
| Dexmedetomidine | HR in the Placebo Group at Pre-induction | Patient number54 | 70 bpm |
| Dexmedetomidine | HR in the Placebo Group at Pre-induction | Patient number55 | 72 bpm |
| Dexmedetomidine | HR in the Placebo Group at Pre-induction | Patient number60 | 78 bpm |
| Dexmedetomidine | HR in the Placebo Group at Pre-induction | Patient number64 | 75 bpm |
| Dexmedetomidine | HR in the Placebo Group at Pre-induction | Patient number68 | 70 bpm |
| Dexmedetomidine | HR in the Placebo Group at Pre-induction | Patient number69 | 69 bpm |
| Dexmedetomidine | HR in the Placebo Group at Pre-induction | Patient number70 | 62 bpm |
| Dexmedetomidine | HR in the Placebo Group at Pre-induction | Patient number73 | 69 bpm |
| Dexmedetomidine | HR in the Placebo Group at Pre-induction | Patient number77 | 66 bpm |
| Dexmedetomidine | HR in the Placebo Group at Pre-induction | Patient number78 | 55 bpm |
| Dexmedetomidine | HR in the Placebo Group at Pre-induction | Patient number81 | 72 bpm |
Other Pre-specified
HR in the Placebo Group Before Intranasal Drugs
HR in the placebo group Before Intranasal Drugs HR was monitored by fiber-optic pulse oximetry during patient transfer from the ward to the operating room
Time frame: 1 day
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Dexmedetomidine | HR in the Placebo Group Before Intranasal Drugs | Patient number12 | 80 bpm |
| Dexmedetomidine | HR in the Placebo Group Before Intranasal Drugs | Patient number13 | 67 bpm |
| Dexmedetomidine | HR in the Placebo Group Before Intranasal Drugs | Patient number14 | 75 bpm |
| Dexmedetomidine | HR in the Placebo Group Before Intranasal Drugs | Patient number15 | 55 bpm |
| Dexmedetomidine | HR in the Placebo Group Before Intranasal Drugs | Patient number16 | 65 bpm |
| Dexmedetomidine | HR in the Placebo Group Before Intranasal Drugs | Patient number1 | 65 bpm |
| Dexmedetomidine | HR in the Placebo Group Before Intranasal Drugs | Patient number4 | 77 bpm |
| Dexmedetomidine | HR in the Placebo Group Before Intranasal Drugs | Patient number8 | 61 bpm |
| Dexmedetomidine | HR in the Placebo Group Before Intranasal Drugs | Patient number17 | 78 bpm |
| Dexmedetomidine | HR in the Placebo Group Before Intranasal Drugs | Patient number19 | 57 bpm |
| Dexmedetomidine | HR in the Placebo Group Before Intranasal Drugs | Patient number20 | 76 bpm |
| Dexmedetomidine | HR in the Placebo Group Before Intranasal Drugs | Patient number21 | 85 bpm |
| Dexmedetomidine | HR in the Placebo Group Before Intranasal Drugs | Patient number22 | 69 bpm |
| Dexmedetomidine | HR in the Placebo Group Before Intranasal Drugs | Patient number23 | 71 bpm |
| Dexmedetomidine | HR in the Placebo Group Before Intranasal Drugs | Patient number26 | 75 bpm |
| Dexmedetomidine | HR in the Placebo Group Before Intranasal Drugs | Patient number27 | 65 bpm |
| Dexmedetomidine | HR in the Placebo Group Before Intranasal Drugs | Patient number30 | 100 bpm |
| Dexmedetomidine | HR in the Placebo Group Before Intranasal Drugs | Patient number32 | 83 bpm |
| Dexmedetomidine | HR in the Placebo Group Before Intranasal Drugs | Patient number34 | 55 bpm |
| Dexmedetomidine | HR in the Placebo Group Before Intranasal Drugs | Patient number35 | 72 bpm |
| Dexmedetomidine | HR in the Placebo Group Before Intranasal Drugs | Patient number37 | 75 bpm |
| Dexmedetomidine | HR in the Placebo Group Before Intranasal Drugs | Patient number39 | 75 bpm |
| Dexmedetomidine | HR in the Placebo Group Before Intranasal Drugs | Patient number41 | 120 bpm |
| Dexmedetomidine | HR in the Placebo Group Before Intranasal Drugs | Patient number42 | 59 bpm |
| Dexmedetomidine | HR in the Placebo Group Before Intranasal Drugs | Patient number43 | 89 bpm |
| Dexmedetomidine | HR in the Placebo Group Before Intranasal Drugs | Patient number45 | 90 bpm |
| Dexmedetomidine | HR in the Placebo Group Before Intranasal Drugs | Patient number47 | 74 bpm |
| Dexmedetomidine | HR in the Placebo Group Before Intranasal Drugs | Patient number48 | 63 bpm |
| Dexmedetomidine | HR in the Placebo Group Before Intranasal Drugs | Patient number49 | 88 bpm |
| Dexmedetomidine | HR in the Placebo Group Before Intranasal Drugs | Patient number51 | 56 bpm |
| Dexmedetomidine | HR in the Placebo Group Before Intranasal Drugs | Patient number54 | 75 bpm |
| Dexmedetomidine | HR in the Placebo Group Before Intranasal Drugs | Patient number55 | 63 bpm |
| Dexmedetomidine | HR in the Placebo Group Before Intranasal Drugs | Patient number60 | 82 bpm |
| Dexmedetomidine | HR in the Placebo Group Before Intranasal Drugs | Patient number64 | 80 bpm |
| Dexmedetomidine | HR in the Placebo Group Before Intranasal Drugs | Patient number68 | 65 bpm |
| Dexmedetomidine | HR in the Placebo Group Before Intranasal Drugs | Patient number69 | 63 bpm |
| Dexmedetomidine | HR in the Placebo Group Before Intranasal Drugs | Patient number70 | 64 bpm |
| Dexmedetomidine | HR in the Placebo Group Before Intranasal Drugs | Patient number73 | 65 bpm |
| Dexmedetomidine | HR in the Placebo Group Before Intranasal Drugs | Patient number77 | 63 bpm |
| Dexmedetomidine | HR in the Placebo Group Before Intranasal Drugs | Patient number78 | 55 bpm |
| Dexmedetomidine | HR in the Placebo Group Before Intranasal Drugs | Patient number81 | 72 bpm |
Other Pre-specified
Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine After Extubation
Modified OAA/S score of patients receiving intranasal dexmedetomidine after extubation. Modified Observer's Assessment of Alertness/Sedation Scale (Modified OAA/S score): 6 Appears alert and awake, responds readily to name spoken in normal tone 5 Appears asleep but responds readily to name spoken in normal tone 4 Lethargic response to name spoken in normal tone 3 Responds only after name is called loudly or repeatedly 2 Responds only after mild prodding or shaking 1 Does not respond to mild prodding or shaking 0 Does not respond to noxious stimulus
Time frame: 1 day
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine After Extubation | Patient number2 | 4 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine After Extubation | Patient number3 | 4 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine After Extubation | Patient number5 | 4 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine After Extubation | Patient number6 | 4 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine After Extubation | Patient number7 | 4 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine After Extubation | Patient number9 | 4 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine After Extubation | Patient number10 | 4 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine After Extubation | Patient number11 | 4 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine After Extubation | Patient number18 | 4 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine After Extubation | Patient number24 | 4 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine After Extubation | Patient number25 | 4 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine After Extubation | Patient number28 | 4 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine After Extubation | Patient number29 | 3 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine After Extubation | Patient number31 | 4 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine After Extubation | Patient number33 | 4 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine After Extubation | Patient number36 | 4 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine After Extubation | Patient number38 | 4 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine After Extubation | Patient number40 | 3 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine After Extubation | Patient number44 | 4 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine After Extubation | Patient number46 | 4 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine After Extubation | Patient number50 | 3 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine After Extubation | Patient number52 | 3 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine After Extubation | Patient number53 | 3 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine After Extubation | Patient number56 | 3 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine After Extubation | Patient number57 | 4 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine After Extubation | Patient number58 | 4 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine After Extubation | Patient number59 | 3 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine After Extubation | Patient number61 | 3 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine After Extubation | Patient number62 | 4 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine After Extubation | Patient number63 | 4 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine After Extubation | Patient number65 | 4 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine After Extubation | Patient number66 | 5 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine After Extubation | Patient number67 | 4 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine After Extubation | Patient number71 | 5 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine After Extubation | Patient number72 | 5 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine After Extubation | Patient number74 | 5 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine After Extubation | Patient number75 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine After Extubation | Patient number76 | 5 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine After Extubation | Patient number79 | 3 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine After Extubation | Patient number80 | 3 units on a scale |
Other Pre-specified
Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine at Pre-induction
Modified OAA/S score of patients receiving intranasal dexmedetomidine at Pre-induction. Modified Observer's Assessment of Alertness/Sedation Scale (Modified OAA/S score): 6 Appears alert and awake, responds readily to name spoken in normal tone 5 Appears asleep but responds readily to name spoken in normal tone 4 Lethargic response to name spoken in normal tone 3 Responds only after name is called loudly or repeatedly 2 Responds only after mild prodding or shaking 1 Does not respond to mild prodding or shaking 0 Does not respond to noxious stimulus
Time frame: 1 day
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine at Pre-induction | Patient number2 | 5 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine at Pre-induction | Patient number3 | 5 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine at Pre-induction | Patient number5 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine at Pre-induction | Patient number6 | 4 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine at Pre-induction | Patient number7 | 4 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine at Pre-induction | Patient number9 | 5 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine at Pre-induction | Patient number10 | 5 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine at Pre-induction | Patient number11 | 4 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine at Pre-induction | Patient number18 | 5 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine at Pre-induction | Patient number24 | 5 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine at Pre-induction | Patient number25 | 4 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine at Pre-induction | Patient number28 | 4 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine at Pre-induction | Patient number29 | 5 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine at Pre-induction | Patient number31 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine at Pre-induction | Patient number33 | 4 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine at Pre-induction | Patient number36 | 4 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine at Pre-induction | Patient number38 | 4 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine at Pre-induction | Patient number40 | 4 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine at Pre-induction | Patient number44 | 5 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine at Pre-induction | Patient number46 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine at Pre-induction | Patient number50 | 4 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine at Pre-induction | Patient number52 | 4 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine at Pre-induction | Patient number53 | 3 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine at Pre-induction | Patient number56 | 4 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine at Pre-induction | Patient number57 | 5 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine at Pre-induction | Patient number58 | 4 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine at Pre-induction | Patient number59 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine at Pre-induction | Patient number61 | 4 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine at Pre-induction | Patient number62 | 4 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine at Pre-induction | Patient number63 | 4 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine at Pre-induction | Patient number65 | 4 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine at Pre-induction | Patient number66 | 5 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine at Pre-induction | Patient number67 | 5 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine at Pre-induction | Patient number71 | 4 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine at Pre-induction | Patient number72 | 4 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine at Pre-induction | Patient number74 | 4 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine at Pre-induction | Patient number75 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine at Pre-induction | Patient number76 | 5 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine at Pre-induction | Patient number79 | 5 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine at Pre-induction | Patient number80 | 5 units on a scale |
Other Pre-specified
Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine Before Intranasal Drugs
Modified OAA/S score of patients receiving intranasal dexmedetomidine Before intranasal drugs Modified Observer's Assessment of Alertness/Sedation Scale (Modified OAA/S score) 6 Appears alert and awake, responds readily to name spoken in normal tone 5 Appears asleep but responds readily to name spoken in normal tone 4 Lethargic response to name spoken in normal tone 3 Responds only after name is called loudly or repeatedly 2 Responds only after mild prodding or shaking 1 Does not respond to mild prodding or shaking 0 Does not respond to noxious stimulus
Time frame: 1 day
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine Before Intranasal Drugs | Patient number2 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine Before Intranasal Drugs | Patient number3 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine Before Intranasal Drugs | Patient number5 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine Before Intranasal Drugs | Patient number6 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine Before Intranasal Drugs | Patient number7 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine Before Intranasal Drugs | Patient number9 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine Before Intranasal Drugs | Patient number10 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine Before Intranasal Drugs | Patient number11 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine Before Intranasal Drugs | Patient number18 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine Before Intranasal Drugs | Patient number24 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine Before Intranasal Drugs | Patient number25 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine Before Intranasal Drugs | Patient number28 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine Before Intranasal Drugs | Patient number29 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine Before Intranasal Drugs | Patient number31 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine Before Intranasal Drugs | Patient number33 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine Before Intranasal Drugs | Patient number36 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine Before Intranasal Drugs | Patient number38 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine Before Intranasal Drugs | Patient number40 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine Before Intranasal Drugs | Patient number44 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine Before Intranasal Drugs | Patient number46 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine Before Intranasal Drugs | Patient number50 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine Before Intranasal Drugs | Patient number52 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine Before Intranasal Drugs | Patient number53 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine Before Intranasal Drugs | Patient number56 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine Before Intranasal Drugs | Patient number57 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine Before Intranasal Drugs | Patient number58 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine Before Intranasal Drugs | Patient number59 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine Before Intranasal Drugs | Patient number61 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine Before Intranasal Drugs | Patient number62 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine Before Intranasal Drugs | Patient number63 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine Before Intranasal Drugs | Patient number65 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine Before Intranasal Drugs | Patient number66 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine Before Intranasal Drugs | Patient number67 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine Before Intranasal Drugs | Patient number71 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine Before Intranasal Drugs | Patient number72 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine Before Intranasal Drugs | Patient number74 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine Before Intranasal Drugs | Patient number75 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine Before Intranasal Drugs | Patient number76 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine Before Intranasal Drugs | Patient number79 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Dexmedetomidine Before Intranasal Drugs | Patient number80 | 6 units on a scale |
Other Pre-specified
Modified OAA/S Score of Patients Receiving Intranasal Placebo After Extubation
Modified OAA/S score of patients receiving intranasal placebo After extubation. Modified Observer's Assessment of Alertness/Sedation Scale (Modified OAA/S score) 6 Appears alert and awake, responds readily to name spoken in normal tone 5 Appears asleep but responds readily to name spoken in normal tone 4 Lethargic response to name spoken in normal tone 3 Responds only after name is called loudly or repeatedly 2 Responds only after mild prodding or shaking 1 Does not respond to mild prodding or shaking 0 Does not respond to noxious stimulus
Time frame: 1 day
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo After Extubation | Patient number54 | 3 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo After Extubation | Patient number55 | 3 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo After Extubation | Patient number60 | 4 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo After Extubation | Patient number64 | 4 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo After Extubation | Patient number68 | 4 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo After Extubation | Patient number69 | 5 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo After Extubation | Patient number1 | 4 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo After Extubation | Patient number4 | 4 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo After Extubation | Patient number8 | 5 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo After Extubation | Patient number12 | 5 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo After Extubation | Patient number13 | 4 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo After Extubation | Patient number14 | 3 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo After Extubation | Patient number15 | 4 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo After Extubation | Patient number16 | 3 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo After Extubation | Patient number17 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo After Extubation | Patient number19 | 3 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo After Extubation | Patient number20 | 3 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo After Extubation | Patient number21 | 3 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo After Extubation | Patient number22 | 4 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo After Extubation | Patient number23 | 5 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo After Extubation | Patient number26 | 5 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo After Extubation | Patient number27 | 4 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo After Extubation | Patient number30 | 5 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo After Extubation | Patient number32 | 4 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo After Extubation | Patient number34 | 4 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo After Extubation | Patient number35 | 4 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo After Extubation | Patient number37 | 3 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo After Extubation | Patient number70 | 5 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo After Extubation | Patient number73 | 4 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo After Extubation | Patient number77 | 5 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo After Extubation | Patient number78 | 4 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo After Extubation | Patient number81 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo After Extubation | Patient number39 | 4 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo After Extubation | Patient number41 | 4 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo After Extubation | Patient number42 | 4 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo After Extubation | Patient number43 | 4 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo After Extubation | Patient number45 | 3 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo After Extubation | Patient number47 | 4 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo After Extubation | Patient number48 | 3 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo After Extubation | Patient number49 | 3 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo After Extubation | Patient number51 | 3 units on a scale |
Other Pre-specified
Modified OAA/S Score of Patients Receiving Intranasal Placebo at Pre-induction
Modified OAA/S score of patients receiving intranasal placebo at Pre-induction. Modified Observer's Assessment of Alertness/Sedation Scale (Modified OAA/S score): 6 Appears alert and awake, responds readily to name spoken in normal tone 5 Appears asleep but responds readily to name spoken in normal tone 4 Lethargic response to name spoken in normal tone 3 Responds only after name is called loudly or repeatedly 2 Responds only after mild prodding or shaking 1 Does not respond to mild prodding or shaking 0 Does not respond to noxious stimulus
Time frame: 1 day
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo at Pre-induction | Patient number1 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo at Pre-induction | Patient number4 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo at Pre-induction | Patient number8 | 5 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo at Pre-induction | Patient number12 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo at Pre-induction | Patient number13 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo at Pre-induction | Patient number14 | 5 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo at Pre-induction | Patient number15 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo at Pre-induction | Patient number16 | 5 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo at Pre-induction | Patient number17 | 5 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo at Pre-induction | Patient number19 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo at Pre-induction | Patient number20 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo at Pre-induction | Patient number21 | 5 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo at Pre-induction | Patient number22 | 5 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo at Pre-induction | Patient number23 | 4 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo at Pre-induction | Patient number26 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo at Pre-induction | Patient number27 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo at Pre-induction | Patient number30 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo at Pre-induction | Patient number32 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo at Pre-induction | Patient number34 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo at Pre-induction | Patient number35 | 5 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo at Pre-induction | Patient number37 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo at Pre-induction | Patient number39 | 5 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo at Pre-induction | Patient number41 | 5 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo at Pre-induction | Patient number42 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo at Pre-induction | Patient number43 | 5 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo at Pre-induction | Patient number45 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo at Pre-induction | Patient number47 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo at Pre-induction | Patient number48 | 4 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo at Pre-induction | Patient number49 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo at Pre-induction | Patient number51 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo at Pre-induction | Patient number54 | 4 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo at Pre-induction | Patient number55 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo at Pre-induction | Patient number60 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo at Pre-induction | Patient number64 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo at Pre-induction | Patient number68 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo at Pre-induction | Patient number69 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo at Pre-induction | Patient number70 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo at Pre-induction | Patient number73 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo at Pre-induction | Patient number77 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo at Pre-induction | Patient number78 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo at Pre-induction | Patient number81 | 6 units on a scale |
Other Pre-specified
Modified OAA/S Score of Patients Receiving Intranasal Placebo Before Intranasal Drugs
Modified OAA/S score of patients receiving intranasal placebo Before intranasal drugs Modified Observer's Assessment of Alertness/Sedation Scale (Modified OAA/S score) 6 Appears alert and awake, responds readily to name spoken in normal tone 5 Appears asleep but responds readily to name spoken in normal tone 4 Lethargic response to name spoken in normal tone 3 Responds only after name is called loudly or repeatedly 2 Responds only after mild prodding or shaking 1 Does not respond to mild prodding or shaking 0 Does not respond to noxious stimulus
Time frame: 1 day
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo Before Intranasal Drugs | Patient number1 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo Before Intranasal Drugs | Patient number4 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo Before Intranasal Drugs | Patient number8 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo Before Intranasal Drugs | Patient number12 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo Before Intranasal Drugs | Patient number13 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo Before Intranasal Drugs | Patient number14 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo Before Intranasal Drugs | Patient number15 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo Before Intranasal Drugs | Patient number16 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo Before Intranasal Drugs | Patient number17 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo Before Intranasal Drugs | Patient number19 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo Before Intranasal Drugs | Patient number20 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo Before Intranasal Drugs | Patient number21 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo Before Intranasal Drugs | Patient number22 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo Before Intranasal Drugs | Patient number23 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo Before Intranasal Drugs | Patient number26 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo Before Intranasal Drugs | Patient number27 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo Before Intranasal Drugs | Patient number30 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo Before Intranasal Drugs | Patient number32 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo Before Intranasal Drugs | Patient number34 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo Before Intranasal Drugs | Patient number35 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo Before Intranasal Drugs | Patient number37 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo Before Intranasal Drugs | Patient number39 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo Before Intranasal Drugs | Patient number41 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo Before Intranasal Drugs | Patient number42 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo Before Intranasal Drugs | Patient number43 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo Before Intranasal Drugs | Patient number45 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo Before Intranasal Drugs | Patient number47 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo Before Intranasal Drugs | Patient number48 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo Before Intranasal Drugs | Patient number49 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo Before Intranasal Drugs | Patient number51 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo Before Intranasal Drugs | Patient number54 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo Before Intranasal Drugs | Patient number55 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo Before Intranasal Drugs | Patient number60 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo Before Intranasal Drugs | Patient number64 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo Before Intranasal Drugs | Patient number68 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo Before Intranasal Drugs | Patient number69 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo Before Intranasal Drugs | Patient number70 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo Before Intranasal Drugs | Patient number73 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo Before Intranasal Drugs | Patient number77 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo Before Intranasal Drugs | Patient number81 | 6 units on a scale |
| Dexmedetomidine | Modified OAA/S Score of Patients Receiving Intranasal Placebo Before Intranasal Drugs | Patient number78 | 6 units on a scale |
Other Pre-specified
Number of Participants With VAS >50
Patients with postoperative analgesia in two groups. analgesic requests within 2 h after extubation were recorded. An investigator who was blinded from the grouping asked the patients to mark their pain level on a 0-100 visual analogue scale (VAS). A VAS higher than 50 was considered a worse outcome and need to be treated with intravenous 40 mg of parecoxib.
Time frame: 1 day
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Dexmedetomidine | Number of Participants With VAS >50 | 5 Number of Participants with VAS >50 |
| Placebo | Number of Participants With VAS >50 | 15 Number of Participants with VAS >50 |
Other Pre-specified
Patients With Intra-operative Awareness in Two Groups
Patients With intra-operative awareness in Two Groups. patients receiving intranasal placebo or dexmedetomidine
Time frame: 1 day
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Dexmedetomidine | Patients With Intra-operative Awareness in Two Groups | 0 participants |
| Placebo | Patients With Intra-operative Awareness in Two Groups | 0 participants |
Other Pre-specified
Patients With Postoperative Nausea in Two Groups
Patients With postoperative nausea in Two Groups. Nausea or vomiting was treated with 4 mg of intravenous ondansetron.
Time frame: 1 day
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Dexmedetomidine | Patients With Postoperative Nausea in Two Groups | 1 participants |
| Placebo | Patients With Postoperative Nausea in Two Groups | 3 participants |
Other Pre-specified
Patients With Postoperative Shivering in Two Groups
Patients With postoperative shivering in Two Groups. the occurrence of postoperative shivering
Time frame: 1 day
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Dexmedetomidine | Patients With Postoperative Shivering in Two Groups | 1 participants |
| Placebo | Patients With Postoperative Shivering in Two Groups | 4 participants |
Other Pre-specified
Patients With Postoperative Vomiting in Two Groups
Patients With postoperative vomiting in Two Groups. Nausea or vomiting was treated with 4 mg of intravenous ondansetron.
Time frame: 1 day
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Dexmedetomidine | Patients With Postoperative Vomiting in Two Groups | 0 participants |
| Placebo | Patients With Postoperative Vomiting in Two Groups | 1 participants |
Other Pre-specified
Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Emergence
Predicted effect-site concentrations of propofol after intranasal dexmedetomidine at emergence. Propofol was infused intraoperatively to a TCI plasma concentration of 2.5μg∙ml-1 using DiprifusorTM software. The infusion rate was adjusted via plasma concentration increments of 0.5 μg∙ml-1 at 2-min intervals to maintain the Narcotrend index between 'D0' and 'E1' until the end of surgery.
Time frame: 1 day
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Emergence | Patient number2 | 1.1 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Emergence | Patient number3 | 0.9 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Emergence | Patient number5 | 0.8 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Emergence | Patient number6 | 1.3 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Emergence | Patient number7 | 0.8 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Emergence | Patient number9 | 1.1 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Emergence | Patient number10 | 0.8 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Emergence | Patient number11 | 1.1 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Emergence | Patient number18 | 1 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Emergence | Patient number24 | 0.6 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Emergence | Patient number25 | 0.9 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Emergence | Patient number28 | 1 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Emergence | Patient number29 | 0.5 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Emergence | Patient number31 | 0.7 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Emergence | Patient number33 | 0.7 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Emergence | Patient number36 | 1.2 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Emergence | Patient number38 | 0.7 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Emergence | Patient number40 | 0.8 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Emergence | Patient number44 | 0.2 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Emergence | Patient number46 | 1.2 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Emergence | Patient number50 | 0.9 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Emergence | Patient number52 | 1.2 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Emergence | Patient number53 | 1.5 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Emergence | Patient number56 | 0.6 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Emergence | Patient number57 | 0.9 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Emergence | Patient number58 | 0.7 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Emergence | Patient number59 | 0.9 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Emergence | Patient number61 | 0.6 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Emergence | Patient number62 | 0.6 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Emergence | Patient number63 | 0.5 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Emergence | Patient number65 | 0.6 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Emergence | Patient number66 | 1.1 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Emergence | Patient number67 | 0.7 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Emergence | Patient number71 | 1.2 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Emergence | Patient number72 | 1.7 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Emergence | Patient number74 | 1.3 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Emergence | Patient number75 | 0.9 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Emergence | Patient number76 | 1.5 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Emergence | Patient number79 | 0.9 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Emergence | Patient number80 | 0.5 µg/ml |
Other Pre-specified
Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Extubation
Predicted effect-site concentrations of propofol after intranasal dexmedetomidine at extubation. Propofol was infused intraoperatively to a TCI plasma concentration of 2.5μg∙ml-1 using DiprifusorTM software. The infusion rate was adjusted via plasma concentration increments of 0.5 μg∙ml-1 at 2-min intervals to maintain the Narcotrend index between 'D0' and 'E1' until the end of surgery.
Time frame: 1 day
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Extubation | Patient number2 | 1 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Extubation | Patient number3 | 0.8 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Extubation | Patient number5 | 0.7 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Extubation | Patient number6 | 1.1 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Extubation | Patient number7 | 0.5 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Extubation | Patient number9 | 0.9 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Extubation | Patient number10 | 0.7 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Extubation | Patient number11 | 0.9 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Extubation | Patient number18 | 0.9 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Extubation | Patient number24 | 0.5 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Extubation | Patient number25 | 0.7 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Extubation | Patient number28 | 0.9 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Extubation | Patient number29 | 0.5 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Extubation | Patient number31 | 0.7 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Extubation | Patient number33 | 0.6 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Extubation | Patient number36 | 0.8 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Extubation | Patient number38 | 0.6 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Extubation | Patient number40 | 0.7 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Extubation | Patient number44 | 0.2 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Extubation | Patient number46 | 1.1 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Extubation | Patient number50 | 0.7 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Extubation | Patient number52 | 1.1 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Extubation | Patient number53 | 1.3 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Extubation | Patient number56 | 0.6 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Extubation | Patient number57 | 0.8 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Extubation | Patient number58 | 0.6 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Extubation | Patient number59 | 0.7 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Extubation | Patient number61 | 0.5 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Extubation | Patient number62 | 0.6 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Extubation | Patient number63 | 0.5 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Extubation | Patient number65 | 0.5 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Extubation | Patient number66 | 0.9 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Extubation | Patient number67 | 0.6 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Extubation | Patient number71 | 1.1 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Extubation | Patient number72 | 1.5 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Extubation | Patient number74 | 1.2 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Extubation | Patient number75 | 0.9 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Extubation | Patient number76 | 1.2 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Extubation | Patient number79 | 0.8 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Extubation | Patient number80 | 0.4 µg/ml |
Other Pre-specified
Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Return of Spontaneous Breathing
Predicted effect-site concentrations of propofol after intranasal dexmedetomidine at return of spontaneous breathing. Propofol was infused intraoperatively to a TCI plasma concentration of 2.5μg∙ml-1 using DiprifusorTM software. The infusion rate was adjusted via plasma concentration increments of 0.5 μg∙ml-1 at 2-min intervals to maintain the Narcotrend index between 'D0' and 'E1' until the end of surgery.
Time frame: 1 day
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Return of Spontaneous Breathing | Patient number2 | 1.9 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Return of Spontaneous Breathing | Patient number3 | 2.1 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Return of Spontaneous Breathing | Patient number5 | 1.7 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Return of Spontaneous Breathing | Patient number6 | 2.3 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Return of Spontaneous Breathing | Patient number7 | 1.1 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Return of Spontaneous Breathing | Patient number9 | 1.9 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Return of Spontaneous Breathing | Patient number10 | 1.9 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Return of Spontaneous Breathing | Patient number11 | 1.5 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Return of Spontaneous Breathing | Patient number18 | 1.7 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Return of Spontaneous Breathing | Patient number24 | 0.7 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Return of Spontaneous Breathing | Patient number25 | 1.2 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Return of Spontaneous Breathing | Patient number28 | 2.1 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Return of Spontaneous Breathing | Patient number29 | 1.9 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Return of Spontaneous Breathing | Patient number31 | 1.2 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Return of Spontaneous Breathing | Patient number33 | 1.7 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Return of Spontaneous Breathing | Patient number36 | 2.3 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Return of Spontaneous Breathing | Patient number38 | 1.7 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Return of Spontaneous Breathing | Patient number40 | 1.7 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Return of Spontaneous Breathing | Patient number44 | 1.2 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Return of Spontaneous Breathing | Patient number46 | 2.5 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Return of Spontaneous Breathing | Patient number50 | 1.7 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Return of Spontaneous Breathing | Patient number52 | 1.7 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Return of Spontaneous Breathing | Patient number53 | 2.5 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Return of Spontaneous Breathing | Patient number56 | 1.7 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Return of Spontaneous Breathing | Patient number57 | 1.7 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Return of Spontaneous Breathing | Patient number58 | 1.9 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Return of Spontaneous Breathing | Patient number59 | 1.7 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Return of Spontaneous Breathing | Patient number61 | 1.9 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Return of Spontaneous Breathing | Patient number62 | 1.7 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Return of Spontaneous Breathing | Patient number63 | 1 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Return of Spontaneous Breathing | Patient number65 | 1.2 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Return of Spontaneous Breathing | Patient number66 | 1.9 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Return of Spontaneous Breathing | Patient number67 | 1.3 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Return of Spontaneous Breathing | Patient number71 | 1.9 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Return of Spontaneous Breathing | Patient number72 | 2.3 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Return of Spontaneous Breathing | Patient number74 | 1.7 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Return of Spontaneous Breathing | Patient number75 | 2.3 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Return of Spontaneous Breathing | Patient number76 | 1.9 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Return of Spontaneous Breathing | Patient number79 | 1.7 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Return of Spontaneous Breathing | Patient number80 | 0.6 µg/ml |
Other Pre-specified
Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Tracheal Intubation
Predicted effect-site concentrations of propofol after intranasal dexmedetomidine at tracheal intubation. Propofol was infused intraoperatively to a TCI plasma concentration of 2.5μg∙ml-1 using DiprifusorTM software. The infusion rate was adjusted via plasma concentration increments of 0.5 μg∙ml-1 at 2-min intervals to maintain the Narcotrend index between 'D0' and 'E1' until the end of surgery.
Time frame: 1 day
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Tracheal Intubation | Patient number2 | 1.4 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Tracheal Intubation | Patient number3 | 1.7 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Tracheal Intubation | Patient number5 | 4 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Tracheal Intubation | Patient number6 | 2.9 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Tracheal Intubation | Patient number7 | 0.7 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Tracheal Intubation | Patient number9 | 2.7 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Tracheal Intubation | Patient number10 | 1.8 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Tracheal Intubation | Patient number11 | 1.6 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Tracheal Intubation | Patient number18 | 1.8 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Tracheal Intubation | Patient number24 | 2 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Tracheal Intubation | Patient number25 | 0.9 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Tracheal Intubation | Patient number28 | 2 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Tracheal Intubation | Patient number29 | 2.5 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Tracheal Intubation | Patient number31 | 1.6 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Tracheal Intubation | Patient number33 | 2.8 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Tracheal Intubation | Patient number36 | 1.9 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Tracheal Intubation | Patient number38 | 1.8 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Tracheal Intubation | Patient number40 | 2.2 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Tracheal Intubation | Patient number44 | 1.8 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Tracheal Intubation | Patient number46 | 3.2 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Tracheal Intubation | Patient number50 | 1.1 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Tracheal Intubation | Patient number52 | 1.4 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Tracheal Intubation | Patient number53 | 2.3 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Tracheal Intubation | Patient number56 | 1.7 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Tracheal Intubation | Patient number57 | 2 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Tracheal Intubation | Patient number58 | 1.6 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Tracheal Intubation | Patient number59 | 2.7 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Tracheal Intubation | Patient number61 | 1.6 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Tracheal Intubation | Patient number62 | 1.5 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Tracheal Intubation | Patient number63 | 2.1 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Tracheal Intubation | Patient number65 | 1.3 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Tracheal Intubation | Patient number66 | 2.1 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Tracheal Intubation | Patient number67 | 2.9 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Tracheal Intubation | Patient number71 | 1.6 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Tracheal Intubation | Patient number72 | 3 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Tracheal Intubation | Patient number74 | 2 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Tracheal Intubation | Patient number75 | 2.3 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Tracheal Intubation | Patient number76 | 4.1 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Tracheal Intubation | Patient number79 | 2.1 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine at Tracheal Intubation | Patient number80 | 1.6 µg/ml |
Other Pre-specified
Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine Before Inserting Operative Laryngoscope
Predicted effect-site concentrations of propofol after intranasal dexmedetomidine before inserting operative laryngoscope. Propofol was infused intraoperatively to a TCI plasma concentration of 2.5μg∙ml-1 using DiprifusorTM software. The infusion rate was adjusted via plasma concentration increments of 0.5 μg∙ml-1 at 2-min intervals to maintain the Narcotrend index between 'D0' and 'E1' until the end of surgery.
Time frame: 1 day
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine Before Inserting Operative Laryngoscope | Patient number2 | 3 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine Before Inserting Operative Laryngoscope | Patient number3 | 2.8 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine Before Inserting Operative Laryngoscope | Patient number5 | 4.9 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine Before Inserting Operative Laryngoscope | Patient number6 | 4 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine Before Inserting Operative Laryngoscope | Patient number7 | 2.4 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine Before Inserting Operative Laryngoscope | Patient number9 | 4 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine Before Inserting Operative Laryngoscope | Patient number10 | 2.9 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine Before Inserting Operative Laryngoscope | Patient number11 | 2.9 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine Before Inserting Operative Laryngoscope | Patient number18 | 2.7 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine Before Inserting Operative Laryngoscope | Patient number24 | 3.3 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine Before Inserting Operative Laryngoscope | Patient number25 | 3 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine Before Inserting Operative Laryngoscope | Patient number28 | 3 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine Before Inserting Operative Laryngoscope | Patient number29 | 3.5 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine Before Inserting Operative Laryngoscope | Patient number31 | 3 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine Before Inserting Operative Laryngoscope | Patient number33 | 3.9 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine Before Inserting Operative Laryngoscope | Patient number36 | 3.5 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine Before Inserting Operative Laryngoscope | Patient number38 | 3.4 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine Before Inserting Operative Laryngoscope | Patient number40 | 3.5 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine Before Inserting Operative Laryngoscope | Patient number44 | 2.9 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine Before Inserting Operative Laryngoscope | Patient number46 | 4.4 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine Before Inserting Operative Laryngoscope | Patient number50 | 3 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine Before Inserting Operative Laryngoscope | Patient number52 | 2.9 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine Before Inserting Operative Laryngoscope | Patient number53 | 3.3 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine Before Inserting Operative Laryngoscope | Patient number56 | 2.9 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine Before Inserting Operative Laryngoscope | Patient number57 | 3.4 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine Before Inserting Operative Laryngoscope | Patient number58 | 3 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine Before Inserting Operative Laryngoscope | Patient number59 | 4 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine Before Inserting Operative Laryngoscope | Patient number61 | 3 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine Before Inserting Operative Laryngoscope | Patient number62 | 3 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine Before Inserting Operative Laryngoscope | Patient number63 | 3.5 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine Before Inserting Operative Laryngoscope | Patient number65 | 3.5 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine Before Inserting Operative Laryngoscope | Patient number66 | 3.5 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine Before Inserting Operative Laryngoscope | Patient number67 | 3.9 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine Before Inserting Operative Laryngoscope | Patient number71 | 3 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine Before Inserting Operative Laryngoscope | Patient number72 | 4.2 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine Before Inserting Operative Laryngoscope | Patient number74 | 3.5 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine Before Inserting Operative Laryngoscope | Patient number75 | 3.5 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine Before Inserting Operative Laryngoscope | Patient number76 | 4.9 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine Before Inserting Operative Laryngoscope | Patient number79 | 3.4 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine Before Inserting Operative Laryngoscope | Patient number80 | 3 µg/ml |
Other Pre-specified
Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine on Removal of Operative Laryngoscope
Predicted effect-site concentrations of propofol after intranasal dexmedetomidine on removal of operative laryngoscope. Propofol was infused intraoperatively to a TCI plasma concentration of 2.5μg∙ml-1 using DiprifusorTM software. The infusion rate was adjusted via plasma concentration increments of 0.5 μg∙ml-1 at 2-min intervals to maintain the Narcotrend index between 'D0' and 'E1' until the end of surgery.
Time frame: 1 day
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine on Removal of Operative Laryngoscope | Patient number11 | 3 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine on Removal of Operative Laryngoscope | Patient number18 | 3 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine on Removal of Operative Laryngoscope | Patient number24 | 3.5 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine on Removal of Operative Laryngoscope | Patient number25 | 3 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine on Removal of Operative Laryngoscope | Patient number28 | 3 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine on Removal of Operative Laryngoscope | Patient number29 | 4 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine on Removal of Operative Laryngoscope | Patient number31 | 3 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine on Removal of Operative Laryngoscope | Patient number33 | 4 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine on Removal of Operative Laryngoscope | Patient number36 | 4 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine on Removal of Operative Laryngoscope | Patient number38 | 3.5 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine on Removal of Operative Laryngoscope | Patient number40 | 3.5 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine on Removal of Operative Laryngoscope | Patient number44 | 3 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine on Removal of Operative Laryngoscope | Patient number46 | 4.5 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine on Removal of Operative Laryngoscope | Patient number50 | 3 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine on Removal of Operative Laryngoscope | Patient number52 | 3 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine on Removal of Operative Laryngoscope | Patient number53 | 4 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine on Removal of Operative Laryngoscope | Patient number56 | 3 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine on Removal of Operative Laryngoscope | Patient number57 | 3.5 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine on Removal of Operative Laryngoscope | Patient number58 | 3 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine on Removal of Operative Laryngoscope | Patient number59 | 4 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine on Removal of Operative Laryngoscope | Patient number61 | 3 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine on Removal of Operative Laryngoscope | Patient number62 | 3 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine on Removal of Operative Laryngoscope | Patient number63 | 3.5 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine on Removal of Operative Laryngoscope | Patient number65 | 3 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine on Removal of Operative Laryngoscope | Patient number66 | 3.5 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine on Removal of Operative Laryngoscope | Patient number67 | 4 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine on Removal of Operative Laryngoscope | Patient number71 | 3 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine on Removal of Operative Laryngoscope | Patient number72 | 4.5 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine on Removal of Operative Laryngoscope | Patient number74 | 3.5 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine on Removal of Operative Laryngoscope | Patient number75 | 3.5 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine on Removal of Operative Laryngoscope | Patient number76 | 5 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine on Removal of Operative Laryngoscope | Patient number79 | 3 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine on Removal of Operative Laryngoscope | Patient number80 | 3 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine on Removal of Operative Laryngoscope | Patient number2 | 3 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine on Removal of Operative Laryngoscope | Patient number3 | 3 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine on Removal of Operative Laryngoscope | Patient number5 | 5 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine on Removal of Operative Laryngoscope | Patient number6 | 4 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine on Removal of Operative Laryngoscope | Patient number7 | 2.5 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine on Removal of Operative Laryngoscope | Patient number9 | 4 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Dexmedetomidine on Removal of Operative Laryngoscope | Patient number10 | 3 µg/ml |
Other Pre-specified
Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Emergence
Predicted effect-site concentrations of propofol after intranasal placebo at emergence. Propofol was infused intraoperatively to a TCI plasma concentration of 2.5μg∙ml-1 using DiprifusorTM software. The infusion rate was adjusted via plasma concentration increments of 0.5 μg∙ml-1 at 2-min intervals to maintain the Narcotrend index between 'D0' and 'E1' until the end of surgery.
Time frame: 1 day
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Emergence | Patient number1 | 1.3 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Emergence | Patient number4 | 1.3 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Emergence | Patient number8 | 1.3 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Emergence | Patient number12 | 1.5 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Emergence | Patient number13 | 0.7 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Emergence | Patient number14 | 1.5 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Emergence | Patient number15 | 0.5 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Emergence | Patient number16 | 0.9 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Emergence | Patient number17 | 0.8 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Emergence | Patient number19 | 0.8 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Emergence | Patient number20 | 0.6 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Emergence | Patient number21 | 1.1 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Emergence | Patient number22 | 1.2 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Emergence | Patient number23 | 0.9 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Emergence | Patient number26 | 1 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Emergence | Patient number27 | 1 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Emergence | Patient number30 | 1.1 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Emergence | Patient number32 | 1.3 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Emergence | Patient number34 | 0.9 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Emergence | Patient number35 | 0.9 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Emergence | Patient number37 | 1.5 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Emergence | Patient number39 | 0.9 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Emergence | Patient number41 | 1 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Emergence | Patient number42 | 0.9 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Emergence | Patient number43 | 0.9 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Emergence | Patient number45 | 1.1 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Emergence | Patient number47 | 1.5 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Emergence | Patient number48 | 1.9 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Emergence | Patient number49 | 0.9 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Emergence | Patient number51 | 0.7 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Emergence | Patient number54 | 2.1 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Emergence | Patient number55 | 0.5 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Emergence | Patient number60 | 1.3 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Emergence | Patient number64 | 1 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Emergence | Patient number68 | 1.2 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Emergence | Patient number69 | 1.1 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Emergence | Patient number70 | 0.9 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Emergence | Patient number73 | 0.6 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Emergence | Patient number77 | 1.1 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Emergence | Patient number78 | 0.2 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Emergence | Patient number81 | 1.1 µg/ml |
Other Pre-specified
Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Extubation
Predicted effect-site concentrations of propofol after intranasal placebo at extubation. Propofol was infused intraoperatively to a TCI plasma concentration of 2.5μg∙ml-1 using DiprifusorTM software. The infusion rate was adjusted via plasma concentration increments of 0.5 μg∙ml-1 at 2-min intervals to maintain the Narcotrend index between 'D0' and 'E1' until the end of surgery.
Time frame: 1 day
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Extubation | Patient number1 | 1.1 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Extubation | Patient number4 | 1.1 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Extubation | Patient number8 | 1.2 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Extubation | Patient number12 | 1.2 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Extubation | Patient number13 | 0.6 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Extubation | Patient number14 | 1.2 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Extubation | Patient number15 | 0.4 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Extubation | Patient number16 | 0.7 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Extubation | Patient number17 | 0.7 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Extubation | Patient number19 | 0.7 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Extubation | Patient number20 | 0.6 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Extubation | Patient number21 | 0.9 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Extubation | Patient number22 | 1 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Extubation | Patient number23 | 0.8 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Extubation | Patient number26 | 0.9 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Extubation | Patient number27 | 0.8 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Extubation | Patient number30 | 0.9 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Extubation | Patient number32 | 1.1 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Extubation | Patient number34 | 0.7 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Extubation | Patient number35 | 0.7 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Extubation | Patient number37 | 1.2 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Extubation | Patient number39 | 0.8 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Extubation | Patient number41 | 0.9 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Extubation | Patient number42 | 0.8 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Extubation | Patient number43 | 0.9 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Extubation | Patient number45 | 0.7 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Extubation | Patient number47 | 1.2 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Extubation | Patient number48 | 1.7 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Extubation | Patient number49 | 0.8 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Extubation | Patient number51 | 0.6 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Extubation | Patient number54 | 1.5 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Extubation | Patient number55 | 0.4 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Extubation | Patient number60 | 1.1 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Extubation | Patient number64 | 0.9 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Extubation | Patient number68 | 1 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Extubation | Patient number69 | 0.9 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Extubation | Patient number70 | 0.7 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Extubation | Patient number73 | 0.5 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Extubation | Patient number77 | 0.9 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Extubation | Patient number78 | 0.2 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Extubation | Patient number81 | 0.9 µg/ml |
Other Pre-specified
Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Return of Spontaneous Breathing
Predicted effect-site concentrations of propofol after intranasal placebo at return of spontaneous breathing. Propofol was infused intraoperatively to a TCI plasma concentration of 2.5μg∙ml-1 using DiprifusorTM software. The infusion rate was adjusted via plasma concentration increments of 0.5 μg∙ml-1 at 2-min intervals to maintain the Narcotrend index between 'D0' and 'E1' until the end of surgery.
Time frame: 1 day
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Return of Spontaneous Breathing | Patient number1 | 2.1 ug/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Return of Spontaneous Breathing | Patient number4 | 2.3 ug/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Return of Spontaneous Breathing | Patient number8 | 1.7 ug/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Return of Spontaneous Breathing | Patient number12 | 1.7 ug/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Return of Spontaneous Breathing | Patient number13 | 1 ug/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Return of Spontaneous Breathing | Patient number14 | 2.5 ug/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Return of Spontaneous Breathing | Patient number15 | 1.2 ug/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Return of Spontaneous Breathing | Patient number16 | 1.3 ug/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Return of Spontaneous Breathing | Patient number17 | 1.7 ug/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Return of Spontaneous Breathing | Patient number19 | 1.9 ug/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Return of Spontaneous Breathing | Patient number20 | 2.3 ug/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Return of Spontaneous Breathing | Patient number21 | 2.1 ug/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Return of Spontaneous Breathing | Patient number22 | 0.7 ug/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Return of Spontaneous Breathing | Patient number23 | 1.1 ug/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Return of Spontaneous Breathing | Patient number26 | 1.9 ug/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Return of Spontaneous Breathing | Patient number27 | 1.8 ug/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Return of Spontaneous Breathing | Patient number30 | 1.3 ug/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Return of Spontaneous Breathing | Patient number32 | 2.5 ug/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Return of Spontaneous Breathing | Patient number34 | 2.1 ug/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Return of Spontaneous Breathing | Patient number35 | 1.5 ug/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Return of Spontaneous Breathing | Patient number37 | 2.3 ug/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Return of Spontaneous Breathing | Patient number39 | 1.7 ug/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Return of Spontaneous Breathing | Patient number41 | 2.3 ug/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Return of Spontaneous Breathing | Patient number42 | 1.7 ug/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Return of Spontaneous Breathing | Patient number43 | 2.1 ug/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Return of Spontaneous Breathing | Patient number45 | 2.3 ug/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Return of Spontaneous Breathing | Patient number47 | 2.1 ug/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Return of Spontaneous Breathing | Patient number48 | 2.3 ug/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Return of Spontaneous Breathing | Patient number49 | 2.5 ug/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Return of Spontaneous Breathing | Patient number51 | 1.5 ug/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Return of Spontaneous Breathing | Patient number54 | 2.5 ug/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Return of Spontaneous Breathing | Patient number55 | 0.9 ug/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Return of Spontaneous Breathing | Patient number60 | 2.9 ug/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Return of Spontaneous Breathing | Patient number64 | 1.3 ug/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Return of Spontaneous Breathing | Patient number68 | 1.9 ug/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Return of Spontaneous Breathing | Patient number69 | 2.1 ug/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Return of Spontaneous Breathing | Patient number70 | 2.3 ug/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Return of Spontaneous Breathing | Patient number73 | 1.7 ug/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Return of Spontaneous Breathing | Patient number77 | 1.5 ug/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Return of Spontaneous Breathing | Patient number78 | 1.9 ug/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Return of Spontaneous Breathing | Patient number81 | 1.9 ug/ml |
Other Pre-specified
Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Tracheal Intubation
Predicted effect-site concentrations of propofol after intranasal placebo at tracheal intubation. Propofol was infused intraoperatively to a target-controlled infusion (TCI) plasma concentration of 2.5μg∙ml-1 using DiprifusorTM software. The infusion rate was adjusted via plasma concentration increments of 0.5 μg∙ml-1 at 2-min intervals to maintain the Narcotrend index between 'D0' and 'E1' until the end of surgery.
Time frame: 1 day
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Tracheal Intubation | Patient number1 | 2.1 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Tracheal Intubation | Patient number4 | 2.5 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Tracheal Intubation | Patient number8 | 1.4 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Tracheal Intubation | Patient number12 | 1.4 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Tracheal Intubation | Patient number13 | 1.1 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Tracheal Intubation | Patient number14 | 3.6 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Tracheal Intubation | Patient number15 | 1.4 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Tracheal Intubation | Patient number16 | 2.4 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Tracheal Intubation | Patient number17 | 2.6 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Tracheal Intubation | Patient number19 | 4.3 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Tracheal Intubation | Patient number20 | 2.1 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Tracheal Intubation | Patient number21 | 3 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Tracheal Intubation | Patient number22 | 1.9 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Tracheal Intubation | Patient number23 | 1 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Tracheal Intubation | Patient number26 | 3.3 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Tracheal Intubation | Patient number27 | 2.5 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Tracheal Intubation | Patient number30 | 3.3 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Tracheal Intubation | Patient number32 | 3.8 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Tracheal Intubation | Patient number34 | 2.2 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Tracheal Intubation | Patient number35 | 1 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Tracheal Intubation | Patient number37 | 2.1 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Tracheal Intubation | Patient number39 | 3.3 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Tracheal Intubation | Patient number41 | 3.5 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Tracheal Intubation | Patient number42 | 2.1 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Tracheal Intubation | Patient number43 | 2.6 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Tracheal Intubation | Patient number45 | 3.2 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Tracheal Intubation | Patient number47 | 2.4 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Tracheal Intubation | Patient number48 | 2.9 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Tracheal Intubation | Patient number49 | 2.2 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Tracheal Intubation | Patient number51 | 1.7 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Tracheal Intubation | Patient number54 | 1.5 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Tracheal Intubation | Patient number55 | 2.2 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Tracheal Intubation | Patient number60 | 2.7 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Tracheal Intubation | Patient number64 | 2.4 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Tracheal Intubation | Patient number68 | 2.5 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Tracheal Intubation | Patient number69 | 2.3 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Tracheal Intubation | Patient number70 | 1.2 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Tracheal Intubation | Patient number73 | 1.7 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Tracheal Intubation | Patient number77 | 1.7 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Tracheal Intubation | Patient number78 | 1.7 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo at Tracheal Intubation | Patient number81 | 2.3 µg/ml |
Other Pre-specified
Predicted Effect-site Concentrations of Propofol After Intranasal Placebo Before Inserting Operative Laryngoscope
Predicted effect-site concentrations of propofol after intranasal placebo before inserting operative laryngoscope. Propofol was infused intraoperatively to a TCI plasma concentration of 2.5μg∙ml-1 using DiprifusorTM software. The infusion rate was adjusted via plasma concentration increments of 0.5 μg∙ml-1 at 2-min intervals to maintain the Narcotrend index between 'D0' and 'E1' until the end of surgery.
Time frame: 1 day
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo Before Inserting Operative Laryngoscope | Patient number1 | 3 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo Before Inserting Operative Laryngoscope | Patient number4 | 3.5 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo Before Inserting Operative Laryngoscope | Patient number8 | 3 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo Before Inserting Operative Laryngoscope | Patient number12 | 3 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo Before Inserting Operative Laryngoscope | Patient number13 | 2.5 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo Before Inserting Operative Laryngoscope | Patient number14 | 4.9 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo Before Inserting Operative Laryngoscope | Patient number15 | 3.4 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo Before Inserting Operative Laryngoscope | Patient number16 | 3.5 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo Before Inserting Operative Laryngoscope | Patient number17 | 4 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo Before Inserting Operative Laryngoscope | Patient number19 | 5 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo Before Inserting Operative Laryngoscope | Patient number20 | 3.5 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo Before Inserting Operative Laryngoscope | Patient number21 | 4.3 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo Before Inserting Operative Laryngoscope | Patient number22 | 3.8 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo Before Inserting Operative Laryngoscope | Patient number23 | 2.5 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo Before Inserting Operative Laryngoscope | Patient number26 | 4.5 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo Before Inserting Operative Laryngoscope | Patient number27 | 3.4 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo Before Inserting Operative Laryngoscope | Patient number30 | 4.5 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo Before Inserting Operative Laryngoscope | Patient number32 | 4.9 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo Before Inserting Operative Laryngoscope | Patient number34 | 3.9 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo Before Inserting Operative Laryngoscope | Patient number35 | 2.9 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo Before Inserting Operative Laryngoscope | Patient number37 | 4.4 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo Before Inserting Operative Laryngoscope | Patient number39 | 4 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo Before Inserting Operative Laryngoscope | Patient number41 | 4.5 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo Before Inserting Operative Laryngoscope | Patient number42 | 3.5 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo Before Inserting Operative Laryngoscope | Patient number43 | 4 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo Before Inserting Operative Laryngoscope | Patient number45 | 3.9 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo Before Inserting Operative Laryngoscope | Patient number47 | 3.9 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo Before Inserting Operative Laryngoscope | Patient number48 | 4 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo Before Inserting Operative Laryngoscope | Patient number49 | 3.5 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo Before Inserting Operative Laryngoscope | Patient number51 | 3 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo Before Inserting Operative Laryngoscope | Patient number54 | 3 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo Before Inserting Operative Laryngoscope | Patient number55 | 3.5 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo Before Inserting Operative Laryngoscope | Patient number60 | 4.5 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo Before Inserting Operative Laryngoscope | Patient number64 | 3.9 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo Before Inserting Operative Laryngoscope | Patient number68 | 3.3 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo Before Inserting Operative Laryngoscope | Patient number69 | 3.4 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo Before Inserting Operative Laryngoscope | Patient number70 | 3 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo Before Inserting Operative Laryngoscope | Patient number73 | 3.4 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo Before Inserting Operative Laryngoscope | Patient number77 | 2.9 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo Before Inserting Operative Laryngoscope | Patient number78 | 3.5 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo Before Inserting Operative Laryngoscope | Patient number81 | 3.7 µg/ml |
Other Pre-specified
Predicted Effect-site Concentrations of Propofol After Intranasal Placebo on Removal of Operative Laryngoscope
Predicted effect-site concentrations of propofol after intranasal placebo on removal of operative laryngoscope. Propofol was infused intraoperatively to a TCI plasma concentration of 2.5μg∙ml-1 using DiprifusorTM software. The infusion rate was adjusted via plasma concentration increments of 0.5 μg∙ml-1 at 2-min intervals to maintain the Narcotrend index between 'D0' and 'E1' until the end of surgery.
Time frame: 1 day
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo on Removal of Operative Laryngoscope | Patient number1 | 3 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo on Removal of Operative Laryngoscope | Patient number4 | 3.5 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo on Removal of Operative Laryngoscope | Patient number8 | 3 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo on Removal of Operative Laryngoscope | Patient number12 | 3 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo on Removal of Operative Laryngoscope | Patient number13 | 2.5 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo on Removal of Operative Laryngoscope | Patient number14 | 4.5 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo on Removal of Operative Laryngoscope | Patient number15 | 3.5 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo on Removal of Operative Laryngoscope | Patient number16 | 3.5 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo on Removal of Operative Laryngoscope | Patient number17 | 4 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo on Removal of Operative Laryngoscope | Patient number19 | 4.5 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo on Removal of Operative Laryngoscope | Patient number20 | 3.5 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo on Removal of Operative Laryngoscope | Patient number21 | 4.5 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo on Removal of Operative Laryngoscope | Patient number22 | 4 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo on Removal of Operative Laryngoscope | Patient number23 | 2.5 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo on Removal of Operative Laryngoscope | Patient number26 | 4 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo on Removal of Operative Laryngoscope | Patient number27 | 3 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo on Removal of Operative Laryngoscope | Patient number30 | 4.5 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo on Removal of Operative Laryngoscope | Patient number32 | 5 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo on Removal of Operative Laryngoscope | Patient number34 | 4 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo on Removal of Operative Laryngoscope | Patient number35 | 3 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo on Removal of Operative Laryngoscope | Patient number37 | 4.5 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo on Removal of Operative Laryngoscope | Patient number39 | 4 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo on Removal of Operative Laryngoscope | Patient number41 | 4.5 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo on Removal of Operative Laryngoscope | Patient number42 | 3.5 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo on Removal of Operative Laryngoscope | Patient number43 | 4 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo on Removal of Operative Laryngoscope | Patient number45 | 4 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo on Removal of Operative Laryngoscope | Patient number47 | 4 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo on Removal of Operative Laryngoscope | Patient number48 | 4 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo on Removal of Operative Laryngoscope | Patient number49 | 3.5 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo on Removal of Operative Laryngoscope | Patient number51 | 3 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo on Removal of Operative Laryngoscope | Patient number54 | 3 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo on Removal of Operative Laryngoscope | Patient number55 | 3.5 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo on Removal of Operative Laryngoscope | Patient number60 | 4.5 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo on Removal of Operative Laryngoscope | Patient number64 | 4 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo on Removal of Operative Laryngoscope | Patient number68 | 3.5 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo on Removal of Operative Laryngoscope | Patient number69 | 3.5 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo on Removal of Operative Laryngoscope | Patient number70 | 3 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo on Removal of Operative Laryngoscope | Patient number73 | 3.5 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo on Removal of Operative Laryngoscope | Patient number77 | 3 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo on Removal of Operative Laryngoscope | Patient number78 | 3.5 µg/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Propofol After Intranasal Placebo on Removal of Operative Laryngoscope | Patient number81 | 3.6 µg/ml |
Other Pre-specified
Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Emergence
Predicted effect-site concentrations of remifentanil after intranasal dexmedetomidine at emergence. Remifentanil was infused to achieve a TCI plasma concentration of 3.0 ng∙ml-1 using the Minto pharmacokinetic model 24 and then adjusted to maintain the systolic blood pressure (SBP) at 25% of the pre-operative value and the HR at less than 90 bpm. To maintain a neuromuscular blockade, 0.15 mg∙kg-1 increments of rocuronium were infused upon observation of the first twitch in a train-of-four response with the nerve stimulator
Time frame: 1 day
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Emergence | Patient number52 | 0.3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Emergence | Patient number53 | 0.3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Emergence | Patient number56 | 0.1 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Emergence | Patient number57 | 0.2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Emergence | Patient number58 | 0.3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Emergence | Patient number59 | 0.14 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Emergence | Patient number61 | 0.2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Emergence | Patient number62 | 0.1 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Emergence | Patient number63 | 0.06 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Emergence | Patient number65 | 0.1 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Emergence | Patient number66 | 0.24 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Emergence | Patient number67 | 0.18 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Emergence | Patient number71 | 0.3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Emergence | Patient number72 | 0.4 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Emergence | Patient number74 | 0.47 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Emergence | Patient number75 | 0.28 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Emergence | Patient number76 | 0.2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Emergence | Patient number79 | 0.18 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Emergence | Patient number80 | 0.05 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Emergence | Patient number10 | 0.23 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Emergence | Patient number2 | 0.27 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Emergence | Patient number3 | 0.18 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Emergence | Patient number5 | 0.2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Emergence | Patient number6 | 0.27 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Emergence | Patient number7 | 0.18 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Emergence | Patient number9 | 0.32 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Emergence | Patient number11 | 0.27 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Emergence | Patient number18 | 0.37 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Emergence | Patient number24 | 0.1 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Emergence | Patient number25 | 0.18 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Emergence | Patient number28 | 0.24 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Emergence | Patient number29 | 0.04 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Emergence | Patient number31 | 0.23 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Emergence | Patient number33 | 0.1 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Emergence | Patient number36 | 0.24 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Emergence | Patient number38 | 0.11 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Emergence | Patient number40 | 0.14 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Emergence | Patient number44 | 0.02 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Emergence | Patient number46 | 0.29 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Emergence | Patient number50 | 0.28 ng/ml |
Other Pre-specified
Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Extubation
Predicted effect-site concentrations of remifentanil after intranasal dexmedetomidine at extubation. Remifentanil was infused to achieve a TCI plasma concentration of 3.0 ng∙ml-1 using the Minto pharmacokinetic model 24 and then adjusted to maintain the systolic blood pressure (SBP) at 25% of the pre-operative value and the HR at less than 90 bpm. To maintain a neuromuscular blockade, 0.15 mg∙kg-1 increments of rocuronium were infused upon observation of the first twitch in a train-of-four response with the nerve stimulator
Time frame: 1 day
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Extubation | Patient number2 | 0.24 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Extubation | Patient number3 | 0.16 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Extubation | Patient number5 | 0.16 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Extubation | Patient number6 | 0.2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Extubation | Patient number7 | 0.14 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Extubation | Patient number9 | 0.29 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Extubation | Patient number14 | 0.23 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Extubation | Patient number11 | 0.2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Extubation | Patient number18 | 0.28 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Extubation | Patient number24 | 0.08 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Extubation | Patient number25 | 0.14 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Extubation | Patient number28 | 0.18 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Extubation | Patient number29 | 0.03 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Extubation | Patient number31 | 0.18 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Extubation | Patient number33 | 0.07 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Extubation | Patient number36 | 0.13 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Extubation | Patient number38 | 0.08 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Extubation | Patient number40 | 0.11 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Extubation | Patient number44 | 0.01 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Extubation | Patient number46 | 0.23 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Extubation | Patient number50 | 0.23 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Extubation | Patient number52 | 0.27 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Extubation | Patient number53 | 0.27 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Extubation | Patient number56 | 0.08 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Extubation | Patient number57 | 0.17 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Extubation | Patient number63 | 0.04 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Extubation | Patient number58 | 0.2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Extubation | Patient number59 | 0.1 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Extubation | Patient number61 | 0.1 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Extubation | Patient number62 | 0.07 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Extubation | Patient number65 | 0.06 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Extubation | Patient number66 | 0.18 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Extubation | Patient number67 | 0.11 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Extubation | Patient number71 | 0.27 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Extubation | Patient number72 | 0.4 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Extubation | Patient number74 | 0.41 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Extubation | Patient number75 | 0.26 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Extubation | Patient number76 | 0.16 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Extubation | Patient number79 | 0.14 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Extubation | Patient number80 | 0.04 ng/ml |
Other Pre-specified
Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Return of Spontaneous Breathing
Predicted effect-site concentrations of remifentanil after intranasal dexmedetomidine at return of spontaneous breathing. Remifentanil was infused to achieve a TCI plasma concentration of 3.0 ng∙ml-1 using the Minto pharmacokinetic model 24 and then adjusted to maintain the systolic blood pressure (SBP) at 25% of the pre-operative value and the HR at less than 90 bpm. To maintain a neuromuscular blockade, 0.15 mg∙kg-1 increments of rocuronium were infused upon observation of the first twitch in a train-of-four response with the nerve stimulator
Time frame: 1 day
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Return of Spontaneous Breathing | Patient number2 | 0.6 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Return of Spontaneous Breathing | Patient number3 | 0.7 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Return of Spontaneous Breathing | Patient number5 | 0.56 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Return of Spontaneous Breathing | Patient number6 | 0.6 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Return of Spontaneous Breathing | Patient number7 | 0.6 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Return of Spontaneous Breathing | Patient number9 | 0.6 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Return of Spontaneous Breathing | Patient number10 | 0.83 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Return of Spontaneous Breathing | Patient number11 | 0.4 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Return of Spontaneous Breathing | Patient number18 | 0.75 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Return of Spontaneous Breathing | Patient number24 | 0.18 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Return of Spontaneous Breathing | Patient number25 | 0.3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Return of Spontaneous Breathing | Patient number28 | 0.7 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Return of Spontaneous Breathing | Patient number29 | 0.6 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Return of Spontaneous Breathing | Patient number31 | 0.47 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Return of Spontaneous Breathing | Patient number33 | 0.35 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Return of Spontaneous Breathing | Patient number36 | 0.6 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Return of Spontaneous Breathing | Patient number38 | 0.4 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Return of Spontaneous Breathing | Patient number40 | 0.4 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Return of Spontaneous Breathing | Patient number44 | 0.47 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Return of Spontaneous Breathing | Patient number46 | 0.71 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Return of Spontaneous Breathing | Patient number50 | 0.75 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Return of Spontaneous Breathing | Patient number52 | 0.5 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Return of Spontaneous Breathing | Patient number52 | 0.7 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Return of Spontaneous Breathing | Patient number56 | 0.5 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Return of Spontaneous Breathing | Patient number57 | 0.56 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Return of Spontaneous Breathing | Patient number58 | 1.28 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Return of Spontaneous Breathing | Patient number59 | 0.35 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Return of Spontaneous Breathing | Patient number61 | 1.28 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Return of Spontaneous Breathing | Patient number62 | 0.5 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Return of Spontaneous Breathing | Patient number63 | 0.2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Return of Spontaneous Breathing | Patient number65 | 0.3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Return of Spontaneous Breathing | Patient number66 | 0.5 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Return of Spontaneous Breathing | Patient number67 | 0.41 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Return of Spontaneous Breathing | Patient number71 | 0.6 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Return of Spontaneous Breathing | Patient number72 | 0.78 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Return of Spontaneous Breathing | Patient number74 | 0.6 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Return of Spontaneous Breathing | Patient number75 | 1 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Return of Spontaneous Breathing | Patient number76 | 0.27 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Return of Spontaneous Breathing | Patient number79 | 0.5 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Return of Spontaneous Breathing | Patient number80 | 0.09 ng/ml |
Other Pre-specified
Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Tracheal Intubation
Predicted effect-site concentrations of remifentanil after intranasal dexmedetomidine at tracheal intubation. Remifentanil was infused to achieve a TCI plasma concentration of 3.0 ng∙ml-1 using the Minto pharmacokinetic model 24 and then adjusted to maintain the systolic blood pressure (SBP) at 25% of the pre-operative value and the HR at less than 90 bpm. To maintain a neuromuscular blockade, 0.15 mg∙kg-1 increments of rocuronium were infused upon observation of the first twitch in a train-of-four response with the nerve stimulator
Time frame: 1 day
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Tracheal Intubation | Patient number2 | 3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Tracheal Intubation | Patient number3 | 3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Tracheal Intubation | Patient number5 | 3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Tracheal Intubation | Patient number6 | 3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Tracheal Intubation | Patient number7 | 3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Tracheal Intubation | Patient number9 | 3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Tracheal Intubation | Patient number10 | 3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Tracheal Intubation | Patient number11 | 3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Tracheal Intubation | Patient number18 | 3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Tracheal Intubation | Patient number24 | 3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Tracheal Intubation | Patient number25 | 3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Tracheal Intubation | Patient number28 | 3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Tracheal Intubation | Patient number61 | 3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Tracheal Intubation | Patient number29 | 3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Tracheal Intubation | Patient number31 | 3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Tracheal Intubation | Patient number33 | 3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Tracheal Intubation | Patient number36 | 3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Tracheal Intubation | Patient number38 | 3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Tracheal Intubation | Patient number40 | 3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Tracheal Intubation | Patient number44 | 3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Tracheal Intubation | Patient number46 | 3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Tracheal Intubation | Patient number50 | 3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Tracheal Intubation | Patient number52 | 3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Tracheal Intubation | Patient number53 | 3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Tracheal Intubation | Patient number56 | 3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Tracheal Intubation | Patient number57 | 3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Tracheal Intubation | Patient number58 | 3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Tracheal Intubation | Patient number59 | 3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Tracheal Intubation | Patient number62 | 3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Tracheal Intubation | Patient number63 | 3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Tracheal Intubation | Patient number65 | 3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Tracheal Intubation | Patient number66 | 3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Tracheal Intubation | Patient number67 | 3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Tracheal Intubation | Patient number71 | 3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Tracheal Intubation | Patient number72 | 3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Tracheal Intubation | Patient number74 | 3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Tracheal Intubation | Patient number75 | 3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Tracheal Intubation | Patient number76 | 3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Tracheal Intubation | Patient number79 | 3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine at Tracheal Intubation | Patient number80 | 3 ng/ml |
Other Pre-specified
Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine Before Inserting Operative Laryngoscope
Predicted effect-site concentrations of remifentanil after intranasal dexmedetomidine before inserting operative laryngoscope. Remifentanil was infused to achieve a TCI plasma concentration of 3.0 ng∙ml-1 using the Minto pharmacokinetic model 24 and then adjusted to maintain the systolic blood pressure (SBP) at 25% of the pre-operative value and the HR at less than 90 bpm. To maintain a neuromuscular blockade, 0.15 mg∙kg-1 increments of rocuronium were infused upon observation of the first twitch in a train-of-four response with the nerve stimulator
Time frame: 1 day
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine Before Inserting Operative Laryngoscope | Patient number2 | 2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine Before Inserting Operative Laryngoscope | Patient number3 | 2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine Before Inserting Operative Laryngoscope | Patient number5 | 2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine Before Inserting Operative Laryngoscope | Patient number6 | 2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine Before Inserting Operative Laryngoscope | Patient number7 | 2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine Before Inserting Operative Laryngoscope | Patient number9 | 2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine Before Inserting Operative Laryngoscope | Patient number10 | 2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine Before Inserting Operative Laryngoscope | Patient number11 | 2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine Before Inserting Operative Laryngoscope | Patient number18 | 2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine Before Inserting Operative Laryngoscope | Patient number24 | 2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine Before Inserting Operative Laryngoscope | Patient number25 | 2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine Before Inserting Operative Laryngoscope | Patient number28 | 2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine Before Inserting Operative Laryngoscope | Patient number29 | 2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine Before Inserting Operative Laryngoscope | Patient number31 | 2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine Before Inserting Operative Laryngoscope | Patient number33 | 2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine Before Inserting Operative Laryngoscope | Patient number36 | 2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine Before Inserting Operative Laryngoscope | Patient number38 | 2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine Before Inserting Operative Laryngoscope | Patient number40 | 2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine Before Inserting Operative Laryngoscope | Patient number44 | 2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine Before Inserting Operative Laryngoscope | Patient number46 | 2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine Before Inserting Operative Laryngoscope | Patient number50 | 2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine Before Inserting Operative Laryngoscope | Patient number52 | 2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine Before Inserting Operative Laryngoscope | Patient number53 | 2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine Before Inserting Operative Laryngoscope | Patient number56 | 2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine Before Inserting Operative Laryngoscope | Patient number57 | 2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine Before Inserting Operative Laryngoscope | Patient number58 | 2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine Before Inserting Operative Laryngoscope | Patient number59 | 2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine Before Inserting Operative Laryngoscope | Patient number61 | 2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine Before Inserting Operative Laryngoscope | Patient number62 | 2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine Before Inserting Operative Laryngoscope | Patient number63 | 2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine Before Inserting Operative Laryngoscope | Patient number65 | 2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine Before Inserting Operative Laryngoscope | Patient number66 | 2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine Before Inserting Operative Laryngoscope | Patient number67 | 2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine Before Inserting Operative Laryngoscope | Patient number71 | 2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine Before Inserting Operative Laryngoscope | Patient number72 | 2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine Before Inserting Operative Laryngoscope | Patient number74 | 2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine Before Inserting Operative Laryngoscope | Patient number75 | 2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine Before Inserting Operative Laryngoscope | Patient number76 | 2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine Before Inserting Operative Laryngoscope | Patient number79 | 2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine Before Inserting Operative Laryngoscope | Patient number80 | 2 ng/ml |
Other Pre-specified
Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine on Removal of Operative Laryngoscope
Predicted effect-site concentrations of remifentanil after intranasal dexmedetomidine on removal of operative laryngoscope. Remifentanil was infused to achieve a TCI plasma concentration of 3.0 ng∙ml-1 using the Minto pharmacokinetic model 24 and then adjusted to maintain the systolic blood pressure (SBP) at 25% of the pre-operative value and the HR at less than 90 bpm. To maintain a neuromuscular blockade, 0.15 mg∙kg-1 increments of rocuronium were infused upon observation of the first twitch in a train-of-four response with the nerve stimulator
Time frame: 1 day
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine on Removal of Operative Laryngoscope | Patient number2 | 2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine on Removal of Operative Laryngoscope | Patient number3 | 2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine on Removal of Operative Laryngoscope | Patient number5 | 2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine on Removal of Operative Laryngoscope | Patient number6 | 2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine on Removal of Operative Laryngoscope | Patient number7 | 2.5 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine on Removal of Operative Laryngoscope | Patient number9 | 2.5 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine on Removal of Operative Laryngoscope | Patient number10 | 2.5 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine on Removal of Operative Laryngoscope | Patient number11 | 2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine on Removal of Operative Laryngoscope | Patient number18 | 3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine on Removal of Operative Laryngoscope | Patient number24 | 2.5 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine on Removal of Operative Laryngoscope | Patient number25 | 2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine on Removal of Operative Laryngoscope | Patient number28 | 2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine on Removal of Operative Laryngoscope | Patient number29 | 3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine on Removal of Operative Laryngoscope | Patient number31 | 3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine on Removal of Operative Laryngoscope | Patient number33 | 2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine on Removal of Operative Laryngoscope | Patient number36 | 2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine on Removal of Operative Laryngoscope | Patient number38 | 2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine on Removal of Operative Laryngoscope | Patient number40 | 2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine on Removal of Operative Laryngoscope | Patient number44 | 3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine on Removal of Operative Laryngoscope | Patient number46 | 2.5 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine on Removal of Operative Laryngoscope | Patient number50 | 3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine on Removal of Operative Laryngoscope | Patient number52 | 2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine on Removal of Operative Laryngoscope | Patient number53 | 2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine on Removal of Operative Laryngoscope | Patient number56 | 2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine on Removal of Operative Laryngoscope | Patient number57 | 2.5 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine on Removal of Operative Laryngoscope | Patient number58 | 4 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine on Removal of Operative Laryngoscope | Patient number59 | 2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine on Removal of Operative Laryngoscope | Patient number61 | 4 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine on Removal of Operative Laryngoscope | Patient number62 | 2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine on Removal of Operative Laryngoscope | Patient number63 | 2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine on Removal of Operative Laryngoscope | Patient number65 | 2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine on Removal of Operative Laryngoscope | Patient number66 | 2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine on Removal of Operative Laryngoscope | Patient number67 | 3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine on Removal of Operative Laryngoscope | Patient number71 | 2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine on Removal of Operative Laryngoscope | Patient number72 | 3.5 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine on Removal of Operative Laryngoscope | Patient number74 | 3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine on Removal of Operative Laryngoscope | Patient number75 | 3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine on Removal of Operative Laryngoscope | Patient number76 | 2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine on Removal of Operative Laryngoscope | Patient number79 | 2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Dexmedetomidine on Removal of Operative Laryngoscope | Patient number80 | 2 ng/ml |
Other Pre-specified
Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Emergence
Predicted effect-site concentrations of remifentanil after intranasal placebo at emergence. Remifentanil was infused to achieve a TCI plasma concentration of 3.0 ng∙ml-1 using the Minto pharmacokinetic model 24 and then adjusted to maintain the systolic blood pressure (SBP) at 25% of the pre-operative value and the HR at less than 90 bpm. To maintain a neuromuscular blockade, 0.15 mg∙kg-1 increments of rocuronium were infused upon observation of the first twitch in a train-of-four response with the nerve stimulator
Time frame: 1 day
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Emergence | Patient number1 | 0.54 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Emergence | Patient number4 | 0.47 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Emergence | Patient number8 | 0.8 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Emergence | Patient number12 | 1.1 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Emergence | Patient number13 | 0.4 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Emergence | Patient number14 | 0.7 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Emergence | Patient number15 | 0.04 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Emergence | Patient number16 | 0.3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Emergence | Patient number17 | 0.13 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Emergence | Patient number19 | 0.1 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Emergence | Patient number20 | 0.14 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Emergence | Patient number21 | 0.16 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Emergence | Patient number22 | 0.37 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Emergence | Patient number23 | 0.41 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Emergence | Patient number26 | 0.4 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Emergence | Patient number27 | 0.3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Emergence | Patient number30 | 0.16 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Emergence | Patient number32 | 0.4 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Emergence | Patient number34 | 0.14 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Emergence | Patient number35 | 0.29 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Emergence | Patient number37 | 0.37 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Emergence | Patient number39 | 0.4 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Emergence | Patient number41 | 0.4 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Emergence | Patient number42 | 0.28 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Emergence | Patient number43 | 0.16 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Emergence | Patient number45 | 0.3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Emergence | Patient number47 | 0.8 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Emergence | Patient number48 | 0.4 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Emergence | Patient number49 | 0.28 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Emergence | Patient number51 | 0.2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Emergence | Patient number54 | 0.98 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Emergence | Patient number55 | 0.04 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Emergence | Patient number60 | 0.32 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Emergence | Patient number64 | 0.29 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Emergence | Patient number68 | 0.27 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Emergence | Patient number69 | 0.24 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Emergence | Patient number70 | 0.29 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Emergence | Patient number73 | 0.1 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Emergence | Patient number77 | 0.2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Emergence | Patient number78 | 0.02 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Emergence | Patient number81 | 0.34 ng/ml |
Other Pre-specified
Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Extubation
Predicted effect-site concentrations of remifentanil after intranasal placebo at extubation. Remifentanil was infused to achieve a TCI plasma concentration of 3.0 ng∙ml-1 using the Minto pharmacokinetic model 24 and then adjusted to maintain the systolic blood pressure (SBP) at 25% of the pre-operative value and the HR at less than 90 bpm. To maintain a neuromuscular blockade, 0.15 mg∙kg-1 increments of rocuronium were infused upon observation of the first twitch in a train-of-four response with the nerve stimulator
Time frame: 1 day
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Extubation | Patient number1 | 0.41 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Extubation | Patient number4 | 0.37 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Extubation | Patient number8 | 0.7 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Extubation | Patient number12 | 0.8 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Extubation | Patient number13 | 0.3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Extubation | Patient number14 | 0.5 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Extubation | Patient number15 | 0.03 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Extubation | Patient number16 | 0.2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Extubation | Patient number17 | 0.1 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Extubation | Patient number19 | 0.08 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Extubation | Patient number20 | 0.11 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Extubation | Patient number21 | 0.13 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Extubation | Patient number22 | 0.29 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Extubation | Patient number23 | 0.37 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Extubation | Patient number26 | 0.3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Extubation | Patient number27 | 0.22 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Extubation | Patient number30 | 0.11 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Extubation | Patient number32 | 0.3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Extubation | Patient number34 | 0.1 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Extubation | Patient number35 | 0.18 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Extubation | Patient number37 | 0.29 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Extubation | Patient number39 | 0.3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Extubation | Patient number41 | 0.3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Extubation | Patient number42 | 0.23 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Extubation | Patient number43 | 0.14 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Extubation | Patient number45 | 0.2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Extubation | Patient number47 | 0.7 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Extubation | Patient number48 | 0.35 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Extubation | Patient number49 | 0.23 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Extubation | Patient number51 | 0.1 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Extubation | Patient number54 | 0.6 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Extubation | Patient number55 | 0.04 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Extubation | Patient number60 | 0.26 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Extubation | Patient number64 | 0.26 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Extubation | Patient number68 | 0.2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Extubation | Patient number69 | 0.14 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Extubation | Patient number70 | 0.23 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Extubation | Patient number73 | 0.1 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Extubation | Patient number77 | 0.16 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Extubation | Patient number78 | 0.02 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Extubation | Patient number81 | 0.26 ng/ml |
Other Pre-specified
Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Return of Spontaneous Breathing
Predicted effect-site concentrations of remifentanil after intranasal placebo at return of spontaneous breathing. Remifentanil was infused to achieve a TCI plasma concentration of 3.0 ng∙ml-1 using the Minto pharmacokinetic model 24 and then adjusted to maintain the systolic blood pressure (SBP) at 25% of the pre-operative value and the HR at less than 90 bpm. To maintain a neuromuscular blockade, 0.15 mg∙kg-1 increments of rocuronium were infused upon observation of the first twitch in a train-of-four response with the nerve stimulator
Time frame: 1 day
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Return of Spontaneous Breathing | Patient number22 | 0.54 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Return of Spontaneous Breathing | Patient number1 | 0.98 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Return of Spontaneous Breathing | Patient number4 | 1.03 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Return of Spontaneous Breathing | Patient number8 | 1 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Return of Spontaneous Breathing | Patient number12 | 1.3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Return of Spontaneous Breathing | Patient number13 | 0.8 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Return of Spontaneous Breathing | Patient number14 | 1.3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Return of Spontaneous Breathing | Patient number15 | 0.27 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Return of Spontaneous Breathing | Patient number16 | 0.7 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Return of Spontaneous Breathing | Patient number17 | 0.35 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Return of Spontaneous Breathing | Patient number19 | 0.3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Return of Spontaneous Breathing | Patient number20 | 0.98 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Return of Spontaneous Breathing | Patient number21 | 0.35 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Return of Spontaneous Breathing | Patient number23 | 0.6 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Return of Spontaneous Breathing | Patient number26 | 0.8 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Return of Spontaneous Breathing | Patient number27 | 0.7 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Return of Spontaneous Breathing | Patient number30 | 0.2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Return of Spontaneous Breathing | Patient number32 | 0.9 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Return of Spontaneous Breathing | Patient number34 | 0.5 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Return of Spontaneous Breathing | Patient number35 | 0.6 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Return of Spontaneous Breathing | Patient number37 | 0.6 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Return of Spontaneous Breathing | Patient number39 | 1 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Return of Spontaneous Breathing | Patient number41 | 1.1 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Return of Spontaneous Breathing | Patient number42 | 0.6 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Return of Spontaneous Breathing | Patient number43 | 0.5 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Return of Spontaneous Breathing | Patient number45 | 1.1 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Return of Spontaneous Breathing | Patient number47 | 1.3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Return of Spontaneous Breathing | Patient number48 | 0.6 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Return of Spontaneous Breathing | Patient number49 | 1.28 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Return of Spontaneous Breathing | Patient number51 | 0.78 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Return of Spontaneous Breathing | Patient number54 | 1.4 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Return of Spontaneous Breathing | Patient number55 | 0.16 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Return of Spontaneous Breathing | Patient number60 | 1 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Return of Spontaneous Breathing | Patient number64 | 0.41 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Return of Spontaneous Breathing | Patient number68 | 0.5 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Return of Spontaneous Breathing | Patient number69 | 0.6 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Return of Spontaneous Breathing | Patient number70 | 1.2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Return of Spontaneous Breathing | Patient number73 | 0.9 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Return of Spontaneous Breathing | Patient number77 | 0.4 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Return of Spontaneous Breathing | Patient number78 | 0.5 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Return of Spontaneous Breathing | Patient number81 | 0.8 ng/ml |
Other Pre-specified
Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Tracheal Intubation
Predicted effect-site concentrations of remifentanil after intranasal placebo at tracheal intubation. Remifentanil was infused to achieve a TCI plasma concentration of 3.0 ng∙ml-1 using the Minto pharmacokinetic model 24 and then adjusted to maintain the systolic blood pressure (SBP) at 25% of the pre-operative value and the HR at less than 90 bpm. To maintain a neuromuscular blockade, 0.15 mg∙kg-1 increments of rocuronium were infused upon observation of the first twitch in a train-of-four response with the nerve stimulator
Time frame: 1 day
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Tracheal Intubation | Patient number1 | 3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Tracheal Intubation | Patient number4 | 3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Tracheal Intubation | Patient number23 | 3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Tracheal Intubation | Patient number8 | 3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Tracheal Intubation | Patient number12 | 3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Tracheal Intubation | Patient number13 | 3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Tracheal Intubation | Patient number14 | 3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Tracheal Intubation | Patient number15 | 3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Tracheal Intubation | Patient number16 | 3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Tracheal Intubation | Patient number17 | 3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Tracheal Intubation | Patient number19 | 3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Tracheal Intubation | Patient number20 | 3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Tracheal Intubation | Patient number21 | 3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Tracheal Intubation | Patient number22 | 3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Tracheal Intubation | Patient number26 | 3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Tracheal Intubation | Patient number27 | 3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Tracheal Intubation | Patient number30 | 3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Tracheal Intubation | Patient number32 | 3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Tracheal Intubation | Patient number34 | 3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Tracheal Intubation | Patient number35 | 3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Tracheal Intubation | Patient number37 | 3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Tracheal Intubation | Patient number39 | 3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Tracheal Intubation | Patient number41 | 3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Tracheal Intubation | Patient number42 | 3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Tracheal Intubation | Patient number43 | 3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Tracheal Intubation | Patient number45 | 3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Tracheal Intubation | Patient number47 | 3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Tracheal Intubation | Patient number48 | 3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Tracheal Intubation | Patient number49 | 3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Tracheal Intubation | Patient number51 | 3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Tracheal Intubation | Patient number54 | 3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Tracheal Intubation | Patient number55 | 3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Tracheal Intubation | Patient number60 | 3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Tracheal Intubation | Patient number64 | 3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Tracheal Intubation | Patient number68 | 3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Tracheal Intubation | Patient number69 | 3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Tracheal Intubation | Patient number70 | 3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Tracheal Intubation | Patient number73 | 3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Tracheal Intubation | Patient number77 | 3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Tracheal Intubation | Patient number81 | 3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo at Tracheal Intubation | Patient number78 | 3 ng/ml |
Other Pre-specified
Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo Before Inserting Operative Laryngoscope
Predicted effect-site concentrations of remifentanil after intranasal placebo before inserting operative laryngoscope. Remifentanil was infused to achieve a TCI plasma concentration of 3.0 ng∙ml-1 using the Minto pharmacokinetic model 24 and then adjusted to maintain the systolic blood pressure (SBP) at 25% of the pre-operative value and the HR at less than 90 bpm. To maintain a neuromuscular blockade, 0.15 mg∙kg-1 increments of rocuronium were infused upon observation of the first twitch in a train-of-four response with the nerve stimulator
Time frame: 1 day
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo Before Inserting Operative Laryngoscope | Patient number73 | 2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo Before Inserting Operative Laryngoscope | Patient number77 | 2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo Before Inserting Operative Laryngoscope | Patient number78 | 2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo Before Inserting Operative Laryngoscope | Patient number81 | 2.5 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo Before Inserting Operative Laryngoscope | Patient number1 | 2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo Before Inserting Operative Laryngoscope | Patient number4 | 2.5 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo Before Inserting Operative Laryngoscope | Patient number8 | 2.5 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo Before Inserting Operative Laryngoscope | Patient number12 | 3.5 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo Before Inserting Operative Laryngoscope | Patient number13 | 2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo Before Inserting Operative Laryngoscope | Patient number14 | 3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo Before Inserting Operative Laryngoscope | Patient number15 | 2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo Before Inserting Operative Laryngoscope | Patient number16 | 3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo Before Inserting Operative Laryngoscope | Patient number17 | 2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo Before Inserting Operative Laryngoscope | Patient number19 | 2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo Before Inserting Operative Laryngoscope | Patient number20 | 2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo Before Inserting Operative Laryngoscope | Patient number21 | 2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo Before Inserting Operative Laryngoscope | Patient number22 | 2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo Before Inserting Operative Laryngoscope | Patient number23 | 2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo Before Inserting Operative Laryngoscope | Patient number26 | 3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo Before Inserting Operative Laryngoscope | Patient number27 | 2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo Before Inserting Operative Laryngoscope | Patient number30 | 2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo Before Inserting Operative Laryngoscope | Patient number32 | 2.5 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo Before Inserting Operative Laryngoscope | Patient number34 | 2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo Before Inserting Operative Laryngoscope | Patient number35 | 2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo Before Inserting Operative Laryngoscope | Patient number37 | 2.5 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo Before Inserting Operative Laryngoscope | Patient number39 | 3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo Before Inserting Operative Laryngoscope | Patient number41 | 2.5 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo Before Inserting Operative Laryngoscope | Patient number42 | 2.5 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo Before Inserting Operative Laryngoscope | Patient number43 | 2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo Before Inserting Operative Laryngoscope | Patient number45 | 3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo Before Inserting Operative Laryngoscope | Patient number47 | 3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo Before Inserting Operative Laryngoscope | Patient number48 | 2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo Before Inserting Operative Laryngoscope | Patient number49 | 2.5 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo Before Inserting Operative Laryngoscope | Patient number51 | 2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo Before Inserting Operative Laryngoscope | Patient number54 | 2.5 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo Before Inserting Operative Laryngoscope | Patient number55 | 2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo Before Inserting Operative Laryngoscope | Patient number60 | 2.5 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo Before Inserting Operative Laryngoscope | Patient number64 | 2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo Before Inserting Operative Laryngoscope | Patient number68 | 2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo Before Inserting Operative Laryngoscope | Patient number69 | 2.5 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo Before Inserting Operative Laryngoscope | Patient number70 | 2 ng/ml |
Other Pre-specified
Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo on Removal of Operative Laryngoscope
Predicted effect-site concentrations of remifentanil after intranasal placebo on removal of operative laryngoscope. Remifentanil was infused to achieve a TCI plasma concentration of 3.0 ng∙ml-1 using the Minto pharmacokinetic model 24 and then adjusted to maintain the systolic blood pressure (SBP) at 25% of the pre-operative value and the HR at less than 90 bpm. To maintain a neuromuscular blockade, 0.15 mg∙kg-1 increments of rocuronium were infused upon observation of the first twitch in a train-of-four response with the nerve stimulator
Time frame: 1 day
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo on Removal of Operative Laryngoscope | Patient number1 | 2.5 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo on Removal of Operative Laryngoscope | Patient number4 | 3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo on Removal of Operative Laryngoscope | Patient number8 | 4 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo on Removal of Operative Laryngoscope | Patient number12 | 5 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo on Removal of Operative Laryngoscope | Patient number13 | 4 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo on Removal of Operative Laryngoscope | Patient number14 | 5 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo on Removal of Operative Laryngoscope | Patient number15 | 2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo on Removal of Operative Laryngoscope | Patient number16 | 4 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo on Removal of Operative Laryngoscope | Patient number17 | 2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo on Removal of Operative Laryngoscope | Patient number19 | 2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo on Removal of Operative Laryngoscope | Patient number20 | 2.5 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo on Removal of Operative Laryngoscope | Patient number21 | 2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo on Removal of Operative Laryngoscope | Patient number22 | 2.5 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo on Removal of Operative Laryngoscope | Patient number23 | 2.5 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo on Removal of Operative Laryngoscope | Patient number26 | 4.5 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo on Removal of Operative Laryngoscope | Patient number27 | 4.5 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo on Removal of Operative Laryngoscope | Patient number30 | 2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo on Removal of Operative Laryngoscope | Patient number32 | 4 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo on Removal of Operative Laryngoscope | Patient number34 | 2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo on Removal of Operative Laryngoscope | Patient number35 | 2.5 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo on Removal of Operative Laryngoscope | Patient number37 | 2.5 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo on Removal of Operative Laryngoscope | Patient number39 | 4.5 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo on Removal of Operative Laryngoscope | Patient number41 | 5 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo on Removal of Operative Laryngoscope | Patient number42 | 3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo on Removal of Operative Laryngoscope | Patient number43 | 2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo on Removal of Operative Laryngoscope | Patient number45 | 3.5 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo on Removal of Operative Laryngoscope | Patient number47 | 5 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo on Removal of Operative Laryngoscope | Patient number48 | 2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo on Removal of Operative Laryngoscope | Patient number49 | 3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo on Removal of Operative Laryngoscope | Patient number51 | 3.5 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo on Removal of Operative Laryngoscope | Patient number54 | 2.5 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo on Removal of Operative Laryngoscope | Patient number55 | 2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo on Removal of Operative Laryngoscope | Patient number60 | 3 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo on Removal of Operative Laryngoscope | Patient number64 | 2.5 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo on Removal of Operative Laryngoscope | Patient number68 | 2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo on Removal of Operative Laryngoscope | Patient number69 | 2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo on Removal of Operative Laryngoscope | Patient number70 | 2.5 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo on Removal of Operative Laryngoscope | Patient number73 | 4 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo on Removal of Operative Laryngoscope | Patient number77 | 2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo on Removal of Operative Laryngoscope | Patient number78 | 2 ng/ml |
| Dexmedetomidine | Predicted Effect-site Concentrations of Remifentanil After Intranasal Placebo on Removal of Operative Laryngoscope | Patient number81 | 3 ng/ml |
Other Pre-specified
Satisfaction Scores of Patients Receiving Intranasal Dexmedetomidine
Satisfaction scores of patients receiving intranasal dexmedetomidine. Satisfaction used a 3-point satisfaction score(1 = highly satisfactory, 2 = acceptable, and 3 = unacceptable).
Time frame: 1 day
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Dexmedetomidine | Satisfaction Scores of Patients Receiving Intranasal Dexmedetomidine | Patient number2 | 1 units on a scale |
| Dexmedetomidine | Satisfaction Scores of Patients Receiving Intranasal Dexmedetomidine | Patient number3 | 1 units on a scale |
| Dexmedetomidine | Satisfaction Scores of Patients Receiving Intranasal Dexmedetomidine | Patient number5 | 1 units on a scale |
| Dexmedetomidine | Satisfaction Scores of Patients Receiving Intranasal Dexmedetomidine | Patient number6 | 1 units on a scale |
| Dexmedetomidine | Satisfaction Scores of Patients Receiving Intranasal Dexmedetomidine | Patient number7 | 1 units on a scale |
| Dexmedetomidine | Satisfaction Scores of Patients Receiving Intranasal Dexmedetomidine | Patient number9 | 1 units on a scale |
| Dexmedetomidine | Satisfaction Scores of Patients Receiving Intranasal Dexmedetomidine | Patient number10 | 1 units on a scale |
| Dexmedetomidine | Satisfaction Scores of Patients Receiving Intranasal Dexmedetomidine | Patient number11 | 2 units on a scale |
| Dexmedetomidine | Satisfaction Scores of Patients Receiving Intranasal Dexmedetomidine | Patient number18 | 1 units on a scale |
| Dexmedetomidine | Satisfaction Scores of Patients Receiving Intranasal Dexmedetomidine | Patient number24 | 1 units on a scale |
| Dexmedetomidine | Satisfaction Scores of Patients Receiving Intranasal Dexmedetomidine | Patient number25 | 1 units on a scale |
| Dexmedetomidine | Satisfaction Scores of Patients Receiving Intranasal Dexmedetomidine | Patient number28 | 1 units on a scale |
| Dexmedetomidine | Satisfaction Scores of Patients Receiving Intranasal Dexmedetomidine | Patient number29 | 1 units on a scale |
| Dexmedetomidine | Satisfaction Scores of Patients Receiving Intranasal Dexmedetomidine | Patient number31 | 2 units on a scale |
| Dexmedetomidine | Satisfaction Scores of Patients Receiving Intranasal Dexmedetomidine | Patient number33 | 1 units on a scale |
| Dexmedetomidine | Satisfaction Scores of Patients Receiving Intranasal Dexmedetomidine | Patient number36 | 1 units on a scale |
| Dexmedetomidine | Satisfaction Scores of Patients Receiving Intranasal Dexmedetomidine | Patient number38 | 1 units on a scale |
| Dexmedetomidine | Satisfaction Scores of Patients Receiving Intranasal Dexmedetomidine | Patient number40 | 1 units on a scale |
| Dexmedetomidine | Satisfaction Scores of Patients Receiving Intranasal Dexmedetomidine | Patient number44 | 2 units on a scale |
| Dexmedetomidine | Satisfaction Scores of Patients Receiving Intranasal Dexmedetomidine | Patient number46 | 1 units on a scale |
| Dexmedetomidine | Satisfaction Scores of Patients Receiving Intranasal Dexmedetomidine | Patient number50 | 1 units on a scale |
| Dexmedetomidine | Satisfaction Scores of Patients Receiving Intranasal Dexmedetomidine | Patient number52 | 1 units on a scale |
| Dexmedetomidine | Satisfaction Scores of Patients Receiving Intranasal Dexmedetomidine | Patient number53 | 1 units on a scale |
| Dexmedetomidine | Satisfaction Scores of Patients Receiving Intranasal Dexmedetomidine | Patient number56 | 1 units on a scale |
| Dexmedetomidine | Satisfaction Scores of Patients Receiving Intranasal Dexmedetomidine | Patient number57 | 1 units on a scale |
| Dexmedetomidine | Satisfaction Scores of Patients Receiving Intranasal Dexmedetomidine | Patient number58 | 2 units on a scale |
| Dexmedetomidine | Satisfaction Scores of Patients Receiving Intranasal Dexmedetomidine | Patient number59 | 1 units on a scale |
| Dexmedetomidine | Satisfaction Scores of Patients Receiving Intranasal Dexmedetomidine | Patient number61 | 1 units on a scale |
| Dexmedetomidine | Satisfaction Scores of Patients Receiving Intranasal Dexmedetomidine | Patient number62 | 1 units on a scale |
| Dexmedetomidine | Satisfaction Scores of Patients Receiving Intranasal Dexmedetomidine | Patient number63 | 1 units on a scale |
| Dexmedetomidine | Satisfaction Scores of Patients Receiving Intranasal Dexmedetomidine | Patient number65 | 1 units on a scale |
| Dexmedetomidine | Satisfaction Scores of Patients Receiving Intranasal Dexmedetomidine | Patient number66 | 1 units on a scale |
| Dexmedetomidine | Satisfaction Scores of Patients Receiving Intranasal Dexmedetomidine | Patient number67 | 1 units on a scale |
| Dexmedetomidine | Satisfaction Scores of Patients Receiving Intranasal Dexmedetomidine | Patient number71 | 1 units on a scale |
| Dexmedetomidine | Satisfaction Scores of Patients Receiving Intranasal Dexmedetomidine | Patient number72 | 1 units on a scale |
| Dexmedetomidine | Satisfaction Scores of Patients Receiving Intranasal Dexmedetomidine | Patient number74 | 1 units on a scale |
| Dexmedetomidine | Satisfaction Scores of Patients Receiving Intranasal Dexmedetomidine | Patient number75 | 1 units on a scale |
| Dexmedetomidine | Satisfaction Scores of Patients Receiving Intranasal Dexmedetomidine | Patient number76 | 1 units on a scale |
| Dexmedetomidine | Satisfaction Scores of Patients Receiving Intranasal Dexmedetomidine | Patient number79 | 2 units on a scale |
| Dexmedetomidine | Satisfaction Scores of Patients Receiving Intranasal Dexmedetomidine | Patient number80 | 2 units on a scale |
Other Pre-specified
Satisfaction Scores of Patients Receiving Intranasal Placebo
Satisfaction scores of patients receiving intranasal placebo. satisfaction was assessed using a 3-point satisfaction score(1 = highly satisfactory, 2 = acceptable, and 3 = unacceptable).
Time frame: 1 day
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Dexmedetomidine | Satisfaction Scores of Patients Receiving Intranasal Placebo | Patient number1 | 1 units on a scale |
| Dexmedetomidine | Satisfaction Scores of Patients Receiving Intranasal Placebo | Patient number4 | 1 units on a scale |
| Dexmedetomidine | Satisfaction Scores of Patients Receiving Intranasal Placebo | Patient number8 | 1 units on a scale |
| Dexmedetomidine | Satisfaction Scores of Patients Receiving Intranasal Placebo | Patient number12 | 2 units on a scale |
| Dexmedetomidine | Satisfaction Scores of Patients Receiving Intranasal Placebo | Patient number13 | 2 units on a scale |
| Dexmedetomidine | Satisfaction Scores of Patients Receiving Intranasal Placebo | Patient number14 | 1 units on a scale |
| Dexmedetomidine | Satisfaction Scores of Patients Receiving Intranasal Placebo | Patient number15 | 3 units on a scale |
| Dexmedetomidine | Satisfaction Scores of Patients Receiving Intranasal Placebo | Patient number16 | 1 units on a scale |
| Dexmedetomidine | Satisfaction Scores of Patients Receiving Intranasal Placebo | Patient number17 | 3 units on a scale |
| Dexmedetomidine | Satisfaction Scores of Patients Receiving Intranasal Placebo | Patient number19 | 2 units on a scale |
| Dexmedetomidine | Satisfaction Scores of Patients Receiving Intranasal Placebo | Patient number20 | 2 units on a scale |
| Dexmedetomidine | Satisfaction Scores of Patients Receiving Intranasal Placebo | Patient number21 | 1 units on a scale |
| Dexmedetomidine | Satisfaction Scores of Patients Receiving Intranasal Placebo | Patient number22 | 2 units on a scale |
| Dexmedetomidine | Satisfaction Scores of Patients Receiving Intranasal Placebo | Patient number23 | 1 units on a scale |
| Dexmedetomidine | Satisfaction Scores of Patients Receiving Intranasal Placebo | Patient number26 | 2 units on a scale |
| Dexmedetomidine | Satisfaction Scores of Patients Receiving Intranasal Placebo | Patient number27 | 1 units on a scale |
| Dexmedetomidine | Satisfaction Scores of Patients Receiving Intranasal Placebo | Patient number30 | 1 units on a scale |
| Dexmedetomidine | Satisfaction Scores of Patients Receiving Intranasal Placebo | Patient number32 | 2 units on a scale |
| Dexmedetomidine | Satisfaction Scores of Patients Receiving Intranasal Placebo | Patient number34 | 1 units on a scale |
| Dexmedetomidine | Satisfaction Scores of Patients Receiving Intranasal Placebo | Patient number35 | 2 units on a scale |
| Dexmedetomidine | Satisfaction Scores of Patients Receiving Intranasal Placebo | Patient number37 | 1 units on a scale |
| Dexmedetomidine | Satisfaction Scores of Patients Receiving Intranasal Placebo | Patient number39 | 2 units on a scale |
| Dexmedetomidine | Satisfaction Scores of Patients Receiving Intranasal Placebo | Patient number41 | 1 units on a scale |
| Dexmedetomidine | Satisfaction Scores of Patients Receiving Intranasal Placebo | Patient number42 | 1 units on a scale |
| Dexmedetomidine | Satisfaction Scores of Patients Receiving Intranasal Placebo | Patient number43 | 1 units on a scale |
| Dexmedetomidine | Satisfaction Scores of Patients Receiving Intranasal Placebo | Patient number45 | 1 units on a scale |
| Dexmedetomidine | Satisfaction Scores of Patients Receiving Intranasal Placebo | Patient number47 | 2 units on a scale |
| Dexmedetomidine | Satisfaction Scores of Patients Receiving Intranasal Placebo | Patient number48 | 1 units on a scale |
| Dexmedetomidine | Satisfaction Scores of Patients Receiving Intranasal Placebo | Patient number49 | 1 units on a scale |
| Dexmedetomidine | Satisfaction Scores of Patients Receiving Intranasal Placebo | Patient number51 | 2 units on a scale |
| Dexmedetomidine | Satisfaction Scores of Patients Receiving Intranasal Placebo | Patient number54 | 1 units on a scale |
| Dexmedetomidine | Satisfaction Scores of Patients Receiving Intranasal Placebo | Patient number55 | 1 units on a scale |
| Dexmedetomidine | Satisfaction Scores of Patients Receiving Intranasal Placebo | Patient number60 | 2 units on a scale |
| Dexmedetomidine | Satisfaction Scores of Patients Receiving Intranasal Placebo | Patient number64 | 1 units on a scale |
| Dexmedetomidine | Satisfaction Scores of Patients Receiving Intranasal Placebo | Patient number68 | 1 units on a scale |
| Dexmedetomidine | Satisfaction Scores of Patients Receiving Intranasal Placebo | Patient number69 | 2 units on a scale |
| Dexmedetomidine | Satisfaction Scores of Patients Receiving Intranasal Placebo | Patient number70 | 1 units on a scale |
| Dexmedetomidine | Satisfaction Scores of Patients Receiving Intranasal Placebo | Patient number73 | 2 units on a scale |
| Dexmedetomidine | Satisfaction Scores of Patients Receiving Intranasal Placebo | Patient number77 | 1 units on a scale |
| Dexmedetomidine | Satisfaction Scores of Patients Receiving Intranasal Placebo | Patient number78 | 1 units on a scale |
| Dexmedetomidine | Satisfaction Scores of Patients Receiving Intranasal Placebo | Patient number81 | 1 units on a scale |
Other Pre-specified
Time to Consciousness of Patients Receiving Intranasal Dexmedetomidine
Time to consciousness of patients receiving intranasal dexmedetomidine. The time elapsed between stopping anesthetic infusions and consciousness.
Time frame: 1 day
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Dexmedetomidine | Time to Consciousness of Patients Receiving Intranasal Dexmedetomidine | Patient number2 | 11 minutes |
| Dexmedetomidine | Time to Consciousness of Patients Receiving Intranasal Dexmedetomidine | Patient number3 | 14 minutes |
| Dexmedetomidine | Time to Consciousness of Patients Receiving Intranasal Dexmedetomidine | Patient number5 | 16 minutes |
| Dexmedetomidine | Time to Consciousness of Patients Receiving Intranasal Dexmedetomidine | Patient number6 | 11 minutes |
| Dexmedetomidine | Time to Consciousness of Patients Receiving Intranasal Dexmedetomidine | Patient number7 | 18 minutes |
| Dexmedetomidine | Time to Consciousness of Patients Receiving Intranasal Dexmedetomidine | Patient number9 | 13 minutes |
| Dexmedetomidine | Time to Consciousness of Patients Receiving Intranasal Dexmedetomidine | Patient number10 | 15 minutes |
| Dexmedetomidine | Time to Consciousness of Patients Receiving Intranasal Dexmedetomidine | Patient number11 | 11 minutes |
| Dexmedetomidine | Time to Consciousness of Patients Receiving Intranasal Dexmedetomidine | Patient number18 | 12 minutes |
| Dexmedetomidine | Time to Consciousness of Patients Receiving Intranasal Dexmedetomidine | Patient number24 | 23 minutes |
| Dexmedetomidine | Time to Consciousness of Patients Receiving Intranasal Dexmedetomidine | Patient number25 | 14 minutes |
| Dexmedetomidine | Time to Consciousness of Patients Receiving Intranasal Dexmedetomidine | Patient number28 | 12 minutes |
| Dexmedetomidine | Time to Consciousness of Patients Receiving Intranasal Dexmedetomidine | Patient number29 | 31 minutes |
| Dexmedetomidine | Time to Consciousness of Patients Receiving Intranasal Dexmedetomidine | Patient number31 | 16 minutes |
| Dexmedetomidine | Time to Consciousness of Patients Receiving Intranasal Dexmedetomidine | Patient number33 | 19 minutes |
| Dexmedetomidine | Time to Consciousness of Patients Receiving Intranasal Dexmedetomidine | Patient number74 | 10 minutes |
| Dexmedetomidine | Time to Consciousness of Patients Receiving Intranasal Dexmedetomidine | Patient number36 | 12 minutes |
| Dexmedetomidine | Time to Consciousness of Patients Receiving Intranasal Dexmedetomidine | Patient number38 | 18 minutes |
| Dexmedetomidine | Time to Consciousness of Patients Receiving Intranasal Dexmedetomidine | Patient number40 | 16 minutes |
| Dexmedetomidine | Time to Consciousness of Patients Receiving Intranasal Dexmedetomidine | Patient number44 | 41 minutes |
| Dexmedetomidine | Time to Consciousness of Patients Receiving Intranasal Dexmedetomidine | Patient number46 | 14 minutes |
| Dexmedetomidine | Time to Consciousness of Patients Receiving Intranasal Dexmedetomidine | Patient number50 | 14 minutes |
| Dexmedetomidine | Time to Consciousness of Patients Receiving Intranasal Dexmedetomidine | Patient number52 | 10 minutes |
| Dexmedetomidine | Time to Consciousness of Patients Receiving Intranasal Dexmedetomidine | Patient number53 | 10 minutes |
| Dexmedetomidine | Time to Consciousness of Patients Receiving Intranasal Dexmedetomidine | Patient number56 | 19 minutes |
| Dexmedetomidine | Time to Consciousness of Patients Receiving Intranasal Dexmedetomidine | Patient number57 | 17 minutes |
| Dexmedetomidine | Time to Consciousness of Patients Receiving Intranasal Dexmedetomidine | Patient number58 | 17 minutes |
| Dexmedetomidine | Time to Consciousness of Patients Receiving Intranasal Dexmedetomidine | Patient number59 | 16 minutes |
| Dexmedetomidine | Time to Consciousness of Patients Receiving Intranasal Dexmedetomidine | Patient number61 | 20 minutes |
| Dexmedetomidine | Time to Consciousness of Patients Receiving Intranasal Dexmedetomidine | Patient number62 | 19 minutes |
| Dexmedetomidine | Time to Consciousness of Patients Receiving Intranasal Dexmedetomidine | Patient number63 | 24 minutes |
| Dexmedetomidine | Time to Consciousness of Patients Receiving Intranasal Dexmedetomidine | Patient number65 | 19 minutes |
| Dexmedetomidine | Time to Consciousness of Patients Receiving Intranasal Dexmedetomidine | Patient number66 | 12 minutes |
| Dexmedetomidine | Time to Consciousness of Patients Receiving Intranasal Dexmedetomidine | Patient number67 | 18 minutes |
| Dexmedetomidine | Time to Consciousness of Patients Receiving Intranasal Dexmedetomidine | Patient number71 | 10 minutes |
| Dexmedetomidine | Time to Consciousness of Patients Receiving Intranasal Dexmedetomidine | Patient number72 | 11 minutes |
| Dexmedetomidine | Time to Consciousness of Patients Receiving Intranasal Dexmedetomidine | Patient number75 | 14 minutes |
| Dexmedetomidine | Time to Consciousness of Patients Receiving Intranasal Dexmedetomidine | Patient number76 | 13 minutes |
| Dexmedetomidine | Time to Consciousness of Patients Receiving Intranasal Dexmedetomidine | Patient number79 | 14 minutes |
| Dexmedetomidine | Time to Consciousness of Patients Receiving Intranasal Dexmedetomidine | Patient number80 | 25 minutes |
Other Pre-specified
Time to Consciousness of Patients Receiving Intranasal Placebo
Time to consciousness of patients receiving intranasal placebo. The time elapsed between stopping anesthetic infusions and consciousness.
Time frame: 1 day
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Dexmedetomidine | Time to Consciousness of Patients Receiving Intranasal Placebo | Patient number22 | 12 minutes |
| Dexmedetomidine | Time to Consciousness of Patients Receiving Intranasal Placebo | Patient number1 | 9 minutes |
| Dexmedetomidine | Time to Consciousness of Patients Receiving Intranasal Placebo | Patient number4 | 10 minutes |
| Dexmedetomidine | Time to Consciousness of Patients Receiving Intranasal Placebo | Patient number8 | 9 minutes |
| Dexmedetomidine | Time to Consciousness of Patients Receiving Intranasal Placebo | Patient number12 | 8 minutes |
| Dexmedetomidine | Time to Consciousness of Patients Receiving Intranasal Placebo | Patient number13 | 14 minutes |
| Dexmedetomidine | Time to Consciousness of Patients Receiving Intranasal Placebo | Patient number14 | 12 minutes |
| Dexmedetomidine | Time to Consciousness of Patients Receiving Intranasal Placebo | Patient number15 | 29 minutes |
| Dexmedetomidine | Time to Consciousness of Patients Receiving Intranasal Placebo | Patient number16 | 15 minutes |
| Dexmedetomidine | Time to Consciousness of Patients Receiving Intranasal Placebo | Patient number17 | 17 minutes |
| Dexmedetomidine | Time to Consciousness of Patients Receiving Intranasal Placebo | Patient number19 | 19 minutes |
| Dexmedetomidine | Time to Consciousness of Patients Receiving Intranasal Placebo | Patient number20 | 20 minutes |
| Dexmedetomidine | Time to Consciousness of Patients Receiving Intranasal Placebo | Patient number21 | 15 minutes |
| Dexmedetomidine | Time to Consciousness of Patients Receiving Intranasal Placebo | Patient number23 | 11 minutes |
| Dexmedetomidine | Time to Consciousness of Patients Receiving Intranasal Placebo | Patient number26 | 16 minutes |
| Dexmedetomidine | Time to Consciousness of Patients Receiving Intranasal Placebo | Patient number27 | 17 minutes |
| Dexmedetomidine | Time to Consciousness of Patients Receiving Intranasal Placebo | Patient number30 | 15 minutes |
| Dexmedetomidine | Time to Consciousness of Patients Receiving Intranasal Placebo | Patient number32 | 14 minutes |
| Dexmedetomidine | Time to Consciousness of Patients Receiving Intranasal Placebo | Patient number34 | 16 minutes |
| Dexmedetomidine | Time to Consciousness of Patients Receiving Intranasal Placebo | Patient number35 | 14 minutes |
| Dexmedetomidine | Time to Consciousness of Patients Receiving Intranasal Placebo | Patient number37 | 12 minutes |
| Dexmedetomidine | Time to Consciousness of Patients Receiving Intranasal Placebo | Patient number39 | 15 minutes |
| Dexmedetomidine | Time to Consciousness of Patients Receiving Intranasal Placebo | Patient number41 | 16 minutes |
| Dexmedetomidine | Time to Consciousness of Patients Receiving Intranasal Placebo | Patient number42 | 14 minutes |
| Dexmedetomidine | Time to Consciousness of Patients Receiving Intranasal Placebo | Patient number43 | 15 minutes |
| Dexmedetomidine | Time to Consciousness of Patients Receiving Intranasal Placebo | Patient number45 | 13 minutes |
| Dexmedetomidine | Time to Consciousness of Patients Receiving Intranasal Placebo | Patient number47 | 10 minutes |
| Dexmedetomidine | Time to Consciousness of Patients Receiving Intranasal Placebo | Patient number48 | 8 minutes |
| Dexmedetomidine | Time to Consciousness of Patients Receiving Intranasal Placebo | Patient number49 | 14 minutes |
| Dexmedetomidine | Time to Consciousness of Patients Receiving Intranasal Placebo | Patient number51 | 16 minutes |
| Dexmedetomidine | Time to Consciousness of Patients Receiving Intranasal Placebo | Patient number54 | 5 minutes |
| Dexmedetomidine | Time to Consciousness of Patients Receiving Intranasal Placebo | Patient number55 | 26 minutes |
| Dexmedetomidine | Time to Consciousness of Patients Receiving Intranasal Placebo | Patient number60 | 13 minutes |
| Dexmedetomidine | Time to Consciousness of Patients Receiving Intranasal Placebo | Patient number64 | 14 minutes |
| Dexmedetomidine | Time to Consciousness of Patients Receiving Intranasal Placebo | Patient number68 | 11 minutes |
| Dexmedetomidine | Time to Consciousness of Patients Receiving Intranasal Placebo | Patient number69 | 12 minutes |
| Dexmedetomidine | Time to Consciousness of Patients Receiving Intranasal Placebo | Patient number70 | 14 minutes |
| Dexmedetomidine | Time to Consciousness of Patients Receiving Intranasal Placebo | Patient number73 | 21 minutes |
| Dexmedetomidine | Time to Consciousness of Patients Receiving Intranasal Placebo | Patient number77 | 11 minutes |
| Dexmedetomidine | Time to Consciousness of Patients Receiving Intranasal Placebo | Patient number78 | 14 minutes |
| Dexmedetomidine | Time to Consciousness of Patients Receiving Intranasal Placebo | Patient number81 | 41 minutes |
Other Pre-specified
Time to Extubation of Patients Receiving Intranasal Dexmedetomidine
Time to extubation of patients receiving intranasal dexmedetomidine. The time elapsed between stopping anesthetic infusions and extubation
Time frame: 1 day
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Dexmedetomidine | Time to Extubation of Patients Receiving Intranasal Dexmedetomidine | Patient number76 | 15 minutes |
| Dexmedetomidine | Time to Extubation of Patients Receiving Intranasal Dexmedetomidine | Patient number2 | 12 minutes |
| Dexmedetomidine | Time to Extubation of Patients Receiving Intranasal Dexmedetomidine | Patient number3 | 15 minutes |
| Dexmedetomidine | Time to Extubation of Patients Receiving Intranasal Dexmedetomidine | Patient number5 | 18 minutes |
| Dexmedetomidine | Time to Extubation of Patients Receiving Intranasal Dexmedetomidine | Patient number6 | 13 minutes |
| Dexmedetomidine | Time to Extubation of Patients Receiving Intranasal Dexmedetomidine | Patient number7 | 20 minutes |
| Dexmedetomidine | Time to Extubation of Patients Receiving Intranasal Dexmedetomidine | Patient number9 | 15 minutes |
| Dexmedetomidine | Time to Extubation of Patients Receiving Intranasal Dexmedetomidine | Patient number10 | 16 minutes |
| Dexmedetomidine | Time to Extubation of Patients Receiving Intranasal Dexmedetomidine | Patient number11 | 13 minutes |
| Dexmedetomidine | Time to Extubation of Patients Receiving Intranasal Dexmedetomidine | Patient number18 | 14 minutes |
| Dexmedetomidine | Time to Extubation of Patients Receiving Intranasal Dexmedetomidine | Patient number24 | 25 minutes |
| Dexmedetomidine | Time to Extubation of Patients Receiving Intranasal Dexmedetomidine | Patient number25 | 16 minutes |
| Dexmedetomidine | Time to Extubation of Patients Receiving Intranasal Dexmedetomidine | Patient number28 | 14 minutes |
| Dexmedetomidine | Time to Extubation of Patients Receiving Intranasal Dexmedetomidine | Patient number29 | 36 minutes |
| Dexmedetomidine | Time to Extubation of Patients Receiving Intranasal Dexmedetomidine | Patient number31 | 18 minutes |
| Dexmedetomidine | Time to Extubation of Patients Receiving Intranasal Dexmedetomidine | Patient number33 | 22 minutes |
| Dexmedetomidine | Time to Extubation of Patients Receiving Intranasal Dexmedetomidine | Patient number36 | 17 minutes |
| Dexmedetomidine | Time to Extubation of Patients Receiving Intranasal Dexmedetomidine | Patient number38 | 21 minutes |
| Dexmedetomidine | Time to Extubation of Patients Receiving Intranasal Dexmedetomidine | Patient number40 | 18 minutes |
| Dexmedetomidine | Time to Extubation of Patients Receiving Intranasal Dexmedetomidine | Patient number44 | 48 minutes |
| Dexmedetomidine | Time to Extubation of Patients Receiving Intranasal Dexmedetomidine | Patient number46 | 16 minutes |
| Dexmedetomidine | Time to Extubation of Patients Receiving Intranasal Dexmedetomidine | Patient number50 | 16 minutes |
| Dexmedetomidine | Time to Extubation of Patients Receiving Intranasal Dexmedetomidine | Patient number52 | 11 minutes |
| Dexmedetomidine | Time to Extubation of Patients Receiving Intranasal Dexmedetomidine | Patient number53 | 11 minutes |
| Dexmedetomidine | Time to Extubation of Patients Receiving Intranasal Dexmedetomidine | Patient number56 | 21 minutes |
| Dexmedetomidine | Time to Extubation of Patients Receiving Intranasal Dexmedetomidine | Patient number57 | 17 minutes |
| Dexmedetomidine | Time to Extubation of Patients Receiving Intranasal Dexmedetomidine | Patient number58 | 19 minutes |
| Dexmedetomidine | Time to Extubation of Patients Receiving Intranasal Dexmedetomidine | Patient number59 | 19 minutes |
| Dexmedetomidine | Time to Extubation of Patients Receiving Intranasal Dexmedetomidine | Patient number61 | 23 minutes |
| Dexmedetomidine | Time to Extubation of Patients Receiving Intranasal Dexmedetomidine | Patient number62 | 22 minutes |
| Dexmedetomidine | Time to Extubation of Patients Receiving Intranasal Dexmedetomidine | Patient number63 | 26 minutes |
| Dexmedetomidine | Time to Extubation of Patients Receiving Intranasal Dexmedetomidine | Patient number65 | 23 minutes |
| Dexmedetomidine | Time to Extubation of Patients Receiving Intranasal Dexmedetomidine | Patient number66 | 14 minutes |
| Dexmedetomidine | Time to Extubation of Patients Receiving Intranasal Dexmedetomidine | Patient number67 | 22 minutes |
| Dexmedetomidine | Time to Extubation of Patients Receiving Intranasal Dexmedetomidine | Patient number71 | 11 minutes |
| Dexmedetomidine | Time to Extubation of Patients Receiving Intranasal Dexmedetomidine | Patient number72 | 12 minutes |
| Dexmedetomidine | Time to Extubation of Patients Receiving Intranasal Dexmedetomidine | Patient number74 | 11 minutes |
| Dexmedetomidine | Time to Extubation of Patients Receiving Intranasal Dexmedetomidine | Patient number75 | 15 minutes |
| Dexmedetomidine | Time to Extubation of Patients Receiving Intranasal Dexmedetomidine | Patient number79 | 16 minutes |
| Dexmedetomidine | Time to Extubation of Patients Receiving Intranasal Dexmedetomidine | Patient number80 | 30 minutes |
Other Pre-specified
Time to Extubation of Patients Receiving Intranasal Placebo
Time to extubation of patients receiving intranasal placebo. The time elapsed between stopping anesthetic infusions and extubation
Time frame: 1 day
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Dexmedetomidine | Time to Extubation of Patients Receiving Intranasal Placebo | Patient number37 | 14 minutes |
| Dexmedetomidine | Time to Extubation of Patients Receiving Intranasal Placebo | Patient number39 | 17 minutes |
| Dexmedetomidine | Time to Extubation of Patients Receiving Intranasal Placebo | Patient number41 | 18 minutes |
| Dexmedetomidine | Time to Extubation of Patients Receiving Intranasal Placebo | Patient number42 | 16 minutes |
| Dexmedetomidine | Time to Extubation of Patients Receiving Intranasal Placebo | Patient number43 | 16 minutes |
| Dexmedetomidine | Time to Extubation of Patients Receiving Intranasal Placebo | Patient number45 | 18 minutes |
| Dexmedetomidine | Time to Extubation of Patients Receiving Intranasal Placebo | Patient number47 | 12 minutes |
| Dexmedetomidine | Time to Extubation of Patients Receiving Intranasal Placebo | Patient number48 | 9 minutes |
| Dexmedetomidine | Time to Extubation of Patients Receiving Intranasal Placebo | Patient number49 | 16 minutes |
| Dexmedetomidine | Time to Extubation of Patients Receiving Intranasal Placebo | Patient number51 | 20 minutes |
| Dexmedetomidine | Time to Extubation of Patients Receiving Intranasal Placebo | Patient number54 | 8 minutes |
| Dexmedetomidine | Time to Extubation of Patients Receiving Intranasal Placebo | Patient number55 | 29 minutes |
| Dexmedetomidine | Time to Extubation of Patients Receiving Intranasal Placebo | Patient number60 | 15 minutes |
| Dexmedetomidine | Time to Extubation of Patients Receiving Intranasal Placebo | Patient number64 | 15 minutes |
| Dexmedetomidine | Time to Extubation of Patients Receiving Intranasal Placebo | Patient number1 | 11 minutes |
| Dexmedetomidine | Time to Extubation of Patients Receiving Intranasal Placebo | Patient number4 | 12 minutes |
| Dexmedetomidine | Time to Extubation of Patients Receiving Intranasal Placebo | Patient number8 | 10 minutes |
| Dexmedetomidine | Time to Extubation of Patients Receiving Intranasal Placebo | Patient number12 | 10 minutes |
| Dexmedetomidine | Time to Extubation of Patients Receiving Intranasal Placebo | Patient number13 | 16 minutes |
| Dexmedetomidine | Time to Extubation of Patients Receiving Intranasal Placebo | Patient number14 | 14 minutes |
| Dexmedetomidine | Time to Extubation of Patients Receiving Intranasal Placebo | Patient number15 | 35 minutes |
| Dexmedetomidine | Time to Extubation of Patients Receiving Intranasal Placebo | Patient number16 | 17 minutes |
| Dexmedetomidine | Time to Extubation of Patients Receiving Intranasal Placebo | Patient number17 | 19 minutes |
| Dexmedetomidine | Time to Extubation of Patients Receiving Intranasal Placebo | Patient number19 | 21 minutes |
| Dexmedetomidine | Time to Extubation of Patients Receiving Intranasal Placebo | Patient number20 | 22 minutes |
| Dexmedetomidine | Time to Extubation of Patients Receiving Intranasal Placebo | Patient number21 | 17 minutes |
| Dexmedetomidine | Time to Extubation of Patients Receiving Intranasal Placebo | Patient number22 | 14 minutes |
| Dexmedetomidine | Time to Extubation of Patients Receiving Intranasal Placebo | Patient number23 | 12 minutes |
| Dexmedetomidine | Time to Extubation of Patients Receiving Intranasal Placebo | Patient number26 | 16 minutes |
| Dexmedetomidine | Time to Extubation of Patients Receiving Intranasal Placebo | Patient number27 | 17 minutes |
| Dexmedetomidine | Time to Extubation of Patients Receiving Intranasal Placebo | Patient number30 | 18 minutes |
| Dexmedetomidine | Time to Extubation of Patients Receiving Intranasal Placebo | Patient number32 | 16 minutes |
| Dexmedetomidine | Time to Extubation of Patients Receiving Intranasal Placebo | Patient number34 | 19 minutes |
| Dexmedetomidine | Time to Extubation of Patients Receiving Intranasal Placebo | Patient number35 | 18 minutes |
| Dexmedetomidine | Time to Extubation of Patients Receiving Intranasal Placebo | Patient number68 | 13 minutes |
| Dexmedetomidine | Time to Extubation of Patients Receiving Intranasal Placebo | Patient number69 | 14 minutes |
| Dexmedetomidine | Time to Extubation of Patients Receiving Intranasal Placebo | Patient number70 | 16 minutes |
| Dexmedetomidine | Time to Extubation of Patients Receiving Intranasal Placebo | Patient number73 | 26 minutes |
| Dexmedetomidine | Time to Extubation of Patients Receiving Intranasal Placebo | Patient number77 | 13 minutes |
| Dexmedetomidine | Time to Extubation of Patients Receiving Intranasal Placebo | Patient number78 | 17 minutes |
| Dexmedetomidine | Time to Extubation of Patients Receiving Intranasal Placebo | Patient number81 | 46 minutes |
Other Pre-specified
Time to Spontaneous Breathing of Patients Receiving Intranasal Dexmedetomidine
Time to spontaneous breathing of patients receiving intranasal dexmedetomidine. The time elapsed between stopping anesthetic infusions and adequate ventilation
Time frame: 1 day
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Dexmedetomidine | Time to Spontaneous Breathing of Patients Receiving Intranasal Dexmedetomidine | Patient number2 | 6 minutes |
| Dexmedetomidine | Time to Spontaneous Breathing of Patients Receiving Intranasal Dexmedetomidine | Patient number3 | 5 minutes |
| Dexmedetomidine | Time to Spontaneous Breathing of Patients Receiving Intranasal Dexmedetomidine | Patient number5 | 8 minutes |
| Dexmedetomidine | Time to Spontaneous Breathing of Patients Receiving Intranasal Dexmedetomidine | Patient number6 | 6 minutes |
| Dexmedetomidine | Time to Spontaneous Breathing of Patients Receiving Intranasal Dexmedetomidine | Patient number7 | 8 minutes |
| Dexmedetomidine | Time to Spontaneous Breathing of Patients Receiving Intranasal Dexmedetomidine | Patient number9 | 8 minutes |
| Dexmedetomidine | Time to Spontaneous Breathing of Patients Receiving Intranasal Dexmedetomidine | Patient number10 | 6 minutes |
| Dexmedetomidine | Time to Spontaneous Breathing of Patients Receiving Intranasal Dexmedetomidine | Patient number11 | 8 minutes |
| Dexmedetomidine | Time to Spontaneous Breathing of Patients Receiving Intranasal Dexmedetomidine | Patient number18 | 7 minutes |
| Dexmedetomidine | Time to Spontaneous Breathing of Patients Receiving Intranasal Dexmedetomidine | Patient number24 | 18 minutes |
| Dexmedetomidine | Time to Spontaneous Breathing of Patients Receiving Intranasal Dexmedetomidine | Patient number25 | 10 minutes |
| Dexmedetomidine | Time to Spontaneous Breathing of Patients Receiving Intranasal Dexmedetomidine | Patient number28 | 5 minutes |
| Dexmedetomidine | Time to Spontaneous Breathing of Patients Receiving Intranasal Dexmedetomidine | Patient number29 | 8 minutes |
| Dexmedetomidine | Time to Spontaneous Breathing of Patients Receiving Intranasal Dexmedetomidine | Patient number31 | 10 minutes |
| Dexmedetomidine | Time to Spontaneous Breathing of Patients Receiving Intranasal Dexmedetomidine | Patient number33 | 9 minutes |
| Dexmedetomidine | Time to Spontaneous Breathing of Patients Receiving Intranasal Dexmedetomidine | Patient number36 | 6 minutes |
| Dexmedetomidine | Time to Spontaneous Breathing of Patients Receiving Intranasal Dexmedetomidine | Patient number38 | 8 minutes |
| Dexmedetomidine | Time to Spontaneous Breathing of Patients Receiving Intranasal Dexmedetomidine | Patient number40 | 8 minutes |
| Dexmedetomidine | Time to Spontaneous Breathing of Patients Receiving Intranasal Dexmedetomidine | Patient number44 | 10 minutes |
| Dexmedetomidine | Time to Spontaneous Breathing of Patients Receiving Intranasal Dexmedetomidine | Patient number46 | 7 minutes |
| Dexmedetomidine | Time to Spontaneous Breathing of Patients Receiving Intranasal Dexmedetomidine | Patient number50 | 7 minutes |
| Dexmedetomidine | Time to Spontaneous Breathing of Patients Receiving Intranasal Dexmedetomidine | Patient number52 | 7 minutes |
| Dexmedetomidine | Time to Spontaneous Breathing of Patients Receiving Intranasal Dexmedetomidine | Patient number53 | 5 minutes |
| Dexmedetomidine | Time to Spontaneous Breathing of Patients Receiving Intranasal Dexmedetomidine | Patient number56 | 7 minutes |
| Dexmedetomidine | Time to Spontaneous Breathing of Patients Receiving Intranasal Dexmedetomidine | Patient number57 | 8 minutes |
| Dexmedetomidine | Time to Spontaneous Breathing of Patients Receiving Intranasal Dexmedetomidine | Patient number58 | 6 minutes |
| Dexmedetomidine | Time to Spontaneous Breathing of Patients Receiving Intranasal Dexmedetomidine | Patient number59 | 9 minutes |
| Dexmedetomidine | Time to Spontaneous Breathing of Patients Receiving Intranasal Dexmedetomidine | Patient number61 | 6 minutes |
| Dexmedetomidine | Time to Spontaneous Breathing of Patients Receiving Intranasal Dexmedetomidine | Patient number62 | 7 minutes |
| Dexmedetomidine | Time to Spontaneous Breathing of Patients Receiving Intranasal Dexmedetomidine | Patient number63 | 13 minutes |
| Dexmedetomidine | Time to Spontaneous Breathing of Patients Receiving Intranasal Dexmedetomidine | Patient number65 | 10 minutes |
| Dexmedetomidine | Time to Spontaneous Breathing of Patients Receiving Intranasal Dexmedetomidine | Patient number66 | 7 minutes |
| Dexmedetomidine | Time to Spontaneous Breathing of Patients Receiving Intranasal Dexmedetomidine | Patient number67 | 11 minutes |
| Dexmedetomidine | Time to Spontaneous Breathing of Patients Receiving Intranasal Dexmedetomidine | Patient number71 | 6 minutes |
| Dexmedetomidine | Time to Spontaneous Breathing of Patients Receiving Intranasal Dexmedetomidine | Patient number72 | 8 minutes |
| Dexmedetomidine | Time to Spontaneous Breathing of Patients Receiving Intranasal Dexmedetomidine | Patient number74 | 8 minutes |
| Dexmedetomidine | Time to Spontaneous Breathing of Patients Receiving Intranasal Dexmedetomidine | Patient number75 | 5 minutes |
| Dexmedetomidine | Time to Spontaneous Breathing of Patients Receiving Intranasal Dexmedetomidine | Patient number76 | 11 minutes |
| Dexmedetomidine | Time to Spontaneous Breathing of Patients Receiving Intranasal Dexmedetomidine | Patient number79 | 7 minutes |
| Dexmedetomidine | Time to Spontaneous Breathing of Patients Receiving Intranasal Dexmedetomidine | Patient number80 | 20 minutes |
Other Pre-specified
Time to Spontaneous Breathing of Patients Receiving Intranasal Placebo
Time to spontaneous breathing of patients receiving intranasal placebo. The time elapsed between stopping anesthetic infusions and adequate ventilation
Time frame: 1 day
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Dexmedetomidine | Time to Spontaneous Breathing of Patients Receiving Intranasal Placebo | Patient number4 | 5 minutes |
| Dexmedetomidine | Time to Spontaneous Breathing of Patients Receiving Intranasal Placebo | Patient number1 | 5 minutes |
| Dexmedetomidine | Time to Spontaneous Breathing of Patients Receiving Intranasal Placebo | Patient number8 | 7 minutes |
| Dexmedetomidine | Time to Spontaneous Breathing of Patients Receiving Intranasal Placebo | Patient number12 | 7 minutes |
| Dexmedetomidine | Time to Spontaneous Breathing of Patients Receiving Intranasal Placebo | Patient number13 | 9 minutes |
| Dexmedetomidine | Time to Spontaneous Breathing of Patients Receiving Intranasal Placebo | Patient number14 | 7 minutes |
| Dexmedetomidine | Time to Spontaneous Breathing of Patients Receiving Intranasal Placebo | Patient number15 | 11 minutes |
| Dexmedetomidine | Time to Spontaneous Breathing of Patients Receiving Intranasal Placebo | Patient number16 | 10 minutes |
| Dexmedetomidine | Time to Spontaneous Breathing of Patients Receiving Intranasal Placebo | Patient number17 | 9 minutes |
| Dexmedetomidine | Time to Spontaneous Breathing of Patients Receiving Intranasal Placebo | Patient number19 | 10 minutes |
| Dexmedetomidine | Time to Spontaneous Breathing of Patients Receiving Intranasal Placebo | Patient number20 | 5 minutes |
| Dexmedetomidine | Time to Spontaneous Breathing of Patients Receiving Intranasal Placebo | Patient number21 | 9 minutes |
| Dexmedetomidine | Time to Spontaneous Breathing of Patients Receiving Intranasal Placebo | Patient number22 | 9 minutes |
| Dexmedetomidine | Time to Spontaneous Breathing of Patients Receiving Intranasal Placebo | Patient number23 | 8 minutes |
| Dexmedetomidine | Time to Spontaneous Breathing of Patients Receiving Intranasal Placebo | Patient number26 | 15 minutes |
| Dexmedetomidine | Time to Spontaneous Breathing of Patients Receiving Intranasal Placebo | Patient number27 | 8 minutes |
| Dexmedetomidine | Time to Spontaneous Breathing of Patients Receiving Intranasal Placebo | Patient number30 | 13 minutes |
| Dexmedetomidine | Time to Spontaneous Breathing of Patients Receiving Intranasal Placebo | Patient number32 | 8 minutes |
| Dexmedetomidine | Time to Spontaneous Breathing of Patients Receiving Intranasal Placebo | Patient number34 | 7 minutes |
| Dexmedetomidine | Time to Spontaneous Breathing of Patients Receiving Intranasal Placebo | Patient number35 | 8 minutes |
| Dexmedetomidine | Time to Spontaneous Breathing of Patients Receiving Intranasal Placebo | Patient number37 | 8 minutes |
| Dexmedetomidine | Time to Spontaneous Breathing of Patients Receiving Intranasal Placebo | Patient number39 | 9 minutes |
| Dexmedetomidine | Time to Spontaneous Breathing of Patients Receiving Intranasal Placebo | Patient number41 | 8 minutes |
| Dexmedetomidine | Time to Spontaneous Breathing of Patients Receiving Intranasal Placebo | Patient number42 | 8 minutes |
| Dexmedetomidine | Time to Spontaneous Breathing of Patients Receiving Intranasal Placebo | Patient number43 | 7 minutes |
| Dexmedetomidine | Time to Spontaneous Breathing of Patients Receiving Intranasal Placebo | Patient number45 | 6 minutes |
| Dexmedetomidine | Time to Spontaneous Breathing of Patients Receiving Intranasal Placebo | Patient number47 | 7 minutes |
| Dexmedetomidine | Time to Spontaneous Breathing of Patients Receiving Intranasal Placebo | Patient number48 | 6 minutes |
| Dexmedetomidine | Time to Spontaneous Breathing of Patients Receiving Intranasal Placebo | Patient number49 | 4 minutes |
| Dexmedetomidine | Time to Spontaneous Breathing of Patients Receiving Intranasal Placebo | Patient number51 | 8 minutes |
| Dexmedetomidine | Time to Spontaneous Breathing of Patients Receiving Intranasal Placebo | Patient number54 | 3 minutes |
| Dexmedetomidine | Time to Spontaneous Breathing of Patients Receiving Intranasal Placebo | Patient number55 | 15 minutes |
| Dexmedetomidine | Time to Spontaneous Breathing of Patients Receiving Intranasal Placebo | Patient number60 | 5 minutes |
| Dexmedetomidine | Time to Spontaneous Breathing of Patients Receiving Intranasal Placebo | Patient number64 | 11 minutes |
| Dexmedetomidine | Time to Spontaneous Breathing of Patients Receiving Intranasal Placebo | Patient number68 | 7 minutes |
| Dexmedetomidine | Time to Spontaneous Breathing of Patients Receiving Intranasal Placebo | Patient number69 | 6 minutes |
| Dexmedetomidine | Time to Spontaneous Breathing of Patients Receiving Intranasal Placebo | Patient number70 | 4 minutes |
| Dexmedetomidine | Time to Spontaneous Breathing of Patients Receiving Intranasal Placebo | Patient number73 | 8 minutes |
| Dexmedetomidine | Time to Spontaneous Breathing of Patients Receiving Intranasal Placebo | Patient number77 | 8 minutes |
| Dexmedetomidine | Time to Spontaneous Breathing of Patients Receiving Intranasal Placebo | Patient number78 | 8 minutes |
| Dexmedetomidine | Time to Spontaneous Breathing of Patients Receiving Intranasal Placebo | Patient number81 | 7 minutes |
Other Pre-specified
Visual Analogue Scale (VAS) in the Dexmedetomidine (DEX) Group
An investigator who was blinded from the grouping asked the patients to mark their pain level on a 0-100 visual analogue scale (VAS). A VAS higher than 50 was considered a worse outcome and need to be treated with intravenous 40 mg of parecoxib.
Time frame: 1 day
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Dexmedetomidine | Visual Analogue Scale (VAS) in the Dexmedetomidine (DEX) Group | Patient number36 | 20 units on a scale |
| Dexmedetomidine | Visual Analogue Scale (VAS) in the Dexmedetomidine (DEX) Group | Patient number2 | 20 units on a scale |
| Dexmedetomidine | Visual Analogue Scale (VAS) in the Dexmedetomidine (DEX) Group | Patient number3 | 20 units on a scale |
| Dexmedetomidine | Visual Analogue Scale (VAS) in the Dexmedetomidine (DEX) Group | Patient number5 | 20 units on a scale |
| Dexmedetomidine | Visual Analogue Scale (VAS) in the Dexmedetomidine (DEX) Group | Patient number6 | 20 units on a scale |
| Dexmedetomidine | Visual Analogue Scale (VAS) in the Dexmedetomidine (DEX) Group | Patient number7 | 80 units on a scale |
| Dexmedetomidine | Visual Analogue Scale (VAS) in the Dexmedetomidine (DEX) Group | Patient number9 | 20 units on a scale |
| Dexmedetomidine | Visual Analogue Scale (VAS) in the Dexmedetomidine (DEX) Group | Patient number10 | 20 units on a scale |
| Dexmedetomidine | Visual Analogue Scale (VAS) in the Dexmedetomidine (DEX) Group | Patient number11 | 20 units on a scale |
| Dexmedetomidine | Visual Analogue Scale (VAS) in the Dexmedetomidine (DEX) Group | Patient number18 | 20 units on a scale |
| Dexmedetomidine | Visual Analogue Scale (VAS) in the Dexmedetomidine (DEX) Group | Patient number24 | 20 units on a scale |
| Dexmedetomidine | Visual Analogue Scale (VAS) in the Dexmedetomidine (DEX) Group | Patient number25 | 20 units on a scale |
| Dexmedetomidine | Visual Analogue Scale (VAS) in the Dexmedetomidine (DEX) Group | Patient number28 | 20 units on a scale |
| Dexmedetomidine | Visual Analogue Scale (VAS) in the Dexmedetomidine (DEX) Group | Patient number29 | 20 units on a scale |
| Dexmedetomidine | Visual Analogue Scale (VAS) in the Dexmedetomidine (DEX) Group | Patient number31 | 20 units on a scale |
| Dexmedetomidine | Visual Analogue Scale (VAS) in the Dexmedetomidine (DEX) Group | Patient number33 | 0 units on a scale |
| Dexmedetomidine | Visual Analogue Scale (VAS) in the Dexmedetomidine (DEX) Group | Patient number38 | 0 units on a scale |
| Dexmedetomidine | Visual Analogue Scale (VAS) in the Dexmedetomidine (DEX) Group | Patient number40 | 80 units on a scale |
| Dexmedetomidine | Visual Analogue Scale (VAS) in the Dexmedetomidine (DEX) Group | Patient number44 | 80 units on a scale |
| Dexmedetomidine | Visual Analogue Scale (VAS) in the Dexmedetomidine (DEX) Group | Patient number46 | 20 units on a scale |
| Dexmedetomidine | Visual Analogue Scale (VAS) in the Dexmedetomidine (DEX) Group | Patient number50 | 20 units on a scale |
| Dexmedetomidine | Visual Analogue Scale (VAS) in the Dexmedetomidine (DEX) Group | Patient number52 | 20 units on a scale |
| Dexmedetomidine | Visual Analogue Scale (VAS) in the Dexmedetomidine (DEX) Group | Patient number53 | 20 units on a scale |
| Dexmedetomidine | Visual Analogue Scale (VAS) in the Dexmedetomidine (DEX) Group | Patient number56 | 20 units on a scale |
| Dexmedetomidine | Visual Analogue Scale (VAS) in the Dexmedetomidine (DEX) Group | Patient number57 | 20 units on a scale |
| Dexmedetomidine | Visual Analogue Scale (VAS) in the Dexmedetomidine (DEX) Group | Patient number58 | 20 units on a scale |
| Dexmedetomidine | Visual Analogue Scale (VAS) in the Dexmedetomidine (DEX) Group | Patient number59 | 20 units on a scale |
| Dexmedetomidine | Visual Analogue Scale (VAS) in the Dexmedetomidine (DEX) Group | Patient number61 | 20 units on a scale |
| Dexmedetomidine | Visual Analogue Scale (VAS) in the Dexmedetomidine (DEX) Group | Patient number62 | 20 units on a scale |
| Dexmedetomidine | Visual Analogue Scale (VAS) in the Dexmedetomidine (DEX) Group | Patient number63 | 20 units on a scale |
| Dexmedetomidine | Visual Analogue Scale (VAS) in the Dexmedetomidine (DEX) Group | Patient number65 | 20 units on a scale |
| Dexmedetomidine | Visual Analogue Scale (VAS) in the Dexmedetomidine (DEX) Group | Patient number66 | 20 units on a scale |
| Dexmedetomidine | Visual Analogue Scale (VAS) in the Dexmedetomidine (DEX) Group | Patient number67 | 20 units on a scale |
| Dexmedetomidine | Visual Analogue Scale (VAS) in the Dexmedetomidine (DEX) Group | Patient number71 | 80 units on a scale |
| Dexmedetomidine | Visual Analogue Scale (VAS) in the Dexmedetomidine (DEX) Group | Patient number72 | 20 units on a scale |
| Dexmedetomidine | Visual Analogue Scale (VAS) in the Dexmedetomidine (DEX) Group | Patient number74 | 20 units on a scale |
| Dexmedetomidine | Visual Analogue Scale (VAS) in the Dexmedetomidine (DEX) Group | Patient number75 | 0 units on a scale |
| Dexmedetomidine | Visual Analogue Scale (VAS) in the Dexmedetomidine (DEX) Group | Patient number76 | 20 units on a scale |
| Dexmedetomidine | Visual Analogue Scale (VAS) in the Dexmedetomidine (DEX) Group | Patient number79 | 20 units on a scale |
| Dexmedetomidine | Visual Analogue Scale (VAS) in the Dexmedetomidine (DEX) Group | Patient number80 | 20 units on a scale |
Other Pre-specified
Visual Analogue Scale (VAS) in the Placebo Group
An investigator who was blinded from the grouping asked the patients to mark their pain level on a 0-100 visual analogue scale (VAS). A VAS higher than 50 was considered a worse outcome and need to be treated with intravenous 40 mg of parecoxib.
Time frame: 1 day
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Dexmedetomidine | Visual Analogue Scale (VAS) in the Placebo Group | Patient number1 | 80 units on a scale |
| Dexmedetomidine | Visual Analogue Scale (VAS) in the Placebo Group | Patient number4 | 20 units on a scale |
| Dexmedetomidine | Visual Analogue Scale (VAS) in the Placebo Group | Patient number8 | 20 units on a scale |
| Dexmedetomidine | Visual Analogue Scale (VAS) in the Placebo Group | Patient number12 | 80 units on a scale |
| Dexmedetomidine | Visual Analogue Scale (VAS) in the Placebo Group | Patient number13 | 80 units on a scale |
| Dexmedetomidine | Visual Analogue Scale (VAS) in the Placebo Group | Patient number14 | 80 units on a scale |
| Dexmedetomidine | Visual Analogue Scale (VAS) in the Placebo Group | Patient number15 | 20 units on a scale |
| Dexmedetomidine | Visual Analogue Scale (VAS) in the Placebo Group | Patient number16 | 0 units on a scale |
| Dexmedetomidine | Visual Analogue Scale (VAS) in the Placebo Group | Patient number17 | 80 units on a scale |
| Dexmedetomidine | Visual Analogue Scale (VAS) in the Placebo Group | Patient number19 | 20 units on a scale |
| Dexmedetomidine | Visual Analogue Scale (VAS) in the Placebo Group | Patient number20 | 80 units on a scale |
| Dexmedetomidine | Visual Analogue Scale (VAS) in the Placebo Group | Patient number21 | 20 units on a scale |
| Dexmedetomidine | Visual Analogue Scale (VAS) in the Placebo Group | Patient number22 | 20 units on a scale |
| Dexmedetomidine | Visual Analogue Scale (VAS) in the Placebo Group | Patient number23 | 20 units on a scale |
| Dexmedetomidine | Visual Analogue Scale (VAS) in the Placebo Group | Patient number26 | 20 units on a scale |
| Dexmedetomidine | Visual Analogue Scale (VAS) in the Placebo Group | Patient number27 | 20 units on a scale |
| Dexmedetomidine | Visual Analogue Scale (VAS) in the Placebo Group | Patient number30 | 80 units on a scale |
| Dexmedetomidine | Visual Analogue Scale (VAS) in the Placebo Group | Patient number32 | 20 units on a scale |
| Dexmedetomidine | Visual Analogue Scale (VAS) in the Placebo Group | Patient number34 | 20 units on a scale |
| Dexmedetomidine | Visual Analogue Scale (VAS) in the Placebo Group | Patient number35 | 20 units on a scale |
| Dexmedetomidine | Visual Analogue Scale (VAS) in the Placebo Group | Patient number37 | 20 units on a scale |
| Dexmedetomidine | Visual Analogue Scale (VAS) in the Placebo Group | Patient number39 | 20 units on a scale |
| Dexmedetomidine | Visual Analogue Scale (VAS) in the Placebo Group | Patient number41 | 20 units on a scale |
| Dexmedetomidine | Visual Analogue Scale (VAS) in the Placebo Group | Patient number42 | 20 units on a scale |
| Dexmedetomidine | Visual Analogue Scale (VAS) in the Placebo Group | Patient number43 | 0 units on a scale |
| Dexmedetomidine | Visual Analogue Scale (VAS) in the Placebo Group | Patient number45 | 20 units on a scale |
| Dexmedetomidine | Visual Analogue Scale (VAS) in the Placebo Group | Patient number47 | 80 units on a scale |
| Dexmedetomidine | Visual Analogue Scale (VAS) in the Placebo Group | Patient number48 | 80 units on a scale |
| Dexmedetomidine | Visual Analogue Scale (VAS) in the Placebo Group | Patient number49 | 80 units on a scale |
| Dexmedetomidine | Visual Analogue Scale (VAS) in the Placebo Group | Patient number51 | 20 units on a scale |
| Dexmedetomidine | Visual Analogue Scale (VAS) in the Placebo Group | Patient number54 | 20 units on a scale |
| Dexmedetomidine | Visual Analogue Scale (VAS) in the Placebo Group | Patient number55 | 80 units on a scale |
| Dexmedetomidine | Visual Analogue Scale (VAS) in the Placebo Group | Patient number60 | 80 units on a scale |
| Dexmedetomidine | Visual Analogue Scale (VAS) in the Placebo Group | Patient number64 | 80 units on a scale |
| Dexmedetomidine | Visual Analogue Scale (VAS) in the Placebo Group | Patient number68 | 20 units on a scale |
| Dexmedetomidine | Visual Analogue Scale (VAS) in the Placebo Group | Patient number69 | 80 units on a scale |
| Dexmedetomidine | Visual Analogue Scale (VAS) in the Placebo Group | Patient number70 | 20 units on a scale |
| Dexmedetomidine | Visual Analogue Scale (VAS) in the Placebo Group | Patient number73 | 80 units on a scale |
| Dexmedetomidine | Visual Analogue Scale (VAS) in the Placebo Group | Patient number77 | 0 units on a scale |
| Dexmedetomidine | Visual Analogue Scale (VAS) in the Placebo Group | Patient number78 | 20 units on a scale |
| Dexmedetomidine | Visual Analogue Scale (VAS) in the Placebo Group | Patient number81 | 20 units on a scale |